WO2024083166A1 - 抗体-药物偶联物及其制备方法和在抗肿瘤中的用途 - Google Patents

抗体-药物偶联物及其制备方法和在抗肿瘤中的用途 Download PDF

Info

Publication number
WO2024083166A1
WO2024083166A1 PCT/CN2023/125269 CN2023125269W WO2024083166A1 WO 2024083166 A1 WO2024083166 A1 WO 2024083166A1 CN 2023125269 W CN2023125269 W CN 2023125269W WO 2024083166 A1 WO2024083166 A1 WO 2024083166A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
ch2ch2o
succinimidyl
ch2ch2
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/125269
Other languages
English (en)
French (fr)
Inventor
孟逊
翁炜宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multitude Therapeutics Inc
Original Assignee
Multitude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multitude Therapeutics Inc filed Critical Multitude Therapeutics Inc
Priority to AU2023362061A priority Critical patent/AU2023362061A1/en
Priority to EP23879154.5A priority patent/EP4606822A1/en
Priority to IL320034A priority patent/IL320034A/en
Priority to CN202380073861.XA priority patent/CN120077074A/zh
Priority to JP2025522931A priority patent/JP2025535442A/ja
Priority to KR1020257016319A priority patent/KR20250089539A/ko
Publication of WO2024083166A1 publication Critical patent/WO2024083166A1/zh
Priority to MX2025004607A priority patent/MX2025004607A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • the present disclosure relates to anti-HER3 antibodies and antibody-drug conjugates, which connect antibodies with specific targeting and anti-tumor drugs or toxins through a linker with improved hydrophobicity, and exert anti-tumor effects by targeting tumor cells expressing HER3.
  • Antibody-drug conjugate is a carrier-based chemotherapy that can selectively deliver effective cytotoxic drugs to tumors/cancer cells
  • ADC Antibody-Drug Conjugates: The Last Decade, Nicolas Joubert et al., Pharmaceuticals (Basel). 2020 Sep 14; 13(9): 245.
  • the marketed ADC drugs Enhertu and Sacituzumab govitecan have excellent effects in treating tumors, especially malignant tumors. Both use DNA topoisomerase inhibitor camptothecin derivatives that are more hydrophobic than microtubule inhibitors (such as MMAE, MMAF) as cytotoxic drugs.
  • Sacituzumab govitecan uses MCC-triazole spacer-PEG7-lysine-PABC as a linker, which is decomposed in the cell lysosome to release camptothecin SN38 (US13/948,732);
  • Enhertu developed by AstraZeneca/Daiichi Sankyo uses a cathepsin B-activated GGFG (an amino acid sequence consisting of glycine-glycine-phenylalanine-glycine connected by peptide bonds) tetrapeptide as a linker, and introduces a self-cleavage structure to release the exatecan derivative Dxd (Yusuke Ogitani et al., Clin Cancer Res (2016) 22(20):5097–5108.).
  • GGFG an amino acid sequence consisting of glycine-glycine-phenylalanine-glycine connected by peptide bonds
  • HER3 (NCBI, Gene ID: 2065) is a member of the HER (EGFR/ErbB) receptor family, which consists of four closely related type 1 transmembrane receptors (EGFR, HER2, HER3 and HER4). Monoclonal antibodies and small molecule inhibitors targeting the tyrosine kinase activity of EGFR and HER2 have shown clinical benefits in the treatment of several types of cancer, but their clinical efficacy is limited by drug resistance. HER3 occupies a special position in the EGFR family. It has almost no intracellular tyrosine kinase activity and cannot form homodimers. It cannot function alone.
  • HER3 protein and HER2 form heterodimers, its downstream pathways will be activated. Inhibiting the activation of HER3 downstream pathways can indirectly inhibit the growth, proliferation and metastasis of cancer cells. Therefore, HER3 plays an important role in the resistance to EGFR and HER2 targeted therapies (Clin Cancer Res; 20(6) March 15, 2014).
  • ADC drug targeting HER3 under development is Daiichi Sankyo's Patritumab Deruxtecan (HER3-DXd, codenamed U3-1402).
  • the ADC structure is derived from the HER3 monoclonal antibody Patritumab and the topoisomerase 1 inhibitor exatecan.
  • the drug (Deruxtecan) is spliced through a cleavable linker GGFG, and is designed to meet the unmet clinical needs of a large group of patients with non-small lung cancer who are resistant to EGFR-TKIs and have failed chemotherapy.
  • the present disclosure provides an anti-HER3 antibody or an antigen-binding fragment thereof, comprising at least one VL and VH, wherein the CDR1 of VL comprises the amino acid sequence shown in SEQ ID NO:1, CDR2 comprises the amino acid sequence shown in SEQ ID NO:2, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:3; the CDR1 of VH comprises the amino acid sequence shown in SEQ ID NO:4, CDR2 comprises an amino acid sequence that differs from the amino acid sequence shown in SEQ ID NO:5 by no more than 5, 4, 3, 2, 1, 0 mutations, and CDR3 comprises the amino acid sequence shown in SEQ ID NO:6.
  • CDR2 of VH comprises one or more mutations selected from (a) or (b);
  • CDR2 of VH comprises a mutation of (a) or (b):
  • the present disclosure provides a nucleic acid encoding the above-mentioned anti-HER3 antibody or an antigen-binding fragment thereof.
  • the present disclosure provides a vector comprising a nucleic acid encoding the above-mentioned anti-HER3 antibody or an antigen-binding fragment thereof.
  • the present disclosure provides a host cell comprising the above-mentioned nucleic acid and/or vector.
  • the present disclosure provides an antibody-drug conjugate having a structure as shown in Formula I,
  • Ab is the aforementioned anti-HER3 antibody or an antigen-binding fragment thereof
  • L is a linker covalently linked to Ab and D respectively;
  • n is a value between 1 and 10.
  • the present disclosure provides a method for preparing an antibody-drug conjugate, comprising the following steps: after the antibody or its antigen-binding fragment is subjected to reduction treatment, the interchain disulfide bonds are at least partially reduced, and react with the reactive groups of the linker in the linker-payload to obtain an antibody-drug conjugate having a structure shown in Formula I,
  • Ab is the above-mentioned anti-HER3 antibody or an antigen-binding fragment thereof
  • L is a linker covalently linked to Ab and D respectively;
  • n is a value between 1 and 10.
  • the present disclosure provides a pharmaceutical composition, which includes the above-mentioned anti-HER3 antibody or its antigen-binding fragment or antibody-drug conjugate, or its isomer, isotope variant, pharmaceutically acceptable salt, prodrug, solvate, or a combination thereof, and a pharmaceutically acceptable excipient.
  • kits which includes the above-mentioned anti-HER3 antibody or its antigen-binding fragment or antibody-drug conjugate, or its isomer, isotopic variant, pharmaceutically acceptable salt, prodrug, solvate, or a combination thereof.
  • the present disclosure provides a use of the above-mentioned anti-HER3 antibody or its antigen-binding fragment, antibody-drug conjugate, antibody-drug conjugate prepared by the above-mentioned method, pharmaceutical composition or the above-mentioned kit in preparing a therapeutic agent for diagnosing, preventing and treating tumor diseases.
  • the use includes use in the preparation of a medicament targeting HER3.
  • the tumor comprises a solid tumor expressing HER3.
  • the present disclosure provides a method for diagnosing, preventing and treating tumor diseases, comprising administering a therapeutic dose of a therapeutic agent to a subject, wherein the therapeutic agent comprises the above-mentioned anti-HER3 antibody or antigen-binding fragment thereof, antibody-drug conjugate, antibody-drug conjugate prepared by the above-mentioned method, the above-mentioned pharmaceutical composition or kit.
  • FIG. 1 A and B respectively show the size exclusion chromatogram and the hydrophobic chromatography chromatogram of the L1H5 antibody (naked antibody) prepared in Example 4;
  • Figure 2 A and B respectively show the size exclusion chromatogram and hydrophobic chromatography detection spectrum of the aggregates in the antibody-drug conjugate L1H5-LP3 prepared in Example 6;
  • Figure 3 A and B respectively show the size exclusion chromatogram and hydrophobic chromatography detection spectrum of the aggregates in the antibody-drug conjugate L1H5-LP1 prepared in Example 7;
  • Figure 4 A and B respectively show the size exclusion chromatogram and hydrophobic chromatography detection spectrum of the aggregates in the antibody-drug conjugate L1H5-LP2 prepared in Example 8;
  • FIG5 shows a flow cytometry statistical diagram of the Mu4O3 antibody prepared in Example 4 and cells with different HER3 expression levels
  • Figure 6 shows the immunofluorescence image of the Mu4O3 antibody prepared in Example 4 in HER3-GFP Tag overexpressing 293T cells;
  • FIG7 shows the cell survival curve of the Mu4O3 antibody prepared in Example 4 in the killing SW620 cell test
  • FIG8 shows the affinity curves of L1H4, L1H5, L2H4, L2H5, L4H4, L4H5 and L4H7 antibodies prepared in Example 4 in the MDA-MB-453 cell line;
  • FIG9 shows the affinity curves of L1H4, L1H5, L2H4, L2H5, L4H4, L4H5 and L4H7 antibodies prepared in Example 4 in the SW620 cell line;
  • FIG10 shows the cell proliferation inhibition rate of the L1H5 antibody prepared in Example 4, the reference antibody and the blank control in the SK-BR-3 cell line;
  • FIG11 shows the tumor volume-time curves of L1H5, reference antibody and blank control PBS prepared in Example 4 in BT-474 breast cancer mouse model
  • FIG12 shows the cell survival curves of the antibody-drug conjugates L1H4-LP1, L1H5-LP1 and L4H4-LP1 prepared in Example 7 and the reference ADC (positive control) prepared in Comparative Example 1 in the SW620 cell line;
  • FIG13 shows the cell survival curves of the L1H5 antibody prepared in Example 4, the L1H5-LP3 prepared in Example 6, the reference antibody and the reference ADC prepared in Comparative Example 1 in the killing test on the SK-BR-3 cell line;
  • FIG14 shows the cell survival curves of the L1H5 antibody prepared in Example 4, the L1H5-LP3 prepared in Example 6, the reference antibody and the reference ADC prepared in Comparative Example 1 in the killing test of the BXPC-3 cell line;
  • FIG15 shows the cell survival curves of the antibody-drug conjugate L1H5-LP1 prepared in Example 7, L1H5-LP2 prepared in Example 8, and the reference ADC prepared in Comparative Example 1 in the HCT-15 cell line;
  • Figure 16 shows the tumor volume-time change curves of the antibody-drug conjugate L1H5-LP prepared in Example 7, L1H5-LP2 prepared in Example 8, the reference ADC prepared in Comparative Example 1, and the blank control group in the HCT-15 colon cancer mouse model;
  • Figure 17 shows the tumor volume-time change curves of the mouse colon cancer PDX model after treatment with the reference ADC prepared in Comparative Example 1, L1H5-LP3 prepared in Example 6, L1H5-LP1 prepared in Example 7, Dxd isotype control ADC prepared in Comparative Example 4, and LP3 isotype control ADC prepared in Comparative Example 5;
  • Figure 18 shows the tumor volume-time change curves of the mouse EGFR-TKI-resistant lung adenocarcinoma PDX model after treatment with the reference ADC prepared in Comparative Example 1, L1H5-LP3 prepared in Example 6, L1H5-LP1 prepared in Example 7, Dxd isotype control ADC prepared in Comparative Example 4, and LP3 isotype control ADC prepared in Comparative Example 5;
  • Figure 19 shows the tumor volume-time change curves of the mouse colon cancer CDX model after treatment with L1H5-DXd prepared in Comparative Example 3, the reference antibody-LP3 prepared in Comparative Example 2, L1H5-LP3 prepared in Example 6, and the reference ADC prepared in Comparative Example 1, and a negative control PBS group is set;
  • FIG20 is a partial enlarged view of FIG19 after removing the negative control PBS group
  • Figure 21 shows a graph of tumor volume-time changes in a mouse pancreatic cancer CDX model after treatment with the reference ADC prepared in Comparative Example 1, L1H5-LP3 prepared in Example 6, L1H5-LP1 prepared in Example 7, Dxd isotype control ADC prepared in Comparative Example 4, and LP3 isotype control ADC prepared in Comparative Example 5;
  • FIG22 shows a comparison of the hydrophobicity measurements of the L1H5 antibody prepared in Example 4, the antibody-drug conjugate L1H5-LP3 prepared in Example 6, the reference antibody, and the reference ADC prepared in Comparative Example 1;
  • Figure 23 A and B respectively show the size exclusion chromatogram and hydrophobic chromatography detection spectrum of the aggregates in the reference ADC prepared in Comparative Example 1;
  • Figure 24 A and B respectively show the size exclusion chromatogram and hydrophobic chromatography detection spectrum of the aggregates in the antibody-drug conjugate reference antibody-LP3 prepared in Comparative Example 2;
  • Figure 25 A and B respectively show the size exclusion chromatogram and hydrophobic chromatography detection spectrum of the aggregates in the antibody-drug conjugate L1H5-DXd prepared in Comparative Example 3;
  • Figure 26 A and B respectively show the size exclusion chromatogram and hydrophobic chromatography detection spectrum of the aggregates in the Dxd isotype control ADC prepared in Comparative Example 4;
  • a and B in Figure 27 respectively show the size exclusion chromatogram and hydrophobic chromatography detection spectrum of the aggregates in the LP3 isotype control ADC prepared in Comparative Example 5.
  • the present disclosure provides an anti-HER3 antibody or an antigen-binding fragment thereof, comprising at least one light chain variable region (Variable Region of Light Chain, VL) and one heavy chain variable region (Variable Region of Heavy Chain, VH), and the VL and VH can be paired and bound.
  • VL light chain variable region
  • VH Heavy Chain variable region
  • the term “antibody” means any antigen binding molecule or molecular complex comprising at least one complementary determining region that specifically binds to or interacts with a specific antigen (e.g., HER3).
  • the term “antibody” includes immunoglobulin molecules and polymers thereof (e.g., IgM), which include four polypeptide chains, i.e., two heavy (H) chains and two light (L) chains interconnected by disulfide bonds.
  • Each heavy chain includes a heavy chain variable region and a heavy chain constant region.
  • the heavy chain constant region includes three domains, i.e., CH1, CH2, and CH3.
  • Each light chain includes a light chain variable region and a light chain constant region.
  • the light chain constant region includes a domain (CL1).
  • VH and VL regions can be further divided into hypervariable regions, called complementary determining regions (CDRs), interspersed with more conservative regions called framework regions (FRs).
  • CDRs complementary determining regions
  • FRs framework regions
  • Each VH and VL is composed of three CDRs and four FRs arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • antibody also includes the antigen binding fragment of a complete antibody molecule.
  • antigen binding fragment includes any naturally occurring, enzymatically obtainable, synthetic or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex.
  • the antigen binding fragment of an antibody can be obtained from, for example, a complete antibody molecule using any suitable standard technology.
  • Non-limiting examples of antigen binding fragments include: Fab fragments, F (ab ') 2 fragments, Fd fragments, Fv fragments, single-chain Fv (scFv) molecules, dAb fragments and minimum recognition units, which are composed of amino acid residues of the hypervariable region (e.g., separated complementary determining regions (CDRs), such as CDR3 peptides) or restrictive FR3-CDR3-FR4 peptides of simulated antibodies.
  • CDRs complementary determining regions
  • the antigen-binding fragment of an antibody will generally comprise at least one variable domain.
  • the variable domain may be of any size or amino acid composition and will generally comprise at least one CDR adjacent to or in frame with one or more framework sequences.
  • the VH and VL domains may be positioned relative to each other in any suitable configuration.
  • the variable region may be a dimer and contain a VH-VH, VH-VL or VL-VL dimer.
  • the antigen-binding fragment of an antibody may contain a monomeric VH or VL domain.
  • CDR1-3 of VL comprises the amino acid sequences shown in SEQ ID NO: 1-3, respectively;
  • CDR1 of VH comprises the amino acid sequence shown in SEQ ID NO: 4,
  • CDR2 of VH comprises an amino acid sequence that differs from the amino acid sequence shown in SEQ ID NO: 5 by no more than 5, 4, 3, 2, 1, 0 mutations, and
  • CDR3 of VH comprises the amino acid sequence shown in SEQ ID NO: 6.
  • the CDRs of the anti-HER3 antibody or antigen-binding fragment thereof are defined and numbered using the Kabat system.
  • the CDR2 of VH comprises an amino acid sequence that differs from the amino acid sequence of SEQ ID NO:5 by no more than 4, 3, 2, 1, or 0 mutations. In some embodiments, the CDR2 of VH comprises an amino acid sequence that differs from the amino acid sequence of SEQ ID NO:5 by no more than 4 mutations. In some embodiments, the CDR2 of VH comprises an amino acid sequence as set forth in SEQ ID NO:5.
  • the CDR2 of VH contains a mutation, and the mutation is selected from any one or a combination of C52N/Y, T62N, T66K and G67S.
  • C52N/Y means that the amino acid "C” at position 52 mutates to "N” or "Y".
  • C", “N”, “Y”, “T”, “K”, “G”, and “S” are standard amino acids represented by single letters, representing cysteine, asparagine, tyrosine, threonine, lysine, glycine, and serine, respectively.
  • the first amino acid refers to the first amino acid from the amino terminus to the carboxyl terminus of VH, and the amino acids at other positions are deduced by analogy.
  • the CDR2 of VH comprises mutations C52N, T62N, T66K and G67S. In some embodiments, in the anti-HER3 antibody or antigen-binding fragment thereof, the CDR2 of VH comprises mutations C52Y, T62N, T66K and G67S.
  • variable region also includes a framework region (FR), which is a region with relatively small changes in amino acid composition and arrangement order except for CDR.
  • FR framework region
  • the anti-HER3 antibody or its antigen-binding fragment also comprises a conservatively modified variant, which includes a single substitution, deletion or addition to the polypeptide sequence, which results in the amino acid being replaced by a chemically similar amino acid. Providing a conservative substitution table of functionally similar amino acids is well known in the art. Such conservatively modified variants are supplementary to polymorphic variants, interspecies homologs and alleles and are not excluded.
  • the following eight groups contain amino acids that are conservatively substituted for each other: 1) alanine (A), glycine (G); 2) aspartic acid (D), glutamic acid (E); 3) asparagine (N), glutamine (Q); 4) arginine (R), lysine (K); 5) isoleucine (I), leucine (L), methionine (M), valine (V); 6) phenylalanine (F), tyrosine (Y), tryptophan (W); 7) serine (S), threonine (T); and 8) cysteine (C), methionine (M) (see, e.g., Creighton, Proteins (1984)).
  • the term "conservative sequence modification” is used to refer to amino acid modifications that do not significantly affect or change the binding characteristics of the antibody comprising the amino acid sequence.
  • VL comprises an amino acid sequence that is at least 70%, 75%, 77%, 78%, 80%, 82%, 84%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the framework region sequence of the amino acid sequence shown in SEQ ID NO:9, 11, 12, 13;
  • VH comprises an amino acid sequence that is at least 70%, 75%, 77%, 78%, 80%, 82%, 84%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the framework region sequence of the amino acid sequence shown in SEQ ID NO:10, 14, 15, 16.
  • VL comprises an amino acid sequence that is at least 70%, 75%, 77%, 78%, 80%, 82%, 84%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence shown in SEQ ID NO:9, 11, 12, 13;
  • VH comprises an amino acid sequence that is at least 70%, 75%, 77%, 78%, 80%, 82%, 84%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence shown in SEQ ID NO:10, 14, 15, 16.
  • % identity refers to the degree to which two or more sequences or subsequences are identical. If two sequences have the same amino acid sequence in the region being compared, they are "identical”. If two sequences have a specified percentage of identical amino acid residues (e.g., 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% identity in a specified region, or, when not specified, over the entire sequence), when comparing and aligning to obtain maximum consistency in a comparison window or a specified region, or using a specified region measured by one of the following sequence comparison algorithms or by manual alignment and visual inspection.
  • identity is present in a region of at least about 10 amino acids in length, or more preferably in a length of 20, 50, 200 or more amino acids.
  • Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms (Altschul et al., Nuc. Acids Res. 25:3389-3402, 1997, and Altschul et al., J. Mol. Biol. 215:403-410, 1990).
  • polypeptides being substantially identical are that the first polypeptide is immunologically cross reactive with the second polypeptide, thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only in conservative substitutions.
  • VL comprises the amino acid sequence shown in SEQ ID NO:9, 11, 12 or 13 and VH comprises the amino acid sequence shown in SEQ ID NO:10, 14, 15 or 16.
  • VL and VH comprise an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence shown in SEQ ID NO: 9 and SEQ ID NO: 10, respectively; VL and VH comprise an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence shown in SEQ ID NO: 11 and SEQ ID NO: 14, respectively; VL and VH comprise an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence shown in SEQ ID NO: 11 and SEQ ID NO: 15, respectively; VL and VH comprise an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence shown in SEQ ID NO: 12 and SEQ ID NO: 13, respectively.
  • amino acid sequence shown in SEQ ID NO:14 has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence shown in SEQ ID NO:14;
  • VL and VH respectively comprise an amino acid sequence that has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence shown in SEQ ID NO:12 and SEQ ID NO:15;
  • VL and VH respectively comprise an amino acid sequence that has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence shown in SEQ ID NO:13 and SEQ ID NO:14;
  • VL and VH respectively comprise an amino acid sequence that has at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to the amino acid sequence shown in SEQ ID NO:13 and SEQ ID NO:15; or VL and VH respectively comprise an amino acid sequence that has at least 85%, 90%, 95%, 96%, 97%, 98%
  • the anti-HER3 antibody or its antigen-binding fragment comprises or has VH and VL as shown in SEQ ID NO: 9 and 10, 11 and 14, 11 and 15, 11 and 16, 12 and 14, 12 and 15, 12 and 16, 13 and 14, 13 and 15, or, 13 and 16, and their conservative substitution variants, and the framework region may have conservative substitutions.
  • the anti-HER3 antibody or its antigen-binding fragment comprises or has VH and VL as shown in SEQ ID NO: 9 and 10, 11 and 14, 11 and 15, 12 and 14, 12 and 15, 13 and 14, 13 and 15, or 13 and 16, and their conservative substitution variants, respectively, and the framework region may have conservative substitutions.
  • the HER3 antibodies or antigen binding fragments thereof provided by the present disclosure can bind to the HER3 protein of a mammal (e.g., a human or a mouse). In some embodiments, the anti-HER3 antibodies or antigen binding fragments thereof specifically bind to human HER3. In some embodiments, the anti-HER3 antibodies or antigen binding fragments thereof specifically bind to mouse HER3.
  • the HER3 antibody or its antigen binding fragment can be of IgM, IgG, IgA, IgD or IgE category. In some embodiments, the HER3 antibody or its antigen binding fragment is an IgG molecule. In some embodiments, the HER3 antibody or its antigen binding fragment is of IgG1, IgG2, IgG3 or IgG4 subtype. In some embodiments, the HER3 antibody or its antigen binding fragment is human IgG1.
  • the class and subclass of the antibody are confirmed according to the usual methods in the art. For example, according to the difference of heavy chain ⁇ , ⁇ , ⁇ , ⁇ and ⁇ , the composed antibodies are called IgA, IgD, IgE, IgG and IgM. Among them, human ⁇ can be further subdivided into ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 4, corresponding to the four subtypes of IgG1, IgG2, IgG3 and IgG4 respectively.
  • the HER3 antibody or antigen-binding fragment thereof may be a human antibody, a humanized antibody or a chimeric antibody, and human antibodies, humanized antibodies or chimeric antibodies are defined in a manner generally understood in the art.
  • a human antibody refers to an antibody that is entirely encoded by human antibody genes
  • a humanized antibody refers to an antibody whose constant region is at least partially encoded by human genes
  • a chimeric antibody refers to a chimeric antibody expressed by a mammalian cell transformed with DNA recombination technology by inserting the light and heavy chain variable region genes of a heterologous monoclonal antibody into an expression vector containing a human antibody constant region.
  • anti-HER3 antibodies or antigen-binding fragments thereof provided by the present disclosure have improved hydrophobicity, which is beneficial for improving the stability in vivo and in vitro.
  • the anti-HER3 antibody or antigen-binding fragment thereof provided by the present disclosure has good targeting properties, can anchor tumor cells expressing HER3, and exert a tumor-killing effect.
  • the anti-HER3 antibody or antigen-binding fragment thereof can exert an anti-tumor effect both in vivo and in vitro.
  • the present disclosure provides a nucleic acid encoding the above-mentioned anti-HER3 antibody or its antigen-binding fragment, a vector comprising the nucleic acid encoding the above-mentioned anti-HER3 antibody or its antigen-binding fragment, and a host cell comprising the nucleic acid and/or the vector.
  • Anti-HER3 antibodies or antigen-binding fragments thereof can be obtained by immunizing animals with HER3 or any polypeptide selected from the amino acid sequence of HER3 according to methods commonly practiced in the art, collecting and purifying antibodies produced in vivo. In this case, by studying the cross-reactivity of antibodies binding to the obtained heterologous HER3 with human HER3, antibodies applicable to human diseases can be selected.
  • monoclonal antibodies can be obtained from hybridomas by fusing antibody-producing cells producing antibodies against HER3 with myeloma cells according to known methods (e.g., Kohler and Milstein, Nature (1975) 256, pp. 495-497; Kennet, R. ed., Monoclonal Antibodies, pp.
  • HER3 used as an antigen can be obtained by expressing the HER3 gene in host cells using genetic engineering.
  • Hybridomas can be engineered to obtain chimeric antibodies, for example, chimeric antibodies in which the variable regions of antibodies derived from mice or rats are linked to constant regions derived from humans (see Proc. Natl. Acad. Sci. U.S.A., 81, 6851-6855, (1984)).
  • Humanized antibodies can be generated by replacing most or all structural parts of non-human monoclonal antibodies with corresponding human antibody sequences. Examples include antibodies obtained by integrating only the complementarity determining region (CDR) into an antibody derived from a human (see Nature (1986) 321, pp. 522-525) and antibodies obtained by transplanting the amino acid residues of a part of the framework into a human antibody in addition to the CDR sequence by the CDR transplantation method (WO 90/07861). Human antibodies can be obtained by a method for producing human antibody-producing mice using human chromosome fragments containing heavy and light chain genes of human antibodies (see Tomizuka, K. et al., Nature Genetics (1997) 16, pp. 133-143; Kuroiwa, Y.
  • CDR complementarity determining region
  • ADC antibody-drug conjugate
  • Ab is the above-mentioned anti-HER3 antibody or an antigen-binding fragment thereof
  • L is a linker covalently linked to Ab and D respectively;
  • n is a value between 1 and 10.
  • antibody-drug conjugate refers to a conjugate of an anti-HER3 antibody or antigen-binding fragment thereof described herein covalently linked to a payload.
  • the antibody-drug conjugate can include an antibody, a payload, and optionally a linker between the antibody and the payload.
  • ADC can provide a therapeutic effect by delivering the payload to HER3 cells, particularly HER3 tumor cells, targeted by the antibody.
  • Antibody-drug conjugates can be prepared by various methods known in the art for preparing antibody-drug conjugates.
  • linkers As the connecting structure between antibodies and effective loads, are key factors in the successful construction of ADC molecules.
  • PK pharmacokinetics
  • PD pharmacodynamics
  • linkers are key determinants of the efficacy of ADCs.
  • an ideal linker should have the following properties: (1) The linker is stable enough in plasma so that the ADC molecule can circulate in the bloodstream and localize to the tumor site without premature cleavage. Unstable linkers can lead to premature release of cytotoxic effective loads and damage non-target healthy cells, resulting in systemic poisoning and adverse reactions.
  • the linker needs to be able to be cleaved quickly so that once the ADC is internalized into the target tumor cells, it can quickly release the free cytotoxic effective load.
  • the design of the linker also needs to consider hydrophobicity.
  • the combination of hydrophobic linkers and hydrophobic cytotoxic payloads usually promotes the aggregation of ADC molecules, which is not only detrimental to the efficacy of ADC but may also lead to liver toxicity or induce unwanted immune responses (Kyoji Tsuchikama et al., Antibody-drug conjugates: recent advances in conjugation and linker chemistrie, Protein Cell. 2018 Jan; 9(1): 33-46).
  • isomers refers to compounds with the same molecular formula but different structures, also known as isomers or structural isomers, usually including structural isomers and stereoisomers.
  • Structural isomers refer to isomers caused by different connection orders of atoms in the molecule or different bonding properties, preferably including tautomers.
  • the tautomers refer to functional group isomers produced by the rapid movement of an atom in two positions in the molecule.
  • Stereoisomers refer to isomers caused by different spatial arrangements of atoms or atomic groups in the molecule, which are the same in order of connection and bonding materials, and preferably include optical isomers.
  • the optical isomers refer to stereoisomers with different optical properties caused by the lack of anti-axis symmetry in the molecule, such as enantiomers, diastereomers, racemates and mesosomes.
  • prodrug refers to a compound that is inactive or less active in vitro after chemical structural modification of a drug, and releases active drugs in vivo through enzymatic or non-enzymatic conversion to exert its efficacy.
  • the prodrug can be an ADC molecule or an effective load.
  • the linker is a cleavable linker and a non-cleavable linker.
  • the linker comprises a cleavable peptide, optionally, the cleavable peptide is cleavable by an enzyme.
  • the enzyme comprises cathepsin B.
  • the cleavable peptide or L comprises amino acid units including a dipeptide, a tripeptide, a tetrapeptide, or a pentapeptide.
  • the amino acid unit is selected from any one or a combination of Val-Cit, Val-Ala, Glu-Val-Cit, Ala-Ala-Asn, Gly-Val-Cit, Gly-Gly-Gly and Gly-Gly-Phe-Gly, wherein Val represents valine, Cit represents citrulline, Ala represents alanine, Glu represents glutamic acid, Asn represents asparagine, Gly represents glycine, and Phe represents phenylalanine.
  • the linker comprises a self-immolative unit, and optionally, the self-immolative unit comprises p-aminobenzyloxycarbonyl (PABC) or p-aminobenzyl (PAB).
  • PABC p-aminobenzyloxycarbonyl
  • PAB p-aminobenzyl
  • the cleavable peptide is cleaved directly to the self-degradable unit.
  • m1 represents 2, 3, 4, 5, 6, 7, or 8.
  • m2 represents 1, 2, 3, 4, 5, 6, 7, or 8.
  • m3 represents 1, 2, 3, 4, 5, 6, 7, or 8.
  • the L is selected from one or more of the following groups:
  • the p-aminobenzyloxycarbonyl group (PABC) or p-aminobenzyl group (PAB) is linked to a polysarcosine (poly-N-methylglycine) residue or a methylamino group.
  • the antibody-drug conjugate comprises an antibody, a payload, and a linker as shown in Formula II,
  • the linker shown in Formula II is covalently bonded to the sulfhydryl part of the antibody interchain disulfide chain after reduction through a succinimide group through a thioether bond;
  • the carbonyl group in the ester group of the linker represented by Formula II is connected to the amino group in the effective load;
  • R 1 and R 2 are each independently selected from hydrogen, methyl or isopropyl
  • R 3 represents -(CR 5 HCONH)n 1 -(CH 2 CONH)n 2 - or a single bond, R 5 is hydrogen or benzyl, n 1 represents an integer of 0 to 2, and n 2 represents an integer of 0 to 2;
  • R4 represents a methylamino group or -( NCH3COCH2 ) n3 - NCH3COCH3 , and n3 represents an integer of 1-20.
  • the term "payload” includes compounds that are cytotoxic or capable of killing cells after release from the antibody-drug conjugate, compounds with radioactive labels, fluorophores, chromophores, imaging agents and/or metal ions as detectable markers or cell-killing effects. substances, radionuclides or polypeptides, compounds that can regulate the body's immune activity (including activation or inhibition), nucleic acids, polypeptides or proteins, enzymes, hormones or nucleic acids.
  • the conjugated effective load in the antibody-drug conjugate has almost no cytotoxicity or the cytotoxicity is so low that the effective therapeutic dose of ADC does not cause systemic toxic reactions in the subject due to the conjugated effective load.
  • the effective load can be a drug that has been clinically verified for the treatment of a specific disease, or a compound, radionuclide, nucleic acid, protein or peptide with acceptable pharmacological activity under clinical use conditions.
  • the linker in Formula I is connected to the antibody through a sulfide bond formed by the succinimide group at the end and the thiol group after the reduction of the interchain disulfide chain of the antibody. It forms a thioether bond with the reduced sulfhydryl group of the antibody interchain disulfide chain through the carbon atom at position 3.
  • the bond represents a chemical bond to other groups.
  • the disulfide bonds of the antibody include interchain disulfide bonds and intrachain disulfide bonds, preferably the interchain disulfide bonds are treated, for example, activated (or reduced) to become sulfhydryl groups and then bonded to the linker.
  • the amino acid in the antibody that is chemically bonded to the succinimidyl group in the linker includes one or a combination of lysine, histidine, tyrosine and cysteine, preferably chemically bonded through cysteine.
  • the linker in Formula I can be attached to the hinge region, variable region and/or constant region of the antibody.
  • R 4 represents -(NCH 3 COCH 2 )n 3 -NCH 3 COCH 3
  • n 3 represents an integer of 1 to 20.
  • the n 3 can be selected from any integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20.
  • R 4 represents -(NCH 3 COCH 2 )n 3 -NCH 3 COCH 3
  • n 3 represents an integer of 8 to 15.
  • R 4 represents -(NCH 3 COCH 2 )n 3 -NCH 3 COCH 3
  • n 3 represents an integer of 10 to 12.
  • R 4 represents a methylamino group.
  • R4 contains a hydrophilic polysarcosine group or a methylamino group, which increases the hydrophilicity of the antibody-drug conjugate.
  • the improvement in the hydrophilicity of the ADC molecule helps to reduce the aggregation of the ADC molecules during the preparation process, thereby improving the stability, uniformity and purity of the antibody-drug conjugate.
  • R 3 represents a single bond.
  • R 3 represents -(CR 5 HCONH)n 1 -(CH 2 CONH)n 2 -, R 5 is a benzyl group, n 1 represents an integer of 1-2, and n 2 represents an integer of 1-2.
  • R 3 represents -CR 5 HCONH-, -CH 2 CONH-, -CR 5 HCONH-CH 2 CONH-; -(CR 5 HCONH) 2 -CH 2 CONH-; -CR 5 HCONH-(CH 2 CONH) 2 -; or, -(CR 5 HCONH) 2 -(CH 2 CONH) 2 -; and R 5 is benzyl.
  • R 1 in the antibody-drug conjugate, in the linker of formula II, R 1 is hydrogen. In some embodiments, in the linker of formula II, R 1 is isopropyl.
  • R 2 in the antibody-drug conjugate, in the linker of formula II, is hydrogen. In some embodiments, in the linker of formula II, R 2 is methyl.
  • the linker in the antibody-drug conjugate is selected from one or more of the following groups:
  • the effective load in the antibody-drug conjugate is a marker containing a radioactive label, a fluorophore, a chromophore, an imaging agent and/or a metal ion as a detection marker, and the marker includes but is not limited to a chemically synthesized organic compound, a radionuclide, a metal complex or a polypeptide.
  • a radioactive label refers to a labeled compound that replaces one or several atoms of a compound molecule with a radionuclide so that it can be identified and used as a tracer, including amino acids, polypeptides, proteins, carbohydrates, nucleotides, nucleosides, purines, pyrimidines, steroids, lipid compounds, and tumor antigens, hormones, receptors, vitamins and drugs used in medical research.
  • Reflective nuclides are usually nuclides that can spontaneously emit radiation, including but not limited to tritium, iodine 125, iodine 131, sulfur 35, phosphorus 32 and carbon 14.
  • Fluorophores are usually groups including conjugated double bonds, and when the molecule returns to the ground state from the excited state, the fluorophore will emit fluorescence. Chromophores refer to unsaturated groups and their related chemical bonds contained in molecules that can absorb light radiation and have transitions. In nuclear medicine, imaging agents usually refer to radioactive drugs that can be introduced into the body to perform organ, tissue or molecular imaging.
  • the effective load in the antibody-drug conjugate is a nucleic acid, which can be ribonucleic acid and/or deoxyribonucleic acid.
  • the effective load in the antibody-drug conjugate is a hormone, a growth factor, a coagulation factor, a fibrinolytic protease (eg, a prodrug converting enzyme, a ribonuclease that can convert a prodrug into an active drug).
  • a fibrinolytic protease eg, a prodrug converting enzyme, a ribonuclease that can convert a prodrug into an active drug.
  • the effective load in the antibody-drug conjugate is an immunomodulator (including cytokines and chemokines that affect immune effects), an agonistic antibody or an antagonistic antibody with biological activity.
  • the effective load in the antibody-drug conjugate is a cytotoxic compound. In some embodiments, the effective load in the antibody-drug conjugate has anti-tumor activity, or is an anti-tumor drug, and the effective load is selected from a DNA topoisomerase inhibitor or a tubulin inhibitor.
  • the DNA topoisomerase inhibitor can be a topoisomerase I inhibitor or a topoisomerase II inhibitor.
  • topoisomerase inhibitor generally refers to a compound that inhibits the activity of topoisomerase.
  • Compounds that are topoisomerase I inhibitors are active against topoisomerase I; topoisomerase II inhibitors are active against topoisomerase II; some compounds are active against both topoisomerase I and topoisomerase II, and are referred to as topoisomerase I/II inhibitors.
  • tubulin inhibitors generally refers to compounds that inhibit the microtubule system of eukaryotic cells, interfere with cell division and inhibit cell proliferation.
  • the effective load is camptothecin or its derivatives having topoisomerase inhibitory effect.
  • derivative refers to a compound formed by substitution of atoms or atomic groups in a parent compound molecule by other atoms or atomic groups, which is called a derivative of the parent compound.
  • camptothecin and its derivatives generally includes camptothecin and camptothecin derivatives, and camptothecin exerts its pharmacological effect by irreversibly inhibiting topoisomerase I.
  • camptothecin derivatives include exatecan, irinotecan, topotecan, lurtotecan, silatecan, etirinotecan pegol, TAS 103, 9-aminocamptothecin, 7-ethylcamptothecin, 10-hydroxycamptothecin, 9-nitrocamptothecin, 10,11-methylenedioxycamptothecin, 9-amino-10,11-methylenedioxycamptothecin, 9-chloro-1 0,11-methylenedioxycamptothecin (9-chloro-10,11-methylenedioxycamptothecin), 7-(4-methylpiperazinomethylene)-10,1 1-ethylenedioxy-20(S)-camptothecin, 7-(4-methylpiperazinomethylene)-10,1 1-ethylenedioxy-20(S)-camptothecin, 7-(4-methylpiperazinomethylene)-10,11-methylenedioxy-20(S)-camptothecin, 7-(2-
  • the effective load is auristatin or its derivatives, maytansine or its derivatives having tubulin inhibitory effects.
  • auristatin and its derivatives generally includes auristatin F and auristatin F derivatives, and the auristatin F derivatives include monomethyl auristatin E (monomethyl auristatin E, MMAE) and monomethyl auristatin F (monomethyl auristatin F, MMAF).
  • the term “maytansine and its derivatives” generally includes maytansine and maytansine derivatives, and the maytansine derivatives include maytansine DM1, maytansine DM2 and maytansine DM4.
  • the effective load is the camptothecin derivative Exatecan, which can act on the entire cell cycle as a topoisomerase inhibitor, and has strong penetration and good efficacy on slow-growing solid tumors. Moreover, the number of intracellular targets is much lower than the number of targets of tubulin inhibitors, and when the ADC molecule carries the same number of effective loads into the cell, it can have a better killing effect. Exatecan molecules are not substrates of P-gp, which is conducive to reducing or alleviating the problem of drug resistance.
  • the effective load is exitecan as shown in Formula III, which is connected to the linker via the nitrogen atom of the amino group on its cyclohexane ring.
  • the structure of the ixotecan molecule is rigid and has poor hydrophilicity.
  • the GGFG tetrapeptide linker commonly used in the prior art to prepare ADC, it is easy to cause polymerization between ADC molecules, which does not meet the development requirements of ADC drugs (Bioorg. Med. Chem. Lett. 26 (2016) 1542-1545). Therefore, the selection and matching of the linker and the effective load have an impact on the safety and stability of ADC drugs.
  • the linker since the linker has multiple hydrophilic groups, the hydrophilicity in the linker-payload structure is improved, and the aggregation and precipitation of ADC molecules caused by the hydrophobic payload can be reduced to a certain extent.
  • the effective load or the compound of the linker (or part of the linker)-effective load structure is released depending on whether the linker is degraded.
  • the amino group on the cyclohexane ring of Exitecan shown in Formula III is bonded to the carbonyl group in the ester group of the linker shown in Formula II to form a linker-effective load structure including a carbamate.
  • the linker-effective load structure provided by the present disclosure, after the ADC molecule is internalized into the cell, the linker is enzymatically hydrolyzed by a tissue protease (e.g., Cathepsin B) to form an intermediate or active metabolite shown in the following formula V,
  • a tissue protease e.g., Cathepsin B
  • R4 represents a methylamino group or -( NCH3COCH2 ) n3 - NCH3COCH3 , and n3 represents an integer of 1-20.
  • the PABC group in the intermediate or active metabolite shown in Formula V then undergoes 1,6-elimination to release exotecan.
  • the mechanism of 1,6-elimination of PABC is described in detail in the document Angew.Chem.Int.Ed.2015,54,7492-7509. Therefore, the linker-payload structure in the ADC molecule provided by the present disclosure has good in vivo stability and biological activity.
  • the cleavage site in the linker-payload structure can be an amide bond in the linker, for example, an amide bond between the carbon atom where the substituent represented by R2 is located and the group represented by R3 , or an amide bond in the group represented by R3 .
  • n is the ratio of the number of molecules of the coupled effective load to each molecule of antibody (Drug to Antibody Ratio, DAR). In some embodiments, in the antibody-drug conjugate, n is 1-10, 1-2, 2-4, 4-6, 2-8, 4-8, 4-10, 6-10, 7-10 or 8-10, and exemplary DAR values are 4, 6, 7.78, 8.038 or 9.92.
  • DAR represents the average value of the number of coupled effective load or drug molecules per antibody molecule, i.e., the average value of the number of coupled drug molecules.
  • the number of effective load molecules coupled to each antibody molecule is a key factor affecting its efficacy and safety.
  • the production of antibody-drug conjugates is carried out by specifying reaction conditions such as the amount of starting materials and reagents used in the reaction to achieve a constant number of coupled effective load molecules. Usually, a mixture containing different numbers of coupled effective load molecules is obtained during the preparation of antibody-drug conjugates.
  • the coupling effective load or drug molecule number per antibody molecule in the present disclosure is defined as the average value, i.e., the average number of coupling effective load or drug molecules.
  • the antibody-drug conjugate comprises any one of the following structures:
  • Ab represents an anti-HER3 antibody or antigen-binding fragment
  • n is 1-10 or 4-10.
  • the antibody in the antibody-drug conjugate is a HER3-targeting specific antibody or an antigen-binding fragment thereof, which is connected to the linker after forming an active thiol group through a disulfide bond.
  • the antibody hinge region is connected to the linker after forming an active thiol group through a disulfide bond.
  • the antibody in the antibody-drug conjugate is an anti-HER3 antibody or an antigen-binding fragment thereof provided in the above [Antibodies] section of the present disclosure.
  • the anti-HER3 antibody or an antigen-binding fragment thereof in the antibody-drug conjugate comprises a VL sequence as shown in SEQ ID NO: 11 and a VH sequence as shown in SEQ ID NO: 15.
  • the hydrophilicity and uniformity of the prepared products are significantly improved, which helps to improve the killing effect of targeted cells, and improves or maintains the drug properties such as biological activity and safety, for example, the in vitro/in vivo stability is improved, and the in vivo drug metabolism properties are improved (longer half-life, lower free small molecule toxins, etc.).
  • the antibody drug provided by the present disclosure has excellent in vivo antibody tumor effect, especially HER3-dependent cell killing or anti-tumor activity, and has different degrees of killing effect on the tumor cells according to the expression level of HER3 in the tumor cells.
  • the antibody-drug conjugate of the present disclosure may absorb water, retain adsorbed water, or become hydrated due to being placed in the atmosphere or recrystallized, and such compounds and salts containing water are also included in the present disclosure.
  • the present disclosure also includes isotope variant compounds labeled with various radioactive or non-radioactive isotopes.
  • One or more of the atoms constituting the antibody-drug conjugate of the present disclosure may also contain atomic isotopes in non-natural proportions.
  • atomic isotopes for example, deuterium (2H), tritium (3H), iodine-125 (125I) or carbon-14 (14C) can be cited.
  • the compounds of the present disclosure can be radiolabeled with radioactive isotopes such as tritium (3H), iodine-125 (125I) or carbon-14 (14C).
  • Radiolabeled compounds are useful as therapeutic or preventive agents, research reagents such as test reagents, and diagnostic agents, such as in vivo imaging diagnostic agents. All isotopic variations of the antibody-drug conjugates of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
  • the present disclosure provides a method for preparing an antibody-drug conjugate, comprising the following steps:
  • the interchain disulfide bonds of the antibody or antigen-binding fragment thereof are at least partially reduced, and react with the linker-payload, in particular, react with the reactive group of the linker in the linker-payload, to obtain an antibody-drug conjugate having a structure as shown in Formula I.
  • Ab is the above-mentioned anti-HER3 antibody or an antigen-binding fragment thereof
  • L is a linker covalently linked to Ab and D respectively;
  • n is a value between 1 and 10.
  • the carbon atom at position 3 of the maleimide-N-group in L-D reacts with the reduced antibody to obtain ADC after covalent bonding.
  • the preparation method comprises the following steps: after the antibody is subjected to reduction treatment, the interchain disulfide bonds are at least partially reduced, and the antibody is coupled with a linker-payload, wherein the thiol group after the disulfide bond reduction reacts with the 3-position carbon atom of the maleimide-N-group of the linker shown in Formula IV in the linker-payload,
  • the carbonyl group in the ester group of the linker represented by Formula IV is connected to the amino group of the effective load in the antibody-drug conjugate;
  • R 1 and R 2 are each independently selected from hydrogen, methyl or isopropyl
  • R 3 represents -(CR 5 HCONH)n 1 -(CH 2 CONH)n 2 - or a single bond, R 5 is selected from hydrogen or benzyl, n 1 represents an integer of 0 to 2, and n 2 represents an integer of 0 to 2;
  • R4 represents a methylamino group or -( NCH3COCH2 ) n3 - NCH3COCH3 , and n3 represents an integer of 1-20.
  • the linker of the structure shown in the above formula IV with a payload is connected to the same antibody molecule with a reactive thiol group.
  • the antibody reacts with a reducing agent such as dithiothreitol (DTT), 2-mercaptoethanol or tris(2-carboxyethyl)phosphine hydrochloride (TCEP) to form a reactive thiol group with disulfide bonds on the antibody chain.
  • DTT dithiothreitol
  • TCEP tris(2-carboxyethyl)phosphine hydrochloride
  • the amount of the reducing agent can be 0.3 to 10 times the molar equivalent of the antibody, for example, 1 to 10, 3 to 10, 5 to 10, 7 to 10 times the molar equivalent.
  • the method further comprises: reacting the antibody with a reducing agent in a buffer solution containing a chelating agent, and then adding a dissolving solution of the linker-payload to react.
  • the linker-payload is specifically a compound formed by bonding the linker and the payload shown in formula IV, wherein the amino group (primary amino group) in the payload is connected to the carbonyl group in the ester group of the linker shown in IV.
  • the payload is selected from the payloads described in [Antibody-Drug Conjugate].
  • the payload is exotecan.
  • chelator refers to a complex that can be combined with metal atoms or ions through coordination bonds to form a cyclic structure.
  • the reducing agent reacts with the antibody in a buffer solution containing a chelating agent to obtain an antibody in which the interchain disulfide bonds are partially or completely reduced.
  • the chelating agent includes but is not limited to ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA).
  • the concentration of the chelating agent is 1mM to 20mM, for example, 2mM to 20mM, 5mM to 20mM, 8mM to 20mM, 1mM to 15mM or 1mM to 10mM.
  • the components of the buffer solution can be buffer salts commonly used in the art, such as sodium phosphate, sodium borate, sodium acetate or similar buffer salts.
  • the reaction of the antibody with the reducing agent is carried out under an adjusted pH condition.
  • the pH of the solution when the antibody reacts with the reducing agent is 5 to 9, and can be selected as pH 6 to 8, pH 6 to 7, pH 6.5 to 7.5 or pH 7 to 8, for example, the solution is reacted at about pH 7.
  • Acidic or alkaline chemicals can be used to adjust the pH value of the solution, and exemplary acidic or alkaline chemicals include acetic acid, hydrochloric acid, phosphoric acid, sulfuric acid, sodium bicarbonate, sodium carbonate, sodium hydroxide and triethylamine.
  • reaction of the antibody with the reducing agent is carried out under adjusted temperature conditions, exemplary reaction temperatures are -10-40°C, -5-40°C, 0-40°C, 5-40°C, 10-40°C, 15-40°C, 20-40°C, 25-40°C, 30-40°C, 35-38°C, such as about 37°C.
  • the linker-payload may be dissolved in an organic solvent selected from any one or a combination of dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA) and N-methyl-2-pyrrolidone (NMP).
  • DMSO dimethyl sulfoxide
  • DMF dimethylformamide
  • DMA dimethylacetamide
  • NMP N-methyl-2-pyrrolidone
  • the linker-payload solution is added to the buffer solution of the reduced or reactive thiol-containing antibody in an amount of 1-20% by volume, based on the volume of the antibody buffer. In some embodiments, the linker-payload solution is added in an amount of 1-20%, 2-20%, 5-20%, 10-20%, 15-20%, 1-18%, 1-15%, 1-13%, 1-10% or 5-15%, based on the volume of the antibody buffer.
  • the molar ratio of linker-payload to antibody is 4-20, optionally 8-20. In some embodiments, the molar ratio of linker-payload to antibody is 10-20, 14-20, 16-20 or 18-20.
  • the temperature for reacting the antibody with the linker-payload is 0-37° C. In some embodiments, the reaction temperature is -10-40° C., -5-40° C., 0-40° C., 5-40° C., 5-37° C., 10-37° C., 10-25° C., or 15-30° C.
  • the antibody reacts with the linker-payload for 0.5 to 2 hours. In some embodiments, the antibody reacts with the linker-payload for 0.5 to 1.75 hours, 0.5 to 1.5 hours, 0.5 to 1.25 hours, 0.75 to 2 hours, or 1 to 2 hours.
  • the reaction can be terminated by inactivating the reactivity of the unreacted linker-payload using a thiol-containing reagent.
  • the thiol-containing reagent includes, but is not limited to, cysteine or N-acetyl-(L)-cysteine (NAC). More specifically, the reaction can be terminated by adding a thiol-containing reagent in a molar equivalent of 1 to 2 times the molar equivalent of the linker-payload to the reaction solution and incubating at room temperature (10 to 25° C.) for 10 to 30 minutes.
  • the antibody-drug conjugate can also be obtained by reacting the compound using a known method (for example, it can be obtained by the method described in patent publication US2016/297890 (for example, it can be obtained by the method described in paragraphs [0336] to [0374])).
  • Antibodies having thiol groups can be obtained by methods well known to those skilled in the art (Hermanson, G.T, Bioconjugate Techniques, pp.56-136, pp.456-493, Academic Press (1996)).
  • the antibody in the antibody-drug conjugate is selected from the anti-HER3 antibodies or antigen-binding fragments thereof disclosed in the [Antibodies] section.
  • the anti-HER3 antibody or antigen-binding fragment thereof in the antibody-drug conjugate comprises a VL sequence as shown in SEQ ID NO: 11 and a VH sequence as shown in SEQ ID NO: 15.
  • the antibody-drug conjugate provided by the present disclosure can be obtained by the above preparation method.
  • the prepared antibody-drug conjugate is subjected to a purification treatment, and the purification treatment includes but is not limited to gel filtration, such as purification using a gel column.
  • the linker and the effective load exotecan are coupled to the antibody targeting HER3 by a simple chemical method.
  • the anti-HER3 antibody-drug conjugate obtained by using this linker has a higher DAR value (e.g., DAR8).
  • the present disclosure provides a pharmaceutical composition, comprising the anti-HER3 antibody or antigen-binding fragment thereof, or antibody-drug conjugate, or isomers, isotopic variants, pharmaceutically acceptable salts, prodrugs, solvates, or combinations thereof, and pharmaceutically acceptable excipients.
  • the pharmaceutical composition disclosed herein can select a suitable administration method according to the specific applicable form, physicochemical characteristics, etc. of the pharmaceutically acceptable excipients.
  • the pharmaceutical composition can be formed into a preparation in the form of a freeze-dried preparation or a liquid preparation, and the preparation can contain appropriate preparation additives in the art.
  • the above-mentioned pharmaceutical composition representatively, contains more than one pharmaceutical carrier, such as a sterilized liquid, such as water and oil (including oils of petroleum, animal, plant, or synthetic origin (such as peanut oil, soybean oil, mineral oil, sesame oil, etc.)).
  • a sterilized liquid such as water and oil (including oils of petroleum, animal, plant, or synthetic origin (such as peanut oil, soybean oil, mineral oil, sesame oil, etc.)).
  • water is a more representative carrier.
  • saline solution as well as glucose aqueous solution and glycerol aqueous solution can also be used as liquid carriers, especially for injection solutions.
  • Suitable pharmaceutical excipients are known in the art.
  • the above-mentioned composition can also contain a trace amount of a wetting agent or emulsifier, or a pH buffering agent.
  • the administration method of the pharmaceutical composition usually selects parenteral administration, which can be intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous injection, but is not limited to these, for example, it can be administered by infusion or bolus injection.
  • the active ingredients e.g., anti-HER3 antibodies or antigen-binding fragments thereof, or antibody-drug conjugates
  • the pharmaceutical composition of the present disclosure may be a pharmaceutical composition containing only the anti-HER3 antibody or its antigen-binding fragment, or the antibody-drug conjugate of the present disclosure, or a pharmaceutical composition containing the anti-HER3 antibody or its antigen-binding fragment, or the antibody-drug conjugate, and at least one second therapeutic agent (e.g., a cancer therapeutic agent).
  • the antibody-drug conjugate of the present disclosure may also be administered together with other cancer therapeutic agents to enhance the anti-cancer effect.
  • Other anticancer agents used for this purpose may be administered to an individual simultaneously, separately or continuously with the antibody-drug conjugate, or may be administered with a changed administration interval.
  • Exemplary other cancer therapeutic agents such as paclitaxel, cisplatin, vinblastine, etc. are not limited as long as they are agents with anti-tumor activity.
  • the present disclosure also provides a kit, the kit comprising the above-mentioned anti-HER3 antibody or its antigen-binding fragment, or antibody-drug conjugate.
  • the kit may also include a container, a buffer reagent, and a control such as a positive control and a negative control as needed. Those skilled in the art may make corresponding selections as needed. Accordingly, the kit may also include instructions for use to facilitate operation and use by those skilled in the art.
  • the present disclosure provides the use of the above-mentioned anti-HER3 antibody or its antigen-binding fragment, antibody-drug conjugate, pharmaceutical composition, and the antibody-drug conjugate and kit prepared by the above-mentioned method in preparing therapeutic agents for diagnosing, preventing and treating tumor diseases.
  • HER3 antibody or its antigen-binding fragment, antibody-drug conjugate, pharmaceutical composition, and antibody-drug conjugate and kit prepared by the above method in preparing anti-tumor drugs, or in preparing drugs targeting HER3.
  • the anti-HER3 antibody or antigen-binding fragment thereof and antibody-drug conjugate provided by the present disclosure have the function of killing cells expressing HER3 and can be used to kill cells expressing HER3 in vivo or in vitro.
  • the tumor disease includes benign tumors and malignant tumors (e.g., cancer), and in particular, the antibody-drug conjugate is suitable for tumors or cancers in which HER3 expression is observed, and in some embodiments, the tumor or cancer is a solid tumor expressing HER3.
  • benign tumors and malignant tumors e.g., cancer
  • the antibody-drug conjugate is suitable for tumors or cancers in which HER3 expression is observed
  • the tumor or cancer is a solid tumor expressing HER3.
  • the tumor or cancer includes but is not limited to lung cancer, renal cancer, urothelial carcinoma, colorectal cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, metastatic breast cancer, luminal breast cancer, melanoma, liver cancer, bladder cancer, gastric cancer, gastrointestinal stromal tumors, cervical cancer, head and neck cancer, esophageal cancer, epidermoid carcinoma, peritoneal cancer, adult glioblastoma multiforme, liver cancer, hepatocellular carcinoma, colon cancer, rectal cancer, colon and rectal cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, liver malignancies, anal cancer, penile cancer, and lung adenocarcinoma (including EGFR-TKI-resistant lung adenocarcinoma).
  • lung cancer includes but is not limited to lung cancer, renal cancer, urothelial carcinoma, colorectal cancer, prostate cancer
  • the cancer is of breast cancer, lung adenocarcinoma, pancreatic cancer, and colon cancer. In some embodiments, the cancer is of breast cancer, EGFR-TKI-resistant lung adenocarcinoma, pancreatic cancer, and colon cancer.
  • a therapeutic dose of a therapeutic agent is administered to the subject, wherein the therapeutic agent includes the above-mentioned anti-HER3 antibody or antigen-binding fragment thereof, antibody-drug conjugate, antibody-drug conjugate prepared by the above-mentioned method, or the above-mentioned pharmaceutical composition, which can be used for the diagnosis, prevention and treatment of tumor diseases.
  • the present disclosure also provides a method for diagnosing, preventing and treating tumor diseases, comprising: administering a therapeutic dose of a therapeutic agent to a subject in need, wherein the therapeutic agent comprises the above-mentioned anti-HER3 antibody or its antigen-binding fragment, antibody-drug conjugate, antibody-drug conjugate prepared by the above-mentioned method, the above-mentioned pharmaceutical composition or kit.
  • the subject is a mammal, including a human, a non-human primate, a dog, a pig, or a mouse.
  • the subject is a human, such as a patient with a tumor expressing HER3.
  • the therapeutic dosage of the therapeutic agent varies depending on the specific condition being treated, the severity of the condition, individual patient parameters including age, physical condition, size, sex and weight, duration of treatment, nature of concurrent therapy (if any), the specific route of administration, and the knowledge of the health practitioner, etc.
  • the dosage of the active ingredient such as an anti-HER3 antibody or antigen-binding fragment thereof, or antibody-drug conjugate, can be determined empirically in individuals who have been given one or more administrations of the antibody.
  • the acceptable therapeutic dose of the anti-HER3 antibody or antigen-binding fragment thereof, or antibody-drug conjugate is 0.1-30 mg/kg, 0.5-30 mg/kg, 1-30 mg/kg, 1-25 mg/kg, 0.1-25 mg/kg, 0.1-20 mg/kg, 1-20 mg/kg or 0.5-20 mg/kg.
  • the dosing frequency is once every 12 hours, daily, weekly, every 2 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks or every 10 weeks; or once every month, every 2 months or every 3 months or longer.
  • the therapeutic dose and dosing frequency can vary with the treatment regimen.
  • anti-HER3 antibodies or antigen-binding fragments thereof, antibody-drug conjugates or pharmaceutical compositions disclosed herein may also be used in combination with one or more second therapeutic agents, which may be administered simultaneously or sequentially through the same or different administration routes. This may vary depending on the metabolic properties of the therapeutic agent itself and the disease being treated.
  • DCM dichloromethane
  • MeOH methanol
  • EEDQ 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline
  • Compound LP-3 is an intermediate of LP-1. After removing step 6, intermediate 11-5 is LP-3.
  • mice (8-12 weeks old) were immunized with human HER3 protein extracellular region fragment antigen (NCBI reference sequence: NM_001982.4, amino acid sequence 20-643), and their serum titer was monitored to determine the number of immunizations. After 3 to 4 booster immunizations after the initial immunization, mouse serum was taken to detect the titer according to the conventional methods in the art. After the titer detection qualified mice were impact immunized once, the whole spleen and 1/2 of the lymph nodes were taken and PEG fused with myeloma SP2/0 cell line.
  • human HER3 protein extracellular region fragment antigen NCBI reference sequence: NM_001982.4, amino acid sequence 20-643
  • the fused cells were plated and cultured, the supernatants of all wells were collected, the antigens were screened using the ELISA method, and the positive wells with cells under microscopy were transferred to 96-well plates for continued cultivation. After 7 days of growth, the supernatants of all wells were collected and the reaction with the antigen was detected using the ELISA method. The positive wells further tested the antigen binding of different dilutions to perform affinity sorting. The 20 parent clones with the highest immunogenic affinity entered the subclone. Subcloning was performed by limiting dilution and ELISA screening to obtain hybridoma cell lines.
  • Mu4O3 Mouse ascites was prepared from the hybridoma cell line, and the monoclonal antibody was obtained after collection and purification, named Mu4O3, and the amino acid sequences of its CDR and variable regions were determined, as shown in Table 1 below, where CDR (Kabat system definition and numbering) is underlined.
  • L1H4, L1H5, L2H4, L2H5, L4H4, L4H5 and L4H7 represent the numbers of the antibody heavy chain variable region sequences
  • the L1H4 antibody includes a light chain variable region numbered L1 and a heavy chain variable region numbered H4
  • the L1H5 antibody includes a light chain variable region numbered L1 and a heavy chain variable region numbered H5
  • the L2H4 antibody includes a light chain variable region numbered L2 and a heavy chain variable region numbered H4
  • the L2H5 antibody includes a light chain variable region numbered L2 and a heavy chain variable region numbered H5
  • the L4H4 antibody includes a light chain variable region numbered L4 and a heavy chain variable region numbered H4
  • the L1H4 antibody includes a light chain variable region numbered L1 and a heavy chain variable region numbered H4
  • the L1H5 antibody includes a light chain variable region numbered L1 and a heavy chain variable region numbered H5
  • CDR sequences underlined and variable region sequences of Hu4O3 are shown in Table 2 below, where the mutated amino acids in CDR2 of VH are shown in bold italics. CDRs are defined and numbered using the Kabat system.
  • the constant region of the above-mentioned antibody is selected from the constant region of human IgG1, wherein the heavy chain constant region sequence is selected from the amino acid sequence shown in SEQ ID NO:17, and the light chain constant region sequence is selected from the amino acid sequence shown in SEQ ID NO:18.
  • the antibody-drug conjugate is concentrated, liquid is replaced, purified, and the antibody concentration is measured according to the following method, and the average number of drug molecules carried by each antibody is calculated to identify the antibody-drug conjugate.
  • the absorbance of the antibody was measured using an ELISA reader (Multiskan GO, Thermo Fisher Scientific) according to the method defined by the manufacturer.
  • the ratio of the absorbance value to the absorption coefficient of the antibody at that wavelength was the concentration of the antibody.
  • a zeba desalting column (5 mL, 40K MWCO) was pre-equilibrated with phosphate buffered saline (PBS7.0/EDTA, 50 mM, pH 7.0) containing sodium chloride (50 mM) and EDTA (2 mM). 2 mL was loaded on each zeba desalting column, centrifuged (1000 g, 4 min), the flow-through fraction was collected and concentrated by operation A, the antibody concentration was determined by operation B, and the antibody concentration was adjusted with PBS7.0/EDTA.
  • PBS7.0/EDTA phosphate buffered saline
  • a zeba desalting column (5 mL, 40K MWCO) was pre-equilibrated with storage buffer according to the instructions provided by the manufacturer (Thermo Fisher Scientific).
  • the storage buffer used was histidine-acetate buffer (20 mM histidine, pH 5.5) containing 150 mM sodium chloride or phosphate buffer (50 mM, pH 7.0) containing 50 mM sodium chloride.
  • the reaction solution containing the antibody-drug conjugate (approximately 2 mL) was added to the zeba desalting column, and the flow-through fraction (approximately 2 mL) was collected after centrifugation (1000 g, 4 minutes). The elution process was repeated twice to remove unbound linker-payload and low molecular weight compounds including reducing agents.
  • Procedure E Measure the concentration of the antibody in the antibody-drug conjugate and the average number of drug molecules attached to each antibody (DAR value)
  • the concentration of the drug coupled to the antibody-drug conjugate can be obtained by measuring the ultraviolet absorption value of the antibody-drug conjugate aqueous solution at 280 nm and 370 nm and calculating it using the following formula.
  • the total absorbance of a system is equal to the sum of the absorbances of all light-absorbing chemicals present in the system (additivity of absorbance). Therefore, assuming that the molar absorption coefficients of the antibody and drug remain unchanged before and after conjugation, the antibody concentration and drug concentration in the antibody-drug conjugate can be expressed by the following formula.
  • a 280 represents the total absorbance of the antibody-drug conjugate aqueous solution at 280 nm
  • a 370 represents the total absorbance of the antibody-drug conjugate aqueous solution at 370 nm.
  • a A,280 represents the absorbance of the antibody at 280 nm
  • a A,370 represents the absorbance of the antibody at 370 nm
  • AD,280 represents the absorbance of the drug molecule at 280 nm
  • AD,370 represents the absorbance of the drug molecule at 370 nm
  • ⁇ A,280 represents the molar extinction coefficient of the antibody at 280 nm
  • ⁇ A,370 represents the molar extinction coefficient of the antibody at 370 nm
  • ⁇ D,280 represents the molar extinction coefficient of the drug molecule at 280 nm
  • ⁇ D,370 represents the molar extinction coefficient of the drug molecule at 370 nm
  • CA represents the concentration of the antibody in the antibody-drug conjugate
  • ⁇ A,280 , ⁇ A,370 , ⁇ D,280 and ⁇ D,370 are known values (calculated from the sequence of the antibody or measured by UV absorption of the compound).
  • ⁇ A,280 can be calculated from the amino acid sequence of the antibody using a known method (Protein Science, 1995, Vol. 4, pp. 2411-2423).
  • Antibodies usually have no absorption at 370 nm, so ⁇ A,370 is usually 0.
  • CA and CD can be obtained by measuring the absorbance values A 280 and A 370 of the antibody-drug conjugate at 280 nm and 370 nm, and then solving the two-variable linear equation system formulas (1) and (2). In addition, by dividing CD by CA , the average number of drug molecules attached to each antibody (DAR value) can be obtained.
  • the size exclusion chromatogram of the quality control (QC, L1H5 naked antibody, i.e., the antibody numbered L1H5 without the conjugated linker-payload) is shown in Figure 1A; the retention time of the main peak (single peak) of the 150 kDa quality control is between 9.5 and 10.5 minutes.
  • the retention time of the aggregate should be earlier than the retention time of the above monomer.
  • the hydrophobicity of the antibody-drug conjugate was analyzed using HPLC hydrophobic chromatography (HIC) as follows:
  • Mobile phase A 1 mol/L (NH 4 ) 2 SO 4 , 50 mmol/L KHPO 4 , pH 7.0
  • Mobile phase B 50mmol/L KHPO 4 , 25% (v/v) isopropanol, pH 7.0
  • the antibody L1H5 prepared in Example 4 was replaced with PBS7.0/EDTA by operation B in Example 5 (the extinction coefficient of the antibody at 280 nm was 1.49 mL mg -1 cm -1 ) and operation C.
  • the antibody concentration after replacement was 20.76 mg/mL.
  • 93.33 ⁇ L of 5 mM TCEP solution (equivalent to 7 times the antibody content) was added to 481.70 ⁇ L of the aqueous solution of the L1H5 antibody, and 200 ⁇ L of 50 mM phosphate buffer (pH 7.0, PBS7.0) and 224.97 ⁇ L of ultrapure water were added at the same time, and the mixture was placed in a 37°C environment for reaction for 2 hours.
  • FIG2A shows the detection spectrum of the aggregates, and the aggregate content of the antibody-drug conjugate L1H5-LP3 measured by operation F is 2.20%.
  • FIG2B shows the hydrophobic chromatography detection spectrum of the antibody-drug conjugate L1H5-LP3, and the retention time of the antibody-drug conjugate measured by operation G is 6.169 min.
  • the antibody solution was replaced with PBS7.0/EDTA by operation B of Example 5 (the extinction coefficient of the antibody at 280 nm was 1.49 mL mg -1 cm -1 ) and operation C.
  • the antibody concentration after the replacement was 11.44 mg/mL.
  • 160 ⁇ L of 5 mM TCEP solution (equivalent to 10 times the antibody content) was added to 1048.95 ⁇ L of the aqueous solution of the L1H5 antibody prepared in Example 4, and 320 ⁇ L of 50 mM PBS7.0 and 71.05 ⁇ L of ultrapure water were added at the same time, and the mixture was placed in a 37°C environment for reaction for 2 hours.
  • FIG3A shows the detection spectrum of the aggregates, and the aggregate content of the antibody-drug conjugate L1H5-LP1 measured by operation F is 1.60%.
  • FIG3B shows the hydrophobic chromatography detection spectrum of the antibody-drug conjugate L1H5-LP1, and the retention time of the antibody-drug conjugate L1H5-LP1 measured by operation G is 6.234 min.
  • Antibody reduction The antibody solution was replaced with PBS7.0/EDTA by operation B of Example 5 (the extinction coefficient of the antibody at 280 nm was 1.49 mL mg -1 cm -1 ) and operation C. The antibody concentration after the replacement was 11.44 mg/mL. 160 ⁇ L of 5 mM TCEP solution (equivalent to the antibody content) was added to 1048.95 ⁇ L of the aqueous solution of the L1H5 antibody prepared in Example 4. 10 times the equivalent of 50 ⁇ L of PBS7.0 (320 ⁇ L) and 71.05 ⁇ L of ultrapure water were added, and the mixture was placed at 37°C for 2 hours.
  • FIG4A shows the detection spectrum of the aggregates, and the aggregate content of the antibody-drug conjugate L1H5-LP2 measured by operation F is 1.89%.
  • FIG4B shows the hydrophobic chromatography detection spectrum of the antibody-drug conjugate L1H5-LP2, and the retention time of the antibody-drug conjugate L1H5-LP2 measured by operation G is 6.599 min.
  • the antibody was replaced with PBS7.0/EDTA by operation B in Example 5 (the extinction coefficient of the antibody at 280nm was 1.77mLmg - 1cm -1 ) and operation C, and the antibody concentration after the replacement was 9.44mg/mL.
  • 3.27 ⁇ L of 5mM TCEP solution (equivalent to 7 times the antibody content) was added to 0.037mL of the reference antibody (see SEQ ID NO: 69-72, U1-59 in patent US20190151328A1 for the antibody sequence), and 14 ⁇ L of 50mM PBS7.0 and 15.66 ⁇ L mL of deionized water were added at the same time, and the mixture was placed in a 37°C environment for reaction for 2 hours.
  • Coupling of antibody and linker-payload Incubate the above mixture at 4°C for 10 minutes. Dissolve the linker-payload GGFG-DXd (purchased from DC Chemicals, DC50025) in DMA and add it to the mixture at a volume of 3.27 ⁇ L (equivalent to 14 times the antibody content). Continue to react at 22°C for 30 minutes.
  • FIG23A shows the detection spectrum of aggregates, and the aggregate content of the antibody-drug conjugate reference ADC measured by operation F was 2.04%.
  • FIG23B shows the detection spectrum of the antibody-drug conjugate reference ADC. According to the hydrophobic chromatography detection spectrum of ADC, the retention time of the antibody-drug conjugate reference antibody-DXd measured by operation G was 8.215 min.
  • FIG. 22 shows a comparison of the hydrophobicity measurements of the L1H5 antibody prepared in Example 4, the antibody-drug conjugate L1H5-LP3 prepared in Example 6, the reference antibody, and the antibody-drug conjugate reference ADC, and Table 3 shows the retention time of each test sample.
  • the results show that the retention time of the L1H5 antibody and L1H5-LP3 is shorter than that of the positive control reference antibody and the drug-antibody conjugate reference ADC, indicating that both the reference antibody and the drug-antibody conjugate reference ADC are more hydrophobic than the L1H5 antibody and the antibody-drug conjugate L1H5-LP3. It can be expected that due to the weak hydrophobicity of the L1H5 antibody and L1H5-LP3, they have higher stability in vivo.
  • Antibody reduction The antibody was replaced with PBS7.0/EDTA by operation B in Example 5 (the extinction coefficient of the antibody at 280 nm was 1.77 mL mg -1 cm -1 ) and operation C.
  • the antibody concentration after replacement was 15.5 mg/mL.
  • 268.80 ⁇ L of 5 mM TCEP solution (equivalent to 7 times the antibody content) was added to 1.858 mL of the aqueous solution of the reference antibody (same sequence as in comparative example 1), and 360 ⁇ L of 100 mM PBS7.0 and 1113.14 ⁇ L of deionized water were added at the same time, and the mixture was placed in a 37°C environment for reaction for 2 hours.
  • FIG24A shows the detection spectrum of aggregates, and the aggregate content of the antibody-drug conjugate reference antibody-LP3 measured by operation F was 1.92%.
  • FIG24B shows the detection spectrum of the antibody-drug conjugate Referring to the hydrophobic chromatography detection spectrum of antibody-LP3, the retention time of the antibody-drug conjugate reference antibody-MCE8 measured by operation G was 6.262 min.
  • Antibody reduction The antibody solution was replaced with PBS7.0/EDTA by operation B in Example 5 (the extinction coefficient of the antibody at 280 nm was 1.49 mL mg -1 cm -1 ) and operation C. The antibody concentration after the replacement was 11.44 mg/mL. 90 ⁇ L of 5 mM TCEP solution (equivalent to 10 times the antibody content) was added to 0.59 mL of the aqueous solution of the L1H5 antibody, and 180 ⁇ L of 50 mM PBS7.0 and 39.97 ⁇ L of deionized water were added at the same time, and the mixture was placed at 37°C for 2 hours.
  • Coupling of antibody and linker-payload Incubate the above mixture at 4°C for 10 minutes. Dissolve the linker-payload GGFG-DXd (purchased from DC Chemicals, DC50025) in DMA and add it to the mixture at a volume of 67.50 ⁇ L (equivalent to 15 times the antibody content). Continue to react at 22°C for 30 minutes.
  • the concentration of the antibody-drug conjugate was calculated by operation E to be 5.17 mg/mL, and the number of effective loads coupled on each antibody was calculated by operation E to be 6.54.
  • Figure 25A shows the detection spectrum of the aggregates, and the aggregate content of the antibody-drug conjugate L1H5-DXd measured by operation F is 2.02%.
  • Figure 25B shows the hydrophobic chromatography detection spectrum of the antibody-drug conjugate L1H5-DXd, and the retention time of the antibody-drug conjugate L1H5-DXd measured by operation G is 7.807 min.
  • the antibody was replaced with PBS7.0/EDTA by operation B in Example 5 (the extinction coefficient of the antibody at 280 nm was 1.35 mL mg -1 cm -1 ) and operation C.
  • the antibody concentration after replacement was 10 mg/mL. 326.67 ⁇ L of 5 mM TCEP solution (equivalent to 10 times the antibody content) was added to 2.45 mL of an aqueous solution of isotype control antibody human IgG (purchased from Beijing Solebow Technology Co., Ltd., product model SP001), and 700 ⁇ L of 50 mM PBS7.0 and 23.33 ⁇ L of deionized water were added at the same time, and the mixture was placed in a 37°C environment for reaction for 2 hours.
  • Coupling of antibody and linker-payload Incubate the above mixture at 4°C for 10 minutes, dissolve the linker-payload GGFG-DXd in DMA and add it to the mixture in a volume of 294 ⁇ L (equivalent to 18 times the antibody content), and continue to react at 22°C for 30 minutes.
  • FIG. 26A shows the detection spectrum of the aggregates, and the aggregate content of the antibody-drug conjugate Dxd isotype control ADC measured by operation F is 4.25%.
  • FIG. 26B shows the hydrophobic chromatography detection spectrum of the antibody-drug conjugate Dxd isotype control ADC, and the retention time of the antibody-drug conjugate Dxd isotype control ADC measured by operation G is 8.222 min.
  • the antibody solution was replaced with PBS7.0/EDTA by operation B in Example 5 (the extinction coefficient of the antibody at 280 nm was 1.35 mL mg -1 cm -1 ) and operation C.
  • the antibody concentration after the replacement was 10 mg/mL.
  • 672 ⁇ L of 5 mM TCEP solution (equivalent to 7 times the antibody content) was added to 4 mL of aqueous solution of isotype control antibody human IgG, and 1440 ⁇ L of 50 mM PBS7.0 and 1088 ⁇ L of deionized water were added at the same time, and the mixture was placed at 37°C for reaction for 2 hours.
  • the concentration of the antibody-drug conjugate was calculated by operation E to be 7.42 mg/mL, and the number of effective loads coupled on each antibody was calculated by operation E to be 7.28.
  • Figure 27A shows the detection spectrum of the aggregates, and the aggregate content of the antibody-drug conjugate LP3 isotype control ADC measured by operation F is 5.37%.
  • Figure 27B shows the hydrophobic chromatography detection spectrum of the antibody-drug conjugate LP3 isotype control ADC, and the retention time of the antibody-drug conjugate LP3 isotype control ADC measured by operation G is 6.450 min.
  • MCF-7 human breast cancer cells, purchased from the Cell Bank of Type Culture Collection Committee of the Chinese Academy of Sciences
  • SW620 human colon cancer cells, purchased from Zhejiang Meisen Cell Technology Co., Ltd.
  • SK-BR-3 human breast cancer cells, purchased from Zhejiang Meisen Cell Technology Co., Ltd.
  • MDA-MB-231 human breast cancer cells, purchased from Subic (Shanghai) Biotechnology Co., Ltd.
  • MDA-MB-231 human breast cancer cells, purchased from Subic (Shanghai) Biotechnology Co., Ltd.
  • the Mu4O3 antibody prepared in Example 4 was added at a final concentration of 20 ⁇ g/mL and incubated for 1h, and then washed twice with phosphate buffer (PBS, pH 7.2-7.4) and FITC-labeled goat anti-mouse secondary antibody (purchased from Jackson ImmunoResarch, item number 111-545-003) was added at 1:500 and incubated for 1h, and finally washed twice with PBS and analyzed using a flow cytometer.
  • PBS phosphate buffer
  • FITC-labeled goat anti-mouse secondary antibody purchased from Jackson ImmunoResarch, item number 111-545-003
  • 293T cells (purchased from the cell bank of the Chinese Academy of Sciences Typical Culture Collection Committee) were inoculated in a 24-well cell culture plate to a cell density of 70%.
  • the human HER3 recombinant plasmid HER3-GFP Tag with a GFP tag (purchased from Hunan Keai Medical Instrument Co., Ltd., catalog number G109862) was transfected with the cationic polymer-polyethyleneimine (PEI) transfection method.
  • the specific method was as follows: 0.5 ⁇ g of plasmid and 1.5 ⁇ g of PEI were mixed in 500 ⁇ L of Opti-MEM medium (purchased from Thermo Fisher Scientific (China) Co., Ltd., catalog number 31985070).
  • FIG. 6 shows the immunofluorescence image of Mu4O3 antibody in HER3-GFP Tag overexpressing 293T cells. The results show that HER3 protein and Mu4O3 antibody staining have obvious co-localization characteristics.
  • the picture marked with GFP shows only green fluorescence, indicating that HER3 protein was successfully transfected into 293T cells and expressed in both the cytoplasm and the cell membrane;
  • the picture marked with Mu4O3 shows only red fluorescence, indicating that the Mu4O3 antibody successfully stained the overexpressed cells, and the staining was membrane-localized;
  • the picture marked with DAPI shows only blue fluorescence, indicating that it was staining of the cell nucleus;
  • the picture marked with MERGED is a merged picture after superimposing the above three separate staining pictures, in which part of the membrane-localized green light can completely overlap with the membrane-localized red light, and the fluorescence intensity is consistent, proving that the Mu4O3 antibody specifically stains the overexpressed HER3 protein, and no Mu4O3-bound red fluorescence staining was found in cells without overexpression (only the cell nucleus is stained with blue, no green light), indicating that the Mu4O3 antibody has no non-specific stain
  • Test Example 3 In vitro killing test of SW620 cells by Mu4O3 antibody
  • SW620 cells human colon cancer cells, purchased from Zhejiang Meisen Cell Technology Co., Ltd.
  • SW620 cells human colon cancer cells, purchased from Zhejiang Meisen Cell Technology Co., Ltd.
  • the cells were collected and plated on a 96-well plate to adjust the cell density to 2-5x 10 4 /ml.
  • 100 ⁇ l was added to each well, and the Mu4O3 antibody or mouse anti-IgG (MouseIgG, purchased from Abimate Pharmaceutical Technology (Shanghai) Co., Ltd.) prepared in Example 4 was diluted 3 times from 300 nM as the starting concentration.
  • the cell culture medium was added, and 2 ⁇ g/mL of MMAE-coupled sheep anti-mouse secondary antibody (purchased from Abimate Pharmaceutical Technology (Shanghai) Co., Ltd., item number B30008) was added at the same time, and the cell apoptosis was observed regularly during the period.
  • 15 ⁇ l of CCK-8 stock solution was added directly to the 96-well plate, and the absorbance at 450 nm was measured after reacting in a 37°C incubator for 0.5-2h, and the cell survival curve was drawn according to the test results and the antibody dilution gradient.
  • Test Example 4 Flow cytometry affinity test of Hu4O3 antibody candidate molecules in MDA-MB-453 and SW620 cell lines
  • SW620 human colon cancer cells
  • MDA-MB-453 human breast cancer cells, purchased from Zhejiang Meisen Cell Technology Co., Ltd.
  • Hu4O3 antibody was diluted 3 times with a starting concentration of 500nM. After completion, the gradient diluted Hu4O3 antibody was added to the cells and incubated for 1h.
  • FITC-labeled goat anti-human secondary antibody purchased from Jackson ImmunoResarch, catalog number 109-545-008 was added at 1:500 and incubated for 1h. Finally, after washing with PBS twice, the results were analyzed by flow cytometry.
  • FIGS 8 and 9 show the flow affinity detection data of Hu4O3 antibody candidate molecules L1H4, L1H5, L2H4, L2H5, L4H4, L4H5, and L4H7 in MDA-MB-453 and SW620 cell lines.
  • the results show that all candidate molecules have specific binding to both cell lines, and the binding affinities are different.
  • L1H4 and L1H5 show better affinity for MDA-MB-453 cells, with EC 50 of 71.5nM and 121.7nM, respectively.
  • L1H4, L1H5, L4H4, and L4H7 show better affinity for SW620 cells, with EC 50 of 193.5nM, 146.7nM, 90.0nM, and 21.9nM, respectively, followed by L2H4, with an EC 50 of 1203nM.
  • Test Example 5 In vitro cell proliferation inhibition experiment of L1H5 antibody and reference antibody on SK-BR-3 cell line
  • SK-BR-3 human breast cancer cells
  • the cell density was adjusted to 2-5x 10 4 /ml. 100 ⁇ l was plated per well, and the antibody was added to the cell culture medium at a final concentration of 100 ⁇ g/ml and cultured for 5 days. Cell apoptosis was observed regularly during this period. After 5 days, 15 ⁇ l of CCK-8 stock solution was added to the 96-well plate, and the absorbance at 450 nm was measured after reacting in a 37°C incubator for 0.5-2 hours. The cell survival ratio was calculated based on the test results compared with the blank control.
  • Figure 10 shows the cell proliferation inhibition rates of the L1H5 antibody, the reference antibody and the blank control in the SK-BR-3 cell line prepared in Example 4. The results show that the in vitro cell proliferation inhibition effect of L1H5 on SK-BR-3 is better than that of the reference antibody.
  • Test Example 6 In vivo tumor inhibition experiment in mouse breast cancer CDX model
  • FIG. 11 shows the in vivo tumor volume-time curve of the BT-474 breast cancer mouse model. The results show that L1H5 can inhibit tumor growth and is comparable to the positive reference antibody.
  • Test Example 7 In vitro killing test of Hu4O3 antibody candidate molecule-drug conjugate on SW620 cells
  • Culture SW620 human colon cancer cells to a cell density of 80%, collect cells, spread on 96-well plates, and adjust the cell density to 2-5x 10 4 /ml. Spread 100 ⁇ l per well, and dilute the ADC molecule 3 times with a starting concentration of 300nM. After the dilution is completed, add cell culture medium and culture for 5 days. During this period, observe cell apoptosis regularly. After 5 days, add 15 ⁇ l CCK-8 stock solution to the 96-well plate, react in a 37°C incubator for 0.5-2h, measure the absorbance at 450nm, and draw a cell survival curve based on the test results and the dilution gradient of ADC.
  • Figure 12 shows the cell survival curves of the antibody-drug conjugates L1H4-LP1, L1H5-LP1, L4H4-LP1 prepared in Example 7 and the antibody-drug conjugate positive control reference ADC prepared in Comparative Example 1 in the SW620 cell line.
  • the results show that the in vitro cell killing effects of L1H4-LP1, L1H5-LP1 and L4H4-LP1 on the SW620 cell line are better than those of the reference ADC, and L1H5-LP1 has the best cell proliferation inhibition effect on the SW620 cell line.
  • Test Example 8 In vitro cell killing experiment of L1H5 antibody, L1H5-LP3, reference antibody, and reference ADC on SK-BR-3 and BXPC-3 cell lines
  • SK-BR-3 human breast cancer cells
  • BXPC-3 human pancreatic cancer cells, purchased from the Cell Bank of the Chinese Academy of Sciences Typical Culture Collection Committee
  • CCK-8 stock solution was added to the 96-well plate, and the absorbance at 450nm was measured after reacting in a 37°C incubator for 0.5-2h.
  • the cell survival curve was drawn based on the test results and the dilution gradient of the antibody and ADC.
  • Figures 13 and 14 are cell survival curves of the L1H5 antibody prepared in Example 4, the antibody-drug conjugate L1H5-LP3 prepared in Example 6, the reference antibody (positive control), and the antibody-drug conjugate reference ADC (positive control) prepared in Comparative Example 1 in SK-BR-3 cell line and BXPC-3 cell line, respectively.
  • the results show that the in vitro cell killing effect of L1H5-LP3 on the two cell lines is significantly better than that of the reference ADC, the cell proliferation inhibition effect of L1H5 antibody on the SK-BR-3 cell line is better than that of the reference antibody, and neither the L1H5 antibody nor the reference antibody exhibits an in vitro killing effect on the BXPC-3 cell line.
  • Test Example 9 In vitro killing test of HCT-15 cells by L1H5-LP1 and L1H5-LP2
  • HCT-15 human colon cancer cells
  • HCT-15 human colon cancer cells
  • the cells were collected and plated on a 96-well plate to adjust the cell density to 2-5x 10 4 /ml. 100 ⁇ l was plated per well, and the ADC molecule was diluted 3 times with a starting concentration of 300nM. After the dilution was completed, the cell culture medium was added and cultured for 5 days. Cell apoptosis was observed regularly during this period. After 5 days, 15 ⁇ l of CCK-8 stock solution was added to the 96-well plate, and the absorbance at 450nm was measured after reacting in a 37°C incubator for 0.5-2h. The cell survival curve was drawn based on the test results and the dilution gradient of the ADC.
  • Figure 15 is a cell survival curve of the antibody-drug conjugate L1H5-LP1 prepared in Example 7, L1H5-LP2 prepared in Example 8, and the antibody-drug conjugate positive control reference ADC prepared in Comparative Example 1 in the HCT-15 cell line. The results show that the in vitro cell killing effects of L1H5-LP1 and L1H5-LP2 on the HCT-15 cell line are significantly better than those of the reference ADC.
  • Test Example 10 In vivo tumor inhibition experiment in mouse colon cancer CDX model
  • Balb/c nude mice aged 6 weeks were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. Five million HCT-15 cells were subcutaneously inoculated in each mouse.
  • the reference ADC prepared in Comparative Example 1 L1H5-LP2 prepared in Example 8, and L1H5-LP1 prepared in Example 7 were intravenously injected at a dose of 10 mg/kg, and a blank control (negative control) group was set up, and the same dose of PBS was intravenously injected. Once a week, a total of three doses.
  • FIG. 16 shows the in vivo tumor volume-time change curve of the HCT-15 colon cancer mouse model. The results show that both L1H5-LP1 and L1H5-LP2 can inhibit tumor growth and are slightly better than the positive reference ADC.
  • Test Example 11 In vivo tumor inhibition experiment in mouse colon cancer PDX model
  • 6-week-old NU/NU mice female, weighing 18-21 g, were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. Mice were subcutaneously inoculated with colon cancer tumors (the specimen number of colon cancer tissue was 361795, from Xi'an Lidi Biotechnology Co., Ltd.).
  • FIG. 17 shows a graph of the in vivo tumor volume-time changes in a colon cancer mouse model. The results show that, compared with the positive control reference ADC, L1H5-LP3 and L1H5-LP1 significantly inhibited tumor growth.
  • Test Example 12 In vivo tumor inhibition experiment in mouse EGFR-TKI-resistant lung adenocarcinoma PDX model
  • 6-week-old female NU/NU mice weighing 18-21 g, were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. Each mouse was subcutaneously inoculated with EGFR-TKI-resistant lung adenocarcinoma tumors (the specimen number of EGFR-TKI-resistant lung adenocarcinoma tissues is 0025- 200717, from Xi'an Lidi Biotechnology Co., Ltd.).
  • FIG. 18 shows the in vivo tumor volume-time curve of the EGFR-TKI-resistant lung adenocarcinoma mouse model. The results show that L1H5-LP3 and L1H5-LP1 significantly inhibited tumor growth compared with the positive control reference ADC.
  • Test Example 13 In vivo tumor inhibition experiment in mouse colon cancer CDX model
  • Balb/c nude mice aged 6 weeks were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. Five million SW620 cells were subcutaneously inoculated in each mouse.
  • L1H5-DXd prepared in Comparative Example 3 reference antibody-LP3 prepared in Comparative Example 2, L1H5-LP3 prepared in Example 6, reference ADC prepared in Comparative Example 1, and negative control PBS were intravenously injected at a dose of 10 mg/kg.
  • FIG19 is an in vivo tumor volume-time curve of the mouse colon cancer CDX model. It can be seen that L1H5-DXd, L1H5-LP3 and reference antibody-LP3 are more advantageous than the positive control reference ADC.
  • Figure 20 is a partial enlarged view after removing the negative control PBS group from Figure 19. It can be clearly seen from the figure that the four active molecules are arranged from high to low according to the overall in vivo tumor inhibition effect, namely L1H5-LP3>L1H5-DXd>reference antibody-LP3>reference ADC.
  • Test Example 14 In vivo tumor inhibition experiment in mouse pancreatic cancer CDX model
  • 6-week-old female NU/NU mice weighing 18-21 g were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. Each mouse was subcutaneously inoculated with a pancreatic cancer tumor (the specimen number of pancreatic cancer tissue is: 0033-361319, from Xi'an Lidi Biotechnology Co., Ltd.).
  • the reference ADC prepared in Comparative Example 1, L1H5-LP3 prepared in Example 6, and L1H5-LP1 prepared in Example 7 were intravenously injected at a dosage of 10 mg/kg; the Dxd isotype control ADC prepared in Comparative Example 4 and the LP3 isotype control ADC prepared in Comparative Example 5 were respectively administered, and a blank control group was set up and intravenously injected with an equal dose of PBS.
  • the administration was once a week for a total of three times.
  • Figure 21 is the in vivo tumor inhibition curve of the pancreatic cancer mouse model.
  • the results show that the positive control reference ADC, L1H5-LP3 and L1H5-LP1 can significantly inhibit tumor growth in the initial stage of administration.
  • the tumor inhibition effects of L1H5-LP3 and L1H5-LP1 are significantly better than those of the positive control reference ADC; and the duration of tumor inhibition is significantly longer than that of the reference ADC.
  • the antibody-drug conjugate prepared in the embodiment of the present disclosure has a more excellent in vivo anti-tumor effect than the ADC coupled with GGFG-DXd.
  • L1H5-LP3 has an in vivo efficacy superior to that of the reference ADC in multiple tumor models; and L1H5-LP3 has a more lasting tumor inhibition effect in individual models.
  • L1H5-LP3 has a similar maximum tolerated dose (MTD) as the GGFG-Dxd ADC. It is expected that the drug conjugate has a higher therapeutic window than the ADC coupled with GGFG-Dxd.
  • the antibody-drug conjugate provided by the present disclosure has excellent safety.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

抗体-药物偶联物及其制备方法和在抗肿瘤中的用途，具体涉及抗HER3抗体或其抗原结合片段和连接该抗体的抗体-药物偶联物。所述抗体-药物偶联物具有如Ab-(L-D)n所示的结构，通过连接子与具有细胞毒性的有效荷载共价连接。所述抗HER3抗体或其抗原结合片段和抗体-药物偶联物具有在制备诊断、预防、治疗肿瘤疾病的治疗剂中的用途。

Description

抗体-药物偶联物及其制备方法和在抗肿瘤中的用途 技术领域
本公开涉及抗HER3的抗体及抗体-药物偶联物，其通过疏水性改善的连接子连接具有特异性靶向的抗体和抗肿瘤的药物或毒素，以表达HER3的肿瘤细胞为靶标发挥抗肿瘤作用。
背景技术
抗体-药物偶联物(Antibody-Drug Conjugate；ADC)是一种基于载体的化疗，能够选择性地向肿瘤/癌细胞递送有效的细胞毒性药物(Antibody-Drug Conjugates:The Last Decade，Nicolas Joubert等，Pharmaceuticals(Basel).2020 Sep 14；13(9):245.)。已上市的ADC药物Enhertu和Sacituzumab govitecan在治疗肿瘤尤其是恶性肿瘤方面具有优越的效果，二者均使用疏水性强于微管蛋白抑制剂(例如MMAE,MMAF)的DNA拓扑异构酶抑制剂喜树碱衍生物为细胞毒性药物。Sacituzumab govitecan以MCC-triazole spacer-PEG7-lysine-PABC为连接子，在细胞溶酶体中分解释放喜树碱SN38(US13/948,732)；阿斯利康/第一三共研发的Enhertu以组织蛋白酶B活化的GGFG(由通过肽键连接的甘氨酸-甘氨酸-苯丙氨酸-甘氨酸组成的氨基酸序列)四肽作为连接子，并引入自裂解结构，释放出Exatecan衍生物Dxd(Yusuke Ogitani等，Clin Cancer Res(2016)22(20):5097–5108.)。然而，由于DNA拓扑异构酶抑制剂的刚性结构及亲水性差等理化特点，上述ADC分子在制备中产生大量聚集体，直接影响ADC治疗的安全性和有效性。
HER3(NCBI，Gene ID:2065)是HER(EGFR/ErbB)受体家族的成员，该家族由四种密切相关的1型跨膜受体(EGFR、HER2、HER3和HER4)组成。靶向EGFR和HER2酪氨酸激酶活性的单克隆抗体和小分子抑制剂在治疗若干类型的癌症中表现出临床益处，但其临床疗效受到耐药性的限制。HER3在EGFR家族中处于特殊地位，它几乎没有细胞内的酪氨酸激酶活性，而且无法形成同源二聚体，无法单独行使功能，其激酶活性依赖于和其他EGFR家族的成员比如EGFR或者HER2形成异源二聚体。当HER3蛋白和HER2形成异源二聚体时，其下游通路就会被激活，抑制HER3下游通路激活可以间接抑制癌细胞的生长，增殖和转移。因此HER3在EGFR和HER2靶向治疗的耐药性中起着重要作用(Clin Cancer Res；20(6)March 15,2014)。
目前，靶向HER3的在研ADC药物仅有第一三共的Patritumab Deruxtecan(HER3-DXd，代号U3-1402)。该ADC结构由HER3单抗Patritumab和拓扑异构酶1抑制剂exatecan衍生 物(Deruxtecan)通过可裂解的连接子GGFG拼接而成，旨在满足EGFR-TKI耐药和化疗失败非小肺癌患者这一广大群体的未满足临床需要。
因此，仍然存在靶向HER3的新的抗体及抗体-药物偶联物的需求。
发明内容
本公开提供了一种抗HER3抗体或其抗原结合片段，包括至少一个VL和VH，其中，VL的CDR1包含如SEQ ID NO:1所示的氨基酸序列，CDR2包含如SEQ ID NO:2所示的氨基酸序列，CDR3包含如SEQ ID NO:3所示的氨基酸序列；VH的CDR1包含如SEQ ID NO:4所示的氨基酸序列，CDR2包含与SEQ ID NO:5所示的氨基酸序列相差不超过5,4,3,2,1,0个突变的氨基酸序列，CDR3包含如SEQ ID NO:6所示的氨基酸序列。
在一些实施方式中，抗HER3抗体或其抗原结合片段中，VH的CDR2包含选自(a)或(b)中的一个或多个突变；
(a)C52N，T62N，T66K和G67S；
(b)C52Y，T62N，T66K和G67S。
在一些实施方式中，抗HER3抗体或其抗原结合片段中，VH的CDR2包含(a)或(b)的突变：
(a)C52N，T62N，T66K和G67S；
(b)C52Y，T62N，T66K和G67S。
本公开提供了一种编码上述抗HER3抗体或其抗原结合片段的核酸。
本公开提供了一种包含编码上述抗HER3抗体或其抗原结合片段的核酸的载体。
本公开提供了一种宿主细胞，其包含上述核酸和/或载体。
本公开提供了一种具有式I所示结构的抗体-药物偶联物，
Ab-(L-D)n(I)
或其异构体、同位素变体、药学上可接受的盐、前药、溶剂合物，或其组合，
其中，Ab是前述的抗HER3抗体或其抗原结合片段；
L是分别与Ab和D共价连接的连接子；
D是有效荷载；
n为1～10之间的数值。
本公开提供了一种抗体-药物偶联物的制备方法，包括以下步骤：抗体或其抗原结合片段经还原处理后链间二硫键至少部分被还原，与连接子-有效荷载中连接子的反应基团反应，得到具有式I所示结构的抗体-药物偶联物，
Ab-(L-D)n(I)
或其异构体、同位素变体、药学上可接受的盐、前药、溶剂合物，或其组合，
其中，Ab是上述的抗HER3抗体或其抗原结合片段；
L是分别与Ab和D共价连接的连接子；
D是有效荷载；
n为1～10之间的数值。
本公开提供了一种药物组合物，其包括上述的抗HER3抗体或其抗原结合片段或抗体-药物偶联物，或其异构体、同位素变体、药学上可接受的盐、前药、溶剂合物，或其组合，以及药学可接受的辅料。
本公开提供了一种试剂盒，其包括上述的抗HER3抗体或其抗原结合片段或抗体-药物偶联物，或其异构体、同位素变体、药学上可接受的盐、前药、溶剂合物，或其组合。
本公开提供了一种上述抗HER3抗体或其抗原结合片段、抗体-药物偶联物、上述方法制备的抗体-药物偶联物、药物组合物或者上述的试剂盒在制备诊断、预防、治疗肿瘤疾病的治疗剂中的用途。
在一些实施方式中，所述用途包括在制备靶向HER3的药物中的用途。
在一些实施方式中，所述肿瘤包括表达HER3的实体瘤。
本公开提供为了一种诊断、预防和治疗肿瘤疾病的方法，包括向受试者给与治疗剂量的治疗剂，所述治疗剂包括上述的抗HER3抗体或其抗原结合片段、抗体-药物偶联物、上述方法制备的抗体-药物偶联物上述的药物组合物或者试剂盒。
附图说明
图1中A和B分别示出实施例4制备的L1H5抗体(裸抗)的体积排阻色谱图和疏水层析色谱图；
图2中A和B分别示出实施例6制备的抗体-药物偶联物L1H5-LP3中聚集体的体积排阻色谱图和疏水层析检测图谱；
图3中A和B分别示出实施例7制备的抗体-药物偶联物L1H5-LP1中聚集体的体积排阻色谱图和疏水层析检测图谱；
图4中A和B分别示出实施例8制备的抗体-药物偶联物L1H5-LP2中聚集体的体积排阻色谱图和疏水层析检测图谱；
图5示出实施例4制备的Mu4O3抗体与不同HER3表达量细胞的细胞流式检测统计图；
图6示出实施例4制备的Mu4O3抗体在HER3-GFP Tag过表达293T细胞中的免疫荧光图像；
图7示出实施例4制备的Mu4O3抗体在杀伤SW620细胞检测中的细胞存活曲线；
图8示出实施例4制备的L1H4、L1H5、L2H4、L2H5、L4H4、L4H5和L4H7抗体在MDA-MB-453细胞系中的亲和力曲线；
图9示出实施例4制备的L1H4、L1H5、L2H4、L2H5、L4H4、L4H5和L4H7抗体在SW620细胞系中的亲和力曲线；
图10示出实施例4制备的L1H5抗体、参照抗体和空白对照在SK-BR-3细胞系中的细胞增殖抑制率；
图11示出实施例4制备的L1H5、参照抗体以及空白对照PBS在BT-474乳腺癌小鼠模型中的肿瘤体积-时间变化曲线；
图12示出实施例7制备的抗体-药物偶联物L1H4-LP1、L1H5-LP1以及L4H4-LP1、对比例1制备的参照ADC(阳性对照)在SW620细胞系中的细胞存活曲线；
图13示出实施例4制备的L1H5抗体、实施例6制备的L1H5-LP3、参照抗体和对比例1制备的参照ADC对SK-BR-3细胞系杀伤测试中的细胞存活曲线；
图14示出实施例4制备的L1H5抗体、实施例6制备的L1H5-LP3、参照抗体和对比例1制备的参照ADC对BXPC-3细胞系杀伤测试中的细胞存活曲线；
图15示出实施例7制备的抗体-药物偶联物L1H5-LP1、实施例8制备的L1H5-LP2、对比例1制备的参照ADC在HCT-15细胞系中的细胞存活曲线；
图16示出实施例7制备的抗体-药物偶联物L1H5-LP、实施例8制备的L1H5-LP2、对比例1制备的参照ADC、以及空白对照组在HCT-15结肠癌小鼠模型中的肿瘤体积-时间变化曲线图；
图17示出小鼠结肠癌PDX模型接受对比例1制备的参照ADC、实施例6制备的L1H5-LP3、实施例7制备的L1H5-LP1、对比例4制备的Dxd同型对照ADC、对比例5制备的LP3同型对照ADC治疗后的肿瘤体积-时间变化曲线；
图18示出小鼠EGFR-TKI耐药肺腺癌PDX模型接受对比例1制备的参照ADC、实施例6制备的L1H5-LP3、实施例7制备的L1H5-LP1、对比例4制备的Dxd同型对照ADC、对比例5制备的LP3同型对照ADC治疗后的肿瘤体积-时间变化曲线；
图19示出小鼠结肠癌CDX模型接受对比例3制备的L1H5-DXd、对比例2制备的参照抗体-LP3、实施例6制备的L1H5-LP3、对比例1制备的参照ADC治疗后的肿瘤体积-时间变化曲线，并设置阴性对照PBS组；
图20为图19去掉阴性对照PBS组后的局部放大图；
图21示出小鼠胰腺癌CDX模型接受对比例1制备的参照ADC、实施例6制备的L1H5-LP3、实施例7制备的L1H5-LP1、对比例4制备的Dxd同型对照ADC、对比例5制备的LP3同型对照ADC治疗后的肿瘤体积-时间变化曲线图；
图22示出实施例4制备的L1H5抗体，实施例6制备的抗体-药物偶联物L1H5-LP3，参照抗体以及对比例1制备的参照ADC的疏水性测量对比图；
图23中A和B分别示出对比例1制备的参照ADC中聚集体的体积排阻色谱图和疏水层析检测图谱；
图24中A和B分别示出对比例2制备的抗体-药物偶联物参照抗体-LP3中聚集体的体积排阻色谱图和疏水层析检测图谱；
图25中A和B分别示出对比例3制备的抗体-药物偶联物L1H5-DXd中聚集体的体积排阻色谱图和疏水层析检测图谱；
图26中A和B分别示出对比例4制备的Dxd同型对照ADC中聚集体的体积排阻色谱图和疏水层析检测图谱；
图27中A和B分别示出对比例5制备的LP3同型对照ADC中聚集体的体积排阻色谱图和疏水层析检测图谱。
具体实施方式
除非另有说明，否则在本说明书和权利要求书中使用的表示含量、浓度、比例、质量、体积、时间、温度、厚度、技术效果等的所有数字在任何情况下均应理解为由术语“约”或“大致”修饰。因此，除非有相反的指示，否则以下说明书和所附权利要求书中列出的数字参数是近似值。对于本领域技术人员来说，其可以根据通过本公开寻求获得的期望性质和效果而变化，应根据有效数字位数和常规舍入方法或者本领域技术人员理解的方式来解释每个数值参数。
尽管阐述了本公开的广泛范围的数值范围和参数是近似值，但是尽可能精确地提供了在具体实施例中阐述的数值。然而，任何数值都会固有地包含某些误差，这些误差由于在其相应的测试测量中发现的标准偏差而必然地导致的。本说明书给出的每个数值范围将包括落入该较宽数值范围内的每个较窄数值范围，就如同这些较窄数值范围均在本文中明确写出一样。
[抗体]
本公开提供了一种抗HER3抗体或其抗原结合片段，包括至少一个轻链可变区(Variable Region of Light Chain,VL)和一个重链可变区(Variable Region of Heavy Chain,VH)，所述VL和VH可以配对结合。
如本文中所使用，术语“抗体”意指任何包含至少一个特异性结合于具体抗原(例如HER3)或与其相互作用的互补决定区的抗原结合分子或分子复合物。术语“抗体”包括免疫球蛋白分子以及其多聚体(例如IgM)，所述免疫球蛋白分子包含四个多肽链，即通过二硫键互连的两个重(H)链和两个轻(L)链。各重链包含重链可变区和重链恒定区。重链恒定区包含三个结构域，即CHl、CH2和CH3。各轻链包含轻链可变区和轻链恒定区。轻链恒定区包含一个结构域(CL1)。VH和VL区可以进一步再分成高变区，称为互补决定区(CDR)，穿插有称为构架区(FR)的保守性更高的区域。各VH及VL是由从氨基端到羧基端按以下顺序排列的三个CDR和四个FR构成：FR1、CDR1、FR2、CDR2、FR3、CDR3、FR4。
如本文中所使用，术语“抗体”也包括完整抗体分子的抗原结合片段。术语“抗原结合片段”包括特异性结合抗原以形成复合物的任何天然存在、可以酶方式获得、合成或经遗传工程改造的多肽或糖蛋白。抗体的抗原结合片段可以使用任何适合的标准技术从例如完整抗体分子获得。抗原结合片段的非限制性实例包括：Fab片段、F(ab’)2片段、Fd片段、Fv片段、单链Fv(scFv)分子、dAb片段和最小识别单元，其由模拟抗体的高变区(例如，经分离的互补决定区(CDR)，如CDR3肽)或限制性FR3-CDR3-FR4肽的氨基酸残基组成。其它经工程改造的分子，如结构域特异性抗体、单域抗体、结构域缺失抗体、嵌合抗体、CDR移植抗体、双功能抗体、三功能抗体、四功能抗体、微型抗体、纳米抗体(例如单价纳米抗体、二价纳米抗体等)也涵盖于如本文中“抗原结合片段”内。抗体的抗原结合片段将通常包含至少一个可变域。可变域可以具有任何尺寸或氨基酸组成并且通常将包含与一个或多个构架序列相邻或同框的至少一个CDR。在具有与VL域相关联的VH域的抗原结合片段中，VH和VL域可以任何适合的配置相对于彼此定位。举例来说，可变区可以是二聚体并且含有VH‐VH、VH‐VL或VL‐VL二聚体。或者，抗体的抗原结合片段可以含有单体VH或VL域。
所述抗HER3抗体或其抗原结合片段中，VL的CDR1-3分别包含如SEQ ID NO:1-3所示的氨基酸序列；VH的CDR1包含如SEQ ID NO:4所示的氨基酸序列，VH的CDR2包含与SEQ ID NO:5所示的氨基酸序列相差不超过5,4,3,2,1,0个突变的氨基酸序列，VH的CDR3包含如SEQ ID NO:6所示的氨基酸序列。所述抗HER3抗体或其抗原结合片段的CDR使用Kabat系统定义和编号。
在一些实施方式中，VH的CDR2包含与SEQ ID NO:5所示的氨基酸序列相差不超过4,3,2,1,0个突变的氨基酸序列。在一些实施方式中，VH的CDR2包含与SEQ ID NO:5所示的氨基酸序列相差不超过4个突变的氨基酸序列。在一些实施方式中，VH的CDR2包含如SEQ ID NO:5所示的氨基酸序列。
VH的CDR2包含突变，所述突变选自包含C52N/Y，T62N，T66K和G67S中的任一或组合。其中，C52N/Y表示第52位的氨基酸“C”突变为“N”或“Y”。本文中，“C”、“N”、“Y”、“T”、“K”、“G”、“S”为单字母表示的标准氨基酸，分别表示半胱氨酸、天冬酰胺、酪氨酸、苏氨酸、赖氨酸、甘氨酸、丝氨酸。其中，第1位氨基酸是指VH自氨基端向羧基端的第一个氨基酸，其他位置的氨基酸以此类推。
在一些实施方式中，抗HER3抗体或其抗原结合片段中，VH的CDR2包含突变C52N，T62N，T66K和G67S。在一些实施方式中，抗HER3抗体或其抗原结合片段中，VH的CDR2包含突变C52Y，T62N，T66K和G67S。
抗HER3抗体或其抗原结合片段中，可变区内还包括框架区(Framework Region，FR)，其为除CDR之外的氨基酸组成和排列顺序变化相对较小的区域。
在一些实施方式中，在框架区内不存在突变或存在不影响抗体可变区与抗原结合的突变，该突变可以提高抗体与抗原的结合亲和力，或者保持大致不变。在一些实施方式中，抗HER3抗体或其抗原结合片段还包含保守修饰的变体，所述保守修饰的变体包括对多肽序列的单独取代、缺失或添加，其导致氨基酸被化学上相似的氨基酸取代。提供功能相似的氨基酸的保守置换表是本领域熟知的。这种保守修饰的变体是对多态性变体、种间同源物和等位基因的补充且不排除。以下八组含有相互保守取代的氨基酸：1)丙氨酸(A)、甘氨酸(G)；2)天冬氨酸(D)、谷氨酸(E)；3)天冬酰胺(N)、谷氨酰胺(Q)；4)精氨酸(R)、赖氨酸(K)；5)异亮氨酸(I)、亮氨酸(L)、蛋氨酸(M)、缬氨酸(V)；6)苯丙氨酸(F)、酪氨酸(Y)、色氨酸(W)；7)丝氨酸(S)、苏氨酸(T)；和8)半胱氨酸(C)、甲硫氨酸(M)(参见，例如，Creighton,Proteins(1984))。在一些方面，术语“保守序列修饰”用于指不显著影响或改变包含氨基酸序列的抗体的结合特征的氨基酸修饰。
在一些实施方式中，抗HER3抗体或其抗原结合片段中，VL包含与SEQ ID NO:9,11,12,13所示氨基酸序列的框架区序列相比至少具有70％，75％，77％，78％，80％，82％，84％，85％，90％，95％，96％，97％，98％，99％同一性的氨基酸序列；VH包含与SEQ ID NO:10,14,15,16所示氨基酸序列的框架区序列相比至少具有70％，75％，77％，78％，80％，82％，84％，85％，90％，95％，96％，97％，98％，99％同一性的氨基酸序列。
在一些实施方式中，抗HER3抗体或其抗原结合片段中，VL包含与SEQ ID NO:9,11,12,13所示氨基酸序列至少具有70％，75％，77％，78％，80％，82％，84％，85％，90％，95％，96％，97％，98％，99％同一性的氨基酸序列；VH包含与SEQ ID NO:10,14,15,16所示氨基酸序列至少具有70％，75％，77％，78％，80％，82％，84％，85％，90％，95％，96％，97％，98％，99％同一性的氨基酸序列。
在本公开中，在两个或更多个多肽序列中，术语“％同一性”是指两个或更多个序列或子序列相同的程度。如果两个序列在被比较的区域上具有相同的氨基酸序列，则它们是“相同的”。如果两个序列具有指定百分比的相同氨基酸残基(例如，60％同一性，任选65％、70％、75％、80％、85％、90％、95％或99％同一性在指定区域，或者，当未指定时，在整个序列上)，当在比较窗口或指定区域进行比较和比对以获得最大一致性时，或使用以下序列比较算法之一测量的指定区域或通过手动对齐和目视检查。任选地，同一性存在于长度为至少约10个氨基酸的区域，或更优选地存在于20、50、200或更多氨基酸的长度。适用于确定百分比序列同一性和序列相似性的算法的两个示例是BLAST和BLAST 2.0算法(Altschul等，Nuc.Acids Res.25:3389-3402,1997，和Altschul等，J.Mol.Biol.215:403-410,1990)。
除了上述序列同一性的百分比之外，两个多肽基本上相同的另一个含义是指由第一个多肽与第二个多肽具有免疫交叉反应性，因此，一种多肽通常与第二种多肽基本相同，例如，其中两种肽仅保守取代不同。
在一些实施方式中，抗HER3抗体或其抗原结合片段中，VL包含如SEQ ID NO:9,11,12或13所示的氨基酸序列，VH包含与SEQ ID NO:10,14,15或16所示的氨基酸序列。
在一些实施方式中，所述抗HER3抗体或其抗原结合片段中，VL和VH分别包含如SEQ ID NO:9与SEQ ID NO:10所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；VL和VH分别包含如SEQ ID NO:11与SEQ ID NO:14所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；VL和VH分别包含如SEQ ID NO:11与SEQ ID NO:15所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；VL和VH分别包含如SEQ ID NO:12与SEQ ID  NO:14所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；VL和VH分别包含如SEQ ID NO:12与SEQ ID NO:15所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；VL和VH分别包含如SEQ ID NO:13与SEQ ID NO:14所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；VL和VH分别包含如SEQ ID NO:13与SEQ ID NO:15所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；或者VL和VH分别包含如SEQ ID NO:13与SEQ ID NO:16所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列。
在一些实施方式中，所述抗HER3抗体或其抗原结合片段包含或具有的VH和VL分别如SEQ ID NO:9和10，11和14，11和15，11和16，12和14，12和15，12和16，13和14，13和15，或者，13和16所示的氨基酸序列及其保守取代变体，可选为框架区具有保守取代。
在一些实施方式中，所述抗HER3抗体或其抗原结合片段包含或具有的VH和VL分别如SEQ ID NO:9和10，11和14，11和15，12和14，12和15，13和14，13和15，或者，13和16所示的氨基酸序列及其保守取代变体，可选为框架区具有保守取代。
本公开提供的HER3抗体或其抗原结合片段可以结合哺乳动物(例如人或鼠)的HER3蛋白。在一些实施方式中，所述抗HER3抗体或其抗原结合片段与人HER3特异性结合。在一些实施方式中，所述抗HER3抗体或其抗原结合片段与鼠HER3特异性结合。
所述HER3抗体或其抗原结合片段可以为IgM、IgG、IgA、IgD或IgE类别。在一些实施方式中，所述HER3抗体或其抗原结合片段为IgG分子。在一些实施方式中，所述HER3抗体或其抗原结合片段为IgG1，IgG2，IgG3或IgG4亚型。在一些实施方式中，所述HER3抗体或其抗原结合片段为人IgG1。抗体的类别和亚类根据本领域通常的方法进行确认，例如，根据重链α、δ、ε、γ和μ的不同，组成的抗体就称为IgA、IgD、IgE、IgG和IgM。其中，人的γ可以进一步细分为γ1、γ2、γ3、γ4，分别对应IgG1,IgG2,IgG3和IgG4四个亚型。
所述HER3抗体或其抗原结合片段可以为人抗体、人源化抗体或嵌合抗体，人抗体、人源化抗体或嵌合抗体使用本领域通常理解的方式进行定义。例如，人抗体指全部由人类抗体基因编码的抗体；人源化抗体指至少恒定区部分由人类基因编码的抗体；嵌合抗体指利用DNA重组技术，将异源单抗的轻、重链可变区基因插入含有人抗体恒定区的表达载体中，转化哺乳动物细胞表达出的嵌合抗体。
本公开提供的抗HER3抗体或其抗原结合片段具有改善的疏水性，有利于提高体内和体外的稳定性。
本公开提供的抗HER3抗体或其抗原结合片段具有良好的靶向性，可以锚定表达HER3的肿瘤细胞，发挥肿瘤杀伤作用，可选地，所述抗HER3抗体或其抗原结合片段在体内和体外均可以发挥抗肿瘤作用。
同时，本公开提供了一种编码上述抗HER3抗体或其抗原结合片段的核酸，包含编码上述抗HER3抗体或其抗原结合片段的核酸的载体，以及包含所述核酸和/或所述载体的宿主细胞。
抗HER3抗体或其抗原结合片段可以通过以下方式得到：通过按照本领域中通常实施的方法用HER3或选自HER3的氨基酸序列的任意多肽免疫动物，收集并纯化在体内制造的抗体。在这种情况下，通过研究与所获异种HER3结合的抗体与人HER3的交叉反应性，可选出可应用于人的疾病的抗体。另外，可通过按照已知的方法(例如，Kohler和Milstein，Nature(1975)256，第495-497页；Kennet，R.编著，Monoclonal Antibodies，第365-367页，Plenum Press，N.Y.(1980)；Goding J.W.,Monoclonal Antibodies:Principles and Practice第3版(1986)Academic Press,San Diego,CA)，将制造针对HER3的抗体的产抗体细胞与骨髓瘤细胞融合而建立杂交瘤，从杂交瘤得到单克隆抗体。用作抗原的HER3可通过利用遗传工程在宿主细胞中表达HER3基因而得到。
杂交瘤通过改造可以获得嵌合抗体，例如其中来源于小鼠或大鼠的抗体可变区连接至来源于人的恒定区的嵌合抗体(参见Proc.Natl.Acad.Sci.U.S.A.,81,6851-6855,(1984))。
人源化抗体，可通过用相应的人抗体序列取代非人单克隆抗体的大部分或所有结构部分来生成人源化抗体。可例示通过仅将互补性决定区(CDR)整合入来源于人的抗体而得到的抗体(参见Nature(1986)321，第522-525页)和通过CDR移植法除了向人抗体移植CDR的序列之外、还移植一部分构架的氨基酸残基而得到的抗体(WO 90/07861)。人抗体可通过使用具有包含人抗体的重链和轻链基因的人染色体片段的制造人抗体的小鼠的方法得到(参见Tomizuka，K.等，Nature Genetics(1997)16，第133-143页；Kuroiwa，Y.等，Nucl.Acids Res.(1998)26，第3447-3448页；Yoshida，H.等，Animal Cell Technology：Basic and Applied Aspects vol.10，第69-73页(Kitagawa，Y.，Matsuda，T.and Iijima，S.编著)，Kluwer Academic Publishers，1999；Tomizuka，K.编著，Proc.Natl.Acad.Sci.USA(2000)97，第722-727页等。)。获得人源化抗体的方法还包括描述于例如以下中的那些：Winter和Milstein,Nature,1991,349:293-299；Rader等,Proc.Nat.Acad.Sci.U.S.A.,1998,95:8910-8915；Steinberger等,J.Biol.Chem.,2000,275:36073-36078；Queen等,Proc.Natl.Acad.Sci.U.S.A.,1989,86:10029-10033；
[抗体-药物偶联物]
本公开提供了一种抗体-药物偶联物(Antibody-Drug Conjugate,ADC)，其具有式I所示结构的抗体-药物偶联物，
Ab-(L-D)n   (I)
或其异构体、同位素变体、药学上可接受的盐、前药、溶剂合物，或其组合，
其中，Ab是上述的抗HER3抗体或其抗原结合片段；
L是分别与Ab和D共价连接的连接子；
D是有效荷载；
n为1～10之间的数值。
术语“抗体‐药物偶联物”或“ADC”是指本文描述的抗HER3抗体或其抗原结合片段与有效荷载共价连接的缀合物。通常，该抗体‐药物偶联物可以包括抗体、有效荷载、以及任选地介于该抗体与该有效荷载之间的连接子。ADC可以通过将有效荷载递送至抗体靶向的HER3细胞、尤其是HER3肿瘤细胞来提供治疗效果。可以通过本领域已知的制备抗体‐药物缀合物的各种方法来制备抗体‐药物缀合物。
ADC分子中，连接子作为连接抗体及有效荷载的连接结构，是成功构建ADC分子的关键因素。就药代动力学(PK)/药效学(PD)和治疗窗口而言，连接子的分子设计和性质是ADC发挥功效的关键决定因素。为了发挥最佳的效力，理想的连接子应该具备如下特性：(1)连接子血浆中足够稳定，ADC分子可以在血流中循环并定位到肿瘤部位而不至于过早裂解。不稳定的连接子会导致细胞毒性有效荷载过早释放，并损害非目标健康细胞，从而造成全身中毒和不良反应。(2)连接子需要具备快速被切割的能力，一旦ADC被内化到靶肿瘤细胞中，能够快速释放出游离的细胞毒性有效荷载。(3)连接子设计还需考虑疏水性。疏水连接子与疏水细胞毒性有效荷载的结合通常会促进ADC分子的聚集，不但不利于ADC药效，还可能导致肝中毒或是引发不希望的免疫反应(Kyoji Tsuchikama et al.,Antibody-drug conjugates:recent advances in conjugation and linker chemistrie,Protein Cell.2018 Jan；9(1):33-46)。
术语“异构体”是指分子式相同、结构不同的化合物，也成为了同分异构体或结构异构体，通常包括构造异构体和立体异构体。构造异构体是指因分子中原子的连接次序不同或者键合性质不同引起的异构体，优选包括互变异构体。所述互变异构体是指因分子中某一原子在两个位置迅速移动而产生的官能团异构体。立体异构体是指分子中原子或原子团互相连接次序及键合物质均相同，但空间排列不同而引起的异构体，优选包括旋光异构体。所述旋光异构体是指因分子中没有反轴对称性而引起的具有不同旋光性能的立体异构体，如，对映异构体、非对映异构体、外消旋体和内消旋体。
术语“前药”是指药物经过化学结构修饰后得到的在体外无活性或活性较小、在体内经酶或非酶的转化释放出活性药物而发挥药效的化合物。本公开中，前药可以是ADC分子，也可以是有效荷载。
在一些实施方式中，所述连接子为可切割连接子和不可切割连接子。
在一些实施方式中，所述连接子包括可切割肽，可选地，所述可切割肽可被酶切割。在一些实施方式中，所述酶包括组织蛋白酶B。
在一些实施方式中，所述可切割肽或L包含氨基酸单元，所述氨基酸单元包括二肽、三肽、四肽或五肽。
在一些实施方式中，所述氨基酸单元选自：Val-Cit、Val-Ala、Glu-Val-Cit、Ala-Ala-Asn、Gly-Val-Cit、Gly-Gly-Gly和Gly-Gly-Phe-Gly中的任意或组合。其中，Val表示缬氨酸，Cit表示瓜氨酸，Ala表示丙氨酸，Glu表示谷氨酸，Asn表示天冬酰胺，Gly表示甘氨酸，Phe表示苯丙氨酸。
在一些实施方式中，所述连接子包含自降解单元，可选地，所述自降解单元包含对氨基苯甲氧基羰基(PABC)或对氨基苄基(PAB)。
在一些实施方式中，所述可切割肽直接剪切至所述自降解单元。
在一些实施方式中，所述连接子包含如-L1-L2-L3-所示的结构，L1表示-(琥珀酰亚胺基-3-基-N)-(CH2)m1-C(＝O)-、-CH2-C(＝O)-NH-(CH2)m2-C(＝O)-或-C(＝O)-(CH2)m3-C(＝O)-，其中m1表示2～8的整数，m2表示1～8的整数，m3表示1～8的整数；L2表示氨基酸单元；L3表示自降解单元。
在一些实施方式中，m1表示2、3、4、5、6、7或8。在一些实施方式中，m2表示1、2、3、4、5、6、7或8。在一些实施方式中，m3表示1、2、3、4、5、6、7或8。
在一些实施方式中，所述L选自以下组中的一种或多种：
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-GGFG-PABC-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-PABC-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-PABC-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-PABC-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-PABC-；
-CH2-C(＝O)-NH-CH2CH2-C(＝O)-GGFG-PABC-；
-C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-GGFG-PABC-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2-O-CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2-O-CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
-CH2-C(＝O)-NH-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
-C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-VA-PABC-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-PABC-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-PABC-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-PABC-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-PABC-；
-CH2-C(＝O)-NH-CH2CH2-C(＝O)-VA-PABC-；
-C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-VA-PABC-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2CH2CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2-O-CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2-O-CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
-(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
-CH2-C(＝O)-NH-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；和
-C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-。
在一些实施方式中，所述对氨基苯甲氧基羰基(PABC)或对氨基苄基(PAB)连接有聚肌氨酸(聚-N-甲基甘氨酸)残基或甲氨基。
在一些实施方式中，所述抗体-药物偶联物包括抗体、有效荷载和式II所示的连接子，
所述式II所示连接子通过琥珀酰亚胺基与抗体链间二硫链还原后的巯基部分通过硫醚键共价键合；
所述式II所示连接子的酯基中的羰基与有效荷载中的氨基连接；
式II中，R1、R2各自独立地选自氢、甲基或异丙基；
R3表示-(CR5HCONH)n1-(CH2CONH)n2-或单键，R5为氢或苯甲基，n1表示0～2的整数，n2表示0～2的整数；
R4表示甲氨基或-(NCH3COCH2)n3-NCH3COCH3，n3表示1～20的整数。
术语“有效荷载”包括从抗体-药物偶联物中释放后具有细胞毒性或能够杀死细胞的化合物、具有放射性标记、荧光团、生色团、显像剂和/或金属离子为检测标记或细胞杀伤作用的化合 物、放射性核素或多肽、可以调节机体免疫活性(包括激活或抑制作用)的化合物、核酸、多肽或蛋白、酶、激素或核酸。
在一些理想情况下，抗体-药物偶联物中缀合形式的有效荷载几乎没有细胞毒性或细胞毒性小至有效治疗剂量的ADC给药后不会由于缀合形式的有效荷载引起受试者的全身毒性反应。所述有效荷载可以是已经经过临床验证的用于治疗特定疾病的药物，或者为在临床使用条件下具有可接受的药理活性的化合物、放射性核素、核酸、蛋白或多肽。
本公开中，所述式I中连接子通过端部的琥珀酰亚胺基与抗体链间二硫链还原后的巯基形成硫醚键与抗体连接。所述琥珀酰亚胺基为其通过3位的碳原子与抗体链间二硫链还原后的巯基形成硫醚键。本公开中，结构式中的带有的键表示与其他基团连接的化学键。
本公开中，抗体的二硫键包括链间二硫键和链内二硫键，优选链间二硫键经过处理，例如，活化(或还原)成为巯基后与连接子键合。抗体中与连接子中琥珀酰亚胺基进行化学键合的氨基酸包括赖氨酸、组氨酸、酪氨酸和半胱氨酸中的一种或组合，优选通过半胱氨酸进行化学键合。
在一些实施方式中，式I中连接子可以连接于抗体的铰链区、可变区和/或恒定区。
本公开中，在一些实施方式中，式II所示的连接子中，R4表示-(NCH3COCH2)n3-NCH3COCH3，n3表示1～20的整数。所述n3可以选取例如1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19和20中的任一整数。
在一些实施方式中，式II所示的连接子中，R4表示-(NCH3COCH2)n3-NCH3COCH3，n3表示8～15的整数。在一些实施方式中，所述抗体-药物偶联物中，式II所示的连接子中，R4表示-(NCH3COCH2)n3-NCH3COCH3，n3表示10～12的整数。
在一些实施方式中，所述抗体-药物偶联物中，式II所示的连接子中，R4表示甲氨基。
本公开式II所示的连接子中，R4中包含有亲水性的聚肌氨酸基团或甲氨基，增加了抗体-药物偶联物的亲水性，特别是当抗体-药物偶联物中缀合疏水性的有效荷载时，ADC分子亲水性的提高有助于降低制备过程中ADC分子的聚集，进而提高抗体-药物偶联物的稳定性、均一性和纯度。
在一些实施方式中，所述抗体-药物偶联物中，式II所示的连接子中，R3表示单键。
在一些实施方式中，所述抗体-药物偶联物中，式II所示的连接子中，R3表示-(CR5HCONH)n1-(CH2CONH)n2-，R5为苯甲基，n1表示1～2的整数，n2表示1～2的整数。
在一些实施方式中，所述抗体-药物偶联物中，式II所示的连接子中，R3表示-CR5HCONH-，-CH2CONH-，-CR5HCONH-CH2CONH-；-(CR5HCONH)2-CH2CONH-；-CR5HCONH-(CH2CONH)2-；或者，-(CR5HCONH)2-(CH2CONH)2-；R5为苯甲基。
在一些实施方式中，所述抗体-药物偶联物中，式II所示的连接子中，R1为氢。在一些实施方式中，所述式II所示的连接子中，R1为异丙基。
在一些实施方式中，所述抗体-药物偶联物中，式II所示的连接子中，R2为氢。在一些实施方式中，所述式II所示的连接子中，R2为甲基。
在一些实施方式中，所述抗体-药物偶联物中的连接子选自以下组中的一种或多种，

在一些实施方式中，所述抗体-药物偶联物中的有效荷载为含有放射性标记、荧光团、生色团、显像剂和/或金属离子为检测标记的标记物，所述标记物包括但不限于化学合成的有机化合物、放射性核素、金属络合物或多肽。其中，放射性标记是指用放射性核素取代化合物分子的一种或几种原子而使它能被识别并可用作示踪剂的标记化合物，包括氨基酸、多肽、蛋白质、糖类、核苷酸、核苷、嘌呤、嘧啶、甾族、类脂化合物，以及医学研究用的肿瘤抗原、激素、受体、维生素和药物等。反射性核素通常为能自发放出射线的核素，包括但不限于氚、碘125、碘131、硫35、磷32和碳14。荧光团通常为包括共轭双键的基团，当分子从激发态恢复到基态时，荧光团会发出荧光。生色团是指分子中含有的，能对光辐射产生吸收、具有跃迁的不饱和基团及其相关的化学键。显像剂通常指在核医学中指引入体内后能进行脏器、组织或分子显像的放射性药物。
在一些实施方式中，所述抗体-药物偶联物中的有效荷载为核酸，所述核酸可以为核糖核酸和/或脱氧核糖核酸。
在一些实施方式中，所述抗体-药物偶联物中的有效荷载为激素、生长因子、凝血因子、纤溶蛋白酶(例如能够将前体药物转化为活性药物的前体药物转化酶、核糖核酸酶)。
在一些实施方式中，所述抗体-药物偶联物中的有效荷载为免疫调节剂(包括具有影响免疫作用的细胞因子、趋化因子)，具有生物活性的激动性抗体或拮抗性抗体。
在一些实施方式中，所述抗体-药物偶联物中有效荷载为细胞毒性化合物。在一些实施方式中，所述抗体-药物偶联物中的有效荷载具有抗肿瘤活性，或者为抗肿瘤药物，所述有效荷载选自DNA拓扑异构酶抑制剂或选自微管蛋白抑制剂。所述DNA拓扑异构酶抑制剂可以为拓扑异构酶I抑制剂或拓扑异构酶II抑制剂。
本公开中，术语“拓扑异构酶抑制剂”通常指抑制拓扑异构酶活性的化合物。拓扑异构酶I抑制剂的化合物对拓扑异构酶I具有活性；拓扑异构酶II抑制剂对拓扑异构酶II具有活性；一些化合物对拓扑异构酶I和拓扑异构酶II都有活性，称为拓扑异构酶I/II抑制剂。
术语“微管蛋白抑制剂”通常指抑制真核细胞微管系统，干扰细胞分裂和抑制细胞增殖的化合物。
在一些实施方式中，所述有效荷载为具有拓扑异构酶抑制作用的喜树碱或其衍生物。术语“衍生物”指母体化合物分子中的原子或原子团被其他原子或原子团取代所形成的化合物，称为该母体化合物的衍生物。术语“喜树碱及其衍生物”通常包括喜树碱(camptothecin)和喜树碱衍生物，喜树碱通过不可逆地抑制拓扑异构酶I发挥其药理作用。所述喜树碱衍生物包括依喜替康(exatecan)、伊立替康(irinotecan)、托泊替康(topotecan)、鲁托替康(lurtotecan)、斯兰替康(silatecan)、依替立替康聚乙二醇(etirinotecan pegol)、TAS 103、9-氨基喜树碱(9-aminocamptothecin)、7-乙基喜树碱(7-ethylcamptothecin)、10-羟基喜树碱(10-hydroxycamptothecin,)、9-硝基喜树碱(9-nitrocamptothecin)、10,11-亚甲二氧基喜树碱(10,11-methylenedioxycamptothecin)、9-氨基-10,11-亚甲基二氧基喜树碱(9-amino-10,11-methylenedioxycamptothecin,)、9-氯-10,11-亚甲基二氧基喜树碱(9-chloro-10,11-methylenedioxycamptothecin)、7-(4-甲基哌嗪亚甲基)-10,1 1-亚乙基二氧基-20(S)-喜树碱(7-(4-methylpiperazinomethylene)-10,1-1-ethylenedioxy-20(S)-camptothecin)，7-(4-甲基哌嗪亚甲基)-10,11-亚甲基二氧基-20(S)-喜树碱(7-(4-methylpiperazinomethylene)-10,11-methylenedioxy-20(S)-camptothecin)，7-(2-(N-异丙基氨基)乙基)-(20S)-喜树碱(7-(2-(N-isopropylamino)ethyl)-(20S)-camptothecin)等及其立体异构体、盐和酯。喜树碱和喜树碱类似物或衍生物的合成方法是已知的，并且在美国专利号5,244,903中进行了总结和阐述，该专利通过引用整体并入本文。
在一些实施方式中，所述有效荷载为具有微管蛋白抑制作用的奥瑞他汀或其衍生物，美登素或其衍生物。术语“奥瑞他汀及其衍生物”通常包括奥瑞他汀F和奥瑞他汀F衍生物，所述奥瑞他汀F衍生物包括单甲基澳瑞他汀E(monomethyl auristatin E,MMAE)和单甲基澳瑞他汀F(monomethyl auristatin F,MMAF)。术语“美登素及其衍生物”通常包括美登素和美登素衍生物，所述美登素衍生物包括美登素DM1，美登素DM2和美登素DM4。
在一些实施方式中，所述有效荷载为喜树碱衍生物依喜替康，作为拓扑异构酶抑制剂能够作用于整个细胞周期，对生长缓慢实体瘤具有强的穿透性和良好的疗效。而且，细胞内靶标数量远低于微管蛋白抑制剂的靶标数量，在ADC分子携带相同数量的有效荷载进入细胞时能够起到更好的杀伤效果。依喜替康(Exatecan)分子不是P-gp的底物，有利于降低或缓解药物耐药的问题。
在一些实施方式中，所述有效荷载为式III所示的依喜替康，其通过其环己烷环上氨基的氮原子与连接子连接，
依喜替康分子的结构具有刚性且亲水性差，与现有技术中常用的GGFG四肽连接子连接后制备ADC时容易引起ADC分子间的聚合，不符合ADC药物的开发要求(Bioorg.Med.Chem.Lett.26(2016)1542-1545)。因此，连接子和有效荷载的选择和匹配对ADC药物的安全性和稳定性是有影响的。
不受任何理论的束缚，本公开提供的抗体-药物偶联物中，由于连接子中具有多个亲水性基团，改善了连接子-有效荷载结构中的亲水性，可以在一定程度上降低由于疏水性有效荷载引起的ADC分子的聚集、沉淀等现象。
ADC分子内吞进入细胞后，根据连接子是否降解释放出有效荷载或连接子(或部分连接子)-有效荷载结构的化合物。在一些实施方式中，式III所示的依喜替康的环己烷环上氨基与式II所示的连接子的酯基中的羰基键合后形成包括氨基甲酸酯的连接子-有效荷载结构。不受任何理论的束缚，本公开提供的连接子-有效荷载结构中，ADC分子内吞进入细胞后，连接子经组织蛋白酶(例如，Cathepsin B)酶解后，形成如下式V所示的中间体或活性代谢产物，
R4表示甲氨基或-(NCH3COCH2)n3-NCH3COCH3，n3表示1～20的整数。
所述式V所示的中间体或活性代谢产物中的PABC基团继而发生1,6-消除从而释放出依喜替康。其中，PABC的1,6-消除的机理在文献Angew.Chem.Int.Ed.2015,54,7492–7509中详细进行了描述。因此，本公开提供的ADC分子中的连接子-有效荷载结构具有良好的体内稳定性与生物活性。
连接子-有效荷载结构中的酶切位点，不受任何理论的束缚，可以是连接子中的酰胺键，例如，R2表示的取代基所在的碳原子和R3表示的基团之间的酰胺键，或者，R3表示的基团中的酰胺键。
在一些实施方式中，抗体-药物偶联物中，n为偶联的有效荷载的分子数相对每一分子抗体的比值(Drug to Antibody Ratio,DAR)。在一些实施方式中，抗体-药物偶联物中，n为1～10，1～2，2～4，4～6,2～8，4～8，4～10，6～10，7～10或者8～10，示例性的DAR值如4，6,7.78，8.038或者9.92。
DAR表示每个抗体分子的偶联有效荷载或药物分子数的平均值，即偶联药物分子数的平均值。在抗体-药物偶联物中，每个抗体分子偶联的有效荷载分子数是影响其疗效和安全性的关键因素。抗体-药物偶联物的生产是通过指定反应条件如反应所用的起始原料和试剂的量来进行的，以达到恒定的偶联有效荷载分子数。通常抗体-药物偶联物制备时会得到含有不同数量的偶联有效荷载分子的混合物。除非另有说明，本公开中每个抗体分子的偶联效荷载或药物分子数定义为平均值，即偶联效荷载或药物分子的平均数。
在一些实施方式中，所述抗体-药物偶联物包括具有以下结构中的任一种：

Ab表示抗HER3的抗体或抗原结合片段；n为1～10或4～10。
抗体-药物偶联物中的抗体为HER3靶向特异性抗体或其抗原结合片段，通过二硫键形成活性巯基后与连接子连接。在一些实施方式中，抗体铰链区的二硫键形成活性巯基后与连接子连接。
在一些实施方式中，抗体-药物偶联物中的抗体为本公开上述[抗体]部分提供的抗HER3抗体或其抗原结合片段。在一些实施方式中，抗体-药物偶联物中的抗HER3抗体或其抗原结合片段包含如SEQ ID NO:11所示的VL序列和如SEQ ID NO:15所示的VH序列。
本公开提供的抗体-药物偶联物中，由于使用了疏水性改善的抗HER3抗体或其抗原结合片段以及连接子，制备的产品亲水性和产品均一性都显著提高，有助于提高靶向细胞的杀伤作用，并在生物学活性、安全性等成药性质方面有所提高或保持，例如，体外/体内稳定性提高，体内药物代谢性质改善(更长的半衰期，更低的游离小分子毒素等)。
本公开提供的抗体药物具有优异的体内抗体肿瘤作用，特别是具有HER3依赖的细胞杀伤或抗肿瘤活性，依据肿瘤细胞HER3的表达水平，对所述肿瘤细胞具有不同程度的杀伤作用。在一些实施方式中，本公开提供的抗体-药物偶联物对HER3高表达的肿瘤细胞具有极高的杀伤活性，HER3表达水平的高低可以根据本领域已知的方法进行判断，例如，H-score评分法，低表达(H-Score＝10-99),中表达(H-Score＝100-199)，高表达(H-Score＝200-300)。
需要说明的是，本公开的抗体-药物偶联物由于在大气中放置、或进行重结晶而有吸收水分、保持吸附的水的情况、或成为水合物的情况，这样的含有水的化合物及盐也包含在本公开之内。另外，本公开中也包括用各种放射性或非放射性同位素标记的同位素变体化合物。构成本公开的抗体-药物偶联物的原子中的一种以上，也可以含有非天然比例的原子同位素。作为原子同位素，可举出例如氘(2H)、氚(3H)、碘-125(125I)或碳-14(14C)等。另外，本公开化合物可以用例如氚(3H)、碘－125(125I)或碳-14(14C)之类的放射性同位素进行放射性标记。经放射性标记的化合物作为治疗或预防剂、研究试剂例如检验试剂、及诊断剂、例如体内图像诊断剂是有用的。对于本公开的抗体-药物偶联物的所有同位素变体而言，无论是否具有放射性，均包含于本公开的范围内。
[抗体-药物偶联物制备方法]
本公开提供了一种抗体-药物偶联物的制备方法，包括以下步骤：
抗体或其抗原结合片段经还原处理后链间二硫键至少部分被还原，与连接子-有效荷载进行反应，特别是与连接子-有效荷载中连接子的反应基团反应，得到具有式I所示结构的抗体-药物偶联物，
Ab-(L-D)n  (I)
或其异构体、同位素变体、药学上可接受的盐、前药、溶剂合物，或其组合，
其中，Ab是上述的抗HER3抗体或其抗原结合片段；
L是分别与Ab和D共价连接的连接子；
D是有效荷载；
n为1～10之间的数值。
在一些实施方式中，L-D中的马来酰亚胺-N-基的3位碳原子与还原处理后的抗体反应，共价连接后得到ADC。
在一些实施方式中，所述制备方法包括以下步骤：抗体经还原处理后链间二硫键至少部分被还原，与连接子-有效荷载偶联，其中二硫键还原后的巯基与连接子-有效荷载中式IV所示连接子的马来酰亚胺-N-基的3位碳原子进行反应，
所述式IV所示连接子的酯基中的羰基与抗体-药物偶联物中有效荷载的氨基连接；
式IV中，R1、R2各自独立地选自氢、甲基或异丙基；
R3表示-(CR5HCONH)n1-(CH2CONH)n2-或单键，R5选自氢或苯甲基，n1表示0～2的整数，n2表示0～2的整数；
R4表示甲氨基或-(NCH3COCH2)n3-NCH3COCH3，n3表示1～20的整数。
抗体-药物偶联物中，在很多实际情况下，带有有效荷载的上述式IV所示结构的连接子连接到具有反应活性巯基的同一个抗体分子上。在一些实施方式中，抗体与还原剂反应如二硫苏糖醇(DTT)、2-巯基乙醇或三(2-羧乙基)盐酸盐膦(TCEP)反应，使抗体链上的二硫键形成活性巯基。所述还原剂的用量可以为抗体摩尔数的0.3～10倍当量，例如，1～10,3～10,5～10,7～10倍摩尔当量。
在一些实施方式中，所述方法还包括：抗体在含有螯合剂的缓冲溶液中与还原剂反应，之后加入连接子-有效荷载的溶解液，进行反应。连接子-有效荷载具体为式IV所示连接子和有效荷载键合后形成的化合物，其中有效荷载中的氨基(伯氨基)与IV所示连接子的酯基中的羰基连接。有效荷载选自[抗体-药物偶联物]中描述的有效荷载。在一些实施方式中，有效荷载为依喜替康。术语“螯合剂”是指能够与金属原子或离子产生通过配位键结合，生成具有环状结构的络合物。
在一些实施方式中，还原剂在含有螯合剂的缓冲溶液中与抗体反应，得到链间二硫键被部分或者完全还原的抗体。所述螯合剂包括但不限于乙二胺四乙酸(EDTA)和二乙三胺五乙酸(DTPA)。螯合剂的使用浓度为1mM～20mM，例如，2mM～20mM，5mM～20mM，8mM～20mM，1mM～15mM或者1mM～10mM。所述缓冲溶液的成分可以是本领域常用的缓冲盐，例如磷酸钠、硼酸钠、乙酸钠或者类似缓冲盐。
抗体与还原剂的反应在调节的pH条件下进行。在一些实施方式中，抗体与还原剂反应时溶液的pH为5～9，可选为pH 6～8，pH 6～7，pH 6.5～7.5或者pH 7～8，例如在溶液约为pH7时进行反应。可以使用具有酸性或碱性的化学物质调节溶液pH值，示例性的具有酸性或碱性的化学物质包括醋酸、盐酸、磷酸、硫酸、碳酸氢钠、碳酸钠、氢氧化钠和三乙胺。
抗体与还原剂的反应在调节的温度条件下进行，示例性的反应温度为-10～40℃，-5～40℃，0～40℃，5～40℃，10～40℃，15～40℃，20～40℃，25～40℃，30～40℃，35～38℃，如约37℃。
连接子-有效荷载可以溶解于有机溶剂，所述有机溶剂选自二甲亚砜(DMSO)、二甲基甲酰胺(DMF)、二甲基乙酰胺(DMA)和N-甲基-2-吡咯烷酮(NMP)中的任意一种或组合。
在一些实施方式中，连接子-有效荷载的溶解液以1～20％体积比的量加入到经还原处理或含有具有活性巯基的抗体的缓冲溶液中，基于抗体缓冲液的体积计。在一些实施方式中，连接子-有效荷载的溶解液的加入体积比为1～20％，2～20％，5～20％，10～20％，15～20％，1～18％，1～15％，1～13％，1～10％或者5～15％，基于抗体缓冲液的体积计。
在一些实施方式中，连接子-有效荷载的与抗体的摩尔用量比值为4～20，可选为8～20。在一些实施方式中，连接子-有效荷载的与抗体的摩尔用量比值为10～20，14～20，16～20或者18～20。
在一些实施方式中，抗体与连接子-有效荷载进行反应的温度为0～37℃。在一些实施方式中，反应温度为-10～40℃，-5～40℃，0～40℃，5～40℃，5～37℃，10～37℃，10～25℃或者15～30℃。
在一些实施方式中，抗体与连接子-有效荷载进行反应的时间为0.5～2小时。在一些实施方式中，抗体与连接子-有效荷载进行反应的时间为0.5～1.75小时，0.5～1.5小时，0.5～1.25小时，0.75～2小时或者1～2小时。
该反应可以通过使用含硫醇的试剂使未反应的连接子-有效荷载的反应活性失活而终止。所述含有硫醇的试剂包括但不局限于半胱氨酸或者N-乙酰-(L)-半胱氨酸(NAC)。更具体的说，向反应溶液中加入摩尔当量为连接子-有效荷载摩尔当量1～2倍的含有硫醇的试剂，并在室温(10～25℃)下孵育10～30分钟，可以终止反应。
在抗体具有巯基的情况下，抗体-药物偶联物还可以通过使用已知方法反应化合物获得(例如，可通过专利公开文献US2016/297890中描述的方法获得(例如，可通过段落[0336]至[0374]中描述的方法获得))。具有巯基的抗体可以通过本领域技术人员熟知的方法获得(Hermanson,G.T,Bioconjugate Techniques,pp.56-136,pp.456-493,Academic Press(1996))。
在一些实施方式中，抗体-药物偶联物中的抗体选自[抗体]部分公开的抗HER3抗体或其抗原结合片段。在一些实施方式中，抗体-药物偶联物中的抗HER3抗体或其抗原结合片段包含如SEQ ID NO:11所示的VL序列和如SEQ ID NO:15所示的VH序列。
通过上述制备方法可以获得本公开提供的抗体-药物偶联物。在一些实施方式中，制备的抗体-药物偶联物经过纯化处理，所述纯化处理包括但不限于凝胶过滤，例如使用凝胶柱进行纯化。
本公开方法制备的抗体-药物偶联物中，连接子与有效荷载依喜替康通过简单的化学方法与靶向HER3的抗体偶联，与传统的随机偶联方式相比，应用这种连接子得到的抗HER3抗体药物偶联物具有更高DAR值(例如DAR8)。
[药物组合物]
本公开提供了一种药物组合物，包括上文所述的抗HER3抗体或其抗原结合片段，或者抗体-药物偶联物，或其异构体、同位素变体、药学上可接受的盐、前药、溶剂合物，或其组合，以及药学可接受的辅料。
本公开的药物组合物可以根据药学可接受的辅料的具体适用形式、理化特征等，选择合适的给予方式。在一些实施方式中，所述药物组合物可以以冷冻干燥制剂或液状制剂的形式形成制剂，所述制剂中可以含有本领域中适当的制剂添加物。例如，上述药物组合物中，代表性地，含有1种以上的药学载体，例如灭菌的液体，如水及油(包含石油、动物、植物、或合成来源的油(例如花生油、大豆油、矿物油、芝麻油等))。在静脉内给予上述药物组合物的情况下，水是更具有代表性的载体。另外，食盐水溶液、以及葡萄糖水溶液及甘油水溶液也可作为液体载体，尤其是可用于注射用溶液。适当药学赋形剂在该领域中是已知的。根据需要，上述组合物中还可以含有微量的润湿剂或乳化剂、或pH缓冲化剂。所述药物组合物的给药方式通常选用肠胃外的给药，可以为皮内、肌肉内、腹腔内、静脉内或皮下注射，但不限于这些，例如可以利用输液或快速浓注(bolus injection)进行给予。通常，可以使用本领域中熟知的技术和方法将活性成分，例如，抗HER3抗体或其抗原结合片段，或者抗体-药物偶联物，制备为药物组合物(参见，例如，Ansel Introduction to Pharmaceutical Dosage Forms,第七版1999)。
本公开的药物组合物，可以是仅含有本公开的抗HER3抗体或其抗原结合片段，或者抗体-药物偶联物的药物组合物，也可以是含有抗HER3抗体或其抗原结合片段，或者抗体-药物偶联物，以及至少一种第二治疗剂(例如，癌治疗剂)的药物组合物。在一些实施方式中，也可将本公开的抗体-药物偶联物与其他癌治疗剂一同给予以增强抗癌效果。出于这种目的使用的其他抗癌剂，可与抗体-药物偶联物同时地、分别地或连续地向个体给予，也可改变给予间隔而进行给予。示例性的其他癌治疗剂如紫杉醇、顺铂、长春碱等，只要是具有抗肿瘤活性的药剂，就不受限制。
[试剂盒]
本公开还提供了一种试剂盒，所述试剂盒包括上述抗HER3抗体或其抗原结合片段、或者抗体-药物偶联物。所述试剂盒还可以根据需要包括容器、缓冲试剂、对照物如阳性对照物和阴性对照物。本领域技术人员可以根据需要进行相应的选择。相应地，试剂盒中还可以包括使用说明书，以便于本领域技术人员的操作和使用。
[用途]
本公开提供了上述抗HER3抗体或其抗原结合片段、抗体-药物偶联物、药物组合物及上述方法制备的抗体-药物偶联物、试剂盒在制备诊断、预防、治疗肿瘤疾病的治疗剂中的用途。
在一些实施方式中，提供了所述HER3抗体或其抗原结合片段、抗体-药物偶联物、药物组合物及上述方法制备的抗体-药物偶联物、试剂盒在制备抗肿瘤药物中的用途，或者，在制备靶向HER3的药物中的用途。
本公开提供的抗HER3抗体或其抗原结合片段、抗体-药物偶联物具有杀伤表达HER3细胞的作用，可以用于体内或体外杀伤表达HER3细胞。
所述肿瘤疾病包括良性肿瘤和恶性肿瘤(例如癌症)，特别地，所述抗体-药物偶联物适用于观察到HER3表达的肿瘤或癌，在一些实施方式中，所述肿瘤或癌为表达HER3的实体瘤。在一些实施方式中，所述肿瘤或癌包括但不限于肺癌、肾癌、尿路上皮癌、结直肠癌、前列腺癌、多形性成胶质细胞瘤、卵巢癌、胰腺癌、乳腺癌、转移性乳腺癌、管腔乳腺癌、黑素瘤、肝癌、膀胱癌、胃癌、胃肠道间质瘤、宫颈癌、头颈癌、食道癌、表皮样癌、腹膜癌、成体多形性成胶质细胞瘤、肝癌、肝细胞癌、结肠癌、直肠癌、结肠和直肠癌、子宫内膜癌、子宫癌、唾液腺癌、肾脏癌、外阴癌、甲状腺癌、肝恶性肿瘤、肛门癌、阴茎癌和肺腺癌(包括EGFR-TKI耐药肺腺癌)。
在一些实施方式中，所述癌的种类为乳腺癌、肺腺癌、胰腺癌和结肠癌。在一些实施方式中，所述癌的种类为乳腺癌、EGFR-TKI耐药肺腺癌、胰腺癌和结肠癌。
当受试者患有或怀疑患有表达HER3的实体瘤时，向受试者给予治疗剂量的治疗剂，所述治疗剂包括上述的抗HER3抗体或其抗原结合片段、抗体-药物偶联物、上述方法制备的抗体-药物偶联物或者上述的药物组合物，可以用于诊断、预防和治疗肿瘤疾病。
本公开还提供了一种诊断、预防和治疗肿瘤疾病的方法，包括：向有需求的受试者给予治疗剂量的治疗剂，所述治疗剂包括上述的抗HER3抗体或其抗原结合片段、抗体-药物偶联物、上述方法制备的抗体-药物偶联物、上述的药物组合物或者试剂盒。
所述受试者为哺乳动物，包括人、非人灵长类动物、狗、猪、鼠，优选所述受试者为人，例如患有表达HER3肿瘤的患者。
治疗剂的治疗剂量根据所治疗的特定病况、病况的严重程度、个体患者参数(包括年龄、身体状况、大小、性别和体重)、治疗持续时间、同时疗法(如果有的话)的性质、具体的施用途径、以及卫生执业医师的知识等因素而变化。在一些实施方式中，可以在已给予一次或多次抗体施用的个体中根据经验来确定活性成分如抗HER3抗体或其抗原结合片段或抗体-药物偶联物的剂量。
在一些实施方式中，抗HER3抗体或其抗原结合片段，或者抗体-药物偶联物的可接受的治疗剂量为0.1～30mg/kg，0.5～30mg/kg，1～30mg/kg，1～25mg/kg，0.1～25mg/kg，0.1～20mg/kg，1～20mg/kg或者0.5～20mg/kg。在一些实施方案中，给药频率为每12小时、每天、每周、每2周、每4周、每5周、每6周、每7周、每8周、每9周或每10周一次；或者每月、每2个月或每3个月或更长时间一次。所述治疗剂量和给药频率可以随治疗方案的变化而改变。
本公开的抗HER3抗体或其抗原结合片段、抗体-药物偶联物或者药物组合物，还可以与一种或多种第二治疗剂联用，联用时可以通过相同或不同的施用途径同时或依次发生。这可以根据治疗剂本身的代谢特性和正在治疗的疾病的不同而变化。
本公开的各种实施方式和优选项可以相互组合(只要它们彼此之间不是内在矛盾的)，由此组合而形成的各种实施方式都视为本公开的一部分。
下面将结合实施例以例证的方式更清楚、明确地阐述本公开的技术方案。应该理解的是，这些实施例仅用于例证的目的，绝不旨在限制本公开的保护范围。本公开的保护范围仅通过权利要求来限定。
实施例
通过以下所示的实施例具体地说明本公开，但本公开不受它们的限制。另外，不对这些实施例进行任何方式的限定性解释。另外，本说明书中，没有特别记载的试剂、溶剂及起始材料可由市售的供给源容易地获得。
实施例1：制备化合物LP-1
步骤1：合成中间体11-1
化合物11-1A(Mc-Val-Ala-OH，购自上海皓元生物医药科技有限公司，2.4g，6.29mmol)以及11-1B(3.18g，6.29mmol)混合溶液中，室温(25℃～30℃)下加入二氯甲烷(DCM)和甲醇(MeOH)的混合溶液(v:v＝2:1，90mL)以及2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉(EEDQ，1.86g，7.55mmol)。室温下反应24小时，真空除去溶剂，粗残余物通过快速色谱法纯化，得到化合物11-1(3.9g，71％)。LC-MS(ESI,m/z):868.49(M+H)。
步骤2：合成中间体11-2
将化合物11-1(2g，2.3mmol)溶解于无水四氢呋喃(THF，50mL)中，在氩气环境下于0℃下加入氟化氢-吡啶(4.6g，46mmol)，搅拌下持续反应2小时后加入水淬灭反应，DCM 萃取，干燥有机相，浓缩。残余物通过硅胶色谱法纯化，得到化合物11-2(1.1g，76％)。LC-MS(ESI,m/z):630.31(M+H)。
步骤3：合成中间体11-3
将化合物11-2(700mg，1.11mmol)溶解在无水N,N-二甲基甲酰胺(DMF，4mL)中，在氩气气氛中于室温条件下加入N,N-二异丙基乙胺(DIPEA，0.39ml，2.23mmol)以及4,4'-碳酸二硝基二苯酯(406mg，1.33mmol)，反应混合物在环境温度下搅拌过夜。浓缩除去溶剂，甲基叔丁基醚(MTBE)沉淀产物，过滤收集黄色固体，乙醚洗涤，干燥得到化合物11-3。LC-MS(ESI,m/z):795.41(M+H)。
步骤4：合成中间体11-4
将化合物11-3(300mg，0.44mmol)溶解于4mL无水DMF中，加入1mL干燥的吡啶，然后加入甲磺酸依喜替康(exatecan mesylate，购自上海皓元生物医药科技有限公司，234mg，0.44mmol)和1-羟基苯并三唑(HOBt，60mg，0.44mmol)。将反应混合物在氩气下于室温搅拌过夜。产物通过制备型高效液相色谱(pre-HPLC)纯化，得到中间体11-4(230mg，48％)。LC-MS(ESI,m/z):1091.53(M+H)。
步骤5：合成中间体11-5
将化合物11-4(200mg,0.183mmol)溶于1mL无水DCM中，0℃加入300μL TFA，混合物室温下搅拌反应30min，浓缩除去溶剂，得到中间体11-5的TFA盐。LC-MS(ESI,m/z):991.47(M+H)。
步骤6：合成化合物LP-1
将化合物11-5(120mg，0.109mmol)溶解在1mL无水DMF中，加入N-乙酰基十聚肌氨酸(Ac-Sar10-COOH，84mg，0.109mmol)，然后加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU，50mg，0.130mmol)和DIPEA(38μL，0.22mmol)，将反应混合物在室温搅拌过夜，浓缩除去溶剂，粗产物通过pre-HPLC纯化，得到化合物LP-1(74mg，38％)。LC-MS(ESI,m/z):1743.85(M+H)。
实施例2：制备化合物LP-2
化合物LP2的合成按照化合物LP-1的步骤，将起始原料11-1A替换为Mc-GGFG-OH(购自上海皓元生物医药科技有限公司，GGFG表示由通过肽键连接的甘氨酸-甘氨酸-苯丙氨酸-甘氨酸组成的氨基酸序列)，得到化合物LP-2，为米色无定形固体。LC-MS(ESI,m/z):1891.90(M+H)。
实施例3：制备化合物LP-3
化合物LP-3为LP-1的中间体，去除步骤6，中间体11-5即为LP-3。
实施例4：单克隆抗体的制备
使用人HER3蛋白胞外区片段抗原(NCBI参考序列:NM_001982.4，氨基酸序列20-643位)免疫Balb/c小鼠(8-12周龄)，并监测其血清效价以决定免疫次数。初次免疫后经过3到4次的加强免疫，取小鼠血清按照本领域常规方法检测滴度。滴度检测合格的小鼠冲击免疫一次后，取全脾和1/2的淋巴结，与骨髓瘤SP2/0细胞系进行PEG融合。融合细胞进行铺板培养，收集所有孔的上清液，使用ELISA方法筛选抗原，将镜检有细胞的阳性孔转到96孔板继续培养。生长7天后，收集所有孔的上清液并使用ELISA方法检测与抗原的反应。阳性孔进一步检测不同稀释度的抗原结合，以进行亲和力排序。免疫原亲和力最高的20个亲代克隆进入亚克隆。通过有限稀释法和ELISA筛选进行亚克隆，得到杂交瘤细胞株。对该杂交瘤细胞株进行小鼠腹水制备，收集纯化后获得单克隆抗体，命名为Mu4O3，测定其CDR及可变区的氨基酸序列，如下表1所示，其中CDR(Kabat系统定义和编号)以下划线示出。
表1杂交瘤可变区氨基酸序列(单字母缩写)
对杂交瘤序列进行人源化修饰，得到人源化4O3抗体(简称“Hu4O3”)L1H4、L1H5、L2H4、L2H5、L4H4、L4H5和L4H7。其中，L1、L2、L4表示抗体轻链可变区序列的编号，H4、H5、H7表示抗体重链可变区序列的编号，即，L1H4抗体包括编号为L1的轻链可变区和编号为H4的重链可变区；L1H5抗体包括编号为L1的轻链可变区和编号为H5的重链可变区；L2H4抗体包括编号为L2的轻链可变区和编号为H4的重链可变区；L2H5抗体包括编号为L2的轻链可变区和编号为H5的重链可变区；L4H4抗体包括编号为L4的轻链可变区和编号为H4的重链可变区；L4H5抗体包括编号为L4的轻链可变区和编号为H5的重链可变区；L4H7抗体包括编号为L4的轻链可变区和编号为H7的重链可变区。
Hu4O3的CDR序列(以下划线示出)及可变区序列如下表2所示，其中，VH的CDR2中的突变氨基酸以粗斜体示出。CDR使用Kabat系统定义和编号。
表2人源化4O3抗体的可变区序列(单字母缩写)
出于实施例制备和/或检测的目的，上述抗体的恒定区选用人IgG1的恒定区，其中重链恒定区序列选用SEQ ID NO:17所示的氨基酸序列，轻链恒定区序列选用SEQ ID NO:18所示的氨基酸序列。
实施例5：抗体-药物偶联物的检测方法
抗体-药物偶联物按照以下方法进行浓缩、换液、纯化以及测量抗体浓度、计算每个抗体所携带的药物分子的平均分子数以鉴别抗体-药物偶联物。
操作A：抗体或抗体-药物偶联物的浓缩
取超滤管(Amicon Ultra，50000MWCO，密理博公司)，加入需要浓缩的抗体或者抗体-药物偶联物的溶液，离心至需要体积后取出。
操作B：抗体浓度的测量
使用酶标仪(Multiskan GO,赛默飞世尔公司)，根据制造商定义的方法测量抗体的吸收值，该吸收值与抗体在该波长下的吸收系数的比值即为抗体的浓度。
操作C：抗体的换液
根据制造商(赛默飞公司)提供的说明书，将zeba脱盐柱(5mL,40K MWCO)事先用含有氯化钠(50mM)和EDTA(2mM)的磷酸盐缓冲液(简称“PBS7.0/EDTA”，50mM,pH 7.0)平衡。每个zeba脱盐柱上样2mL，离心(1000g，4分钟)，收集流穿部分并通过操作A进行浓缩，通过操作B测定抗体浓度，用PBS7.0/EDTA对抗体浓度进行调整。
操作D：抗体-药物偶联物的纯化
根据制造商(赛默飞公司)提供的说明书，将zeba脱盐柱(5mL,40K MWCO)事先用存储缓冲液进行平衡。存储缓冲液使用含有150mM氯化钠的组氨酸-醋酸缓冲液(20mM组氨酸，pH 5.5)或含有50mM氯化钠的磷酸缓冲液(50mM,pH 7.0)。将含有抗体-药物偶联物的反应液(约2mL)加入zeba脱盐柱，离心(1000g，4分钟)后收集流穿部分(约2mL)，重复两次洗脱过程，除去未结合的连接子-有效荷载和包括还原剂的低分子量化合物。
操作E：测量抗体-药物偶联物中抗体的浓度以及平均每个抗体上连接的药物分子个数(DAR值)
抗体-药物偶联物上偶联的药物浓度可以通过测量抗体-药物偶联物水溶液在280nm和370nm下的紫外吸收值并通过下面的公式计算而得到。
在任何给定的波长下，一个体系的总吸光度等于该系统中存在的所有吸光化学物质的吸光度之和(吸光度的可加和性)。因此，假设抗体与药物在偶联前后，抗体与药物的摩尔吸收系数不变，则抗体-药物偶联物中的抗体浓度和药物浓度可以用如下公式表示。
A280＝AD,280+AA,280＝εD,280CD+εA,280CA     公式(1)
A370＝AD,370+AA,370＝εD,370CD+εA,370CA     公式(2)
A280代表抗体-药物偶联物水溶液在280nm下的总吸收值，A370代表抗体-药物偶联物水溶液在370nm下的总吸收值。AA,280代表抗体在280nm下的吸收值，AA,370代表抗体在370nm下的吸收值，AD,280代表药物分子在280nm下的吸收值，AD,370代表药物分子在370nm下的吸收值，εA,280代表抗体在280nm下的摩尔消光系数，εA,370代表抗体在370nm下的摩尔消光系数，εD,280代表药物分子在280nm下的摩尔消光系数，εD,370代表药物分子在370nm下的摩尔消光系数，CA代表抗体-药物偶联物中抗体的浓度，CD代表抗体-药物偶联物中药物分子的浓度。
εA,280，εA,370，εD,280和εD,370为已知数值(通过抗体的序列计算得到或者化合物的UV吸收测量得到)。例如，εA,280可以通过抗体的氨基酸序列利用一种已知的方法计算得到(蛋白质科学(Protein Science)，1995年，第4卷，第2411-2423页)。抗体在370nm下通常没有吸收，所以εA,370通常是0。εD,280和εD,370的值可以通过测量药物分子分别在280nm和370nm下吸光度随浓度的变化值，利用朗伯-比尔定律(吸光度＝摩尔浓度×摩尔消光系数×光程)计算得到。CA和CD可以通过测量抗体-药物偶联物在280nm和370nm下的吸光值A280和A370，然后解二元一次方程组公式(1)和(2)得到。另外，通过CD除以CA，可以得到平均每个抗体上连接的药物分子的数量(DAR值)。
操作F:抗体-药物偶联物中聚集体的测量
使用高效液相色谱中体积排阻色谱检测抗体-药物偶联物中的聚集体，方法如下：
高效液相色谱系统：Agilent 1260 Infinity II HPLC system
检测器：Ultraviolet absorption spectrometer(检测波长：280nm)
色谱柱型号:TOSOH TSKgel G3000SWXL(7.8×300mm,5μm)
流动相：200mmol/L KHPO4,150mmol/L NaCl,15％(v/v)异丙醇,pH7.0
流速：0.75mL/min
分析时间：18min
柱温：室温
进样量：50μg
数据分析：
质控品(QC，L1H5裸抗，即没有偶联连接子-有效荷载的编号为L1H5的抗体)的体积排阻色谱图如图1A所示；150kDa的质控品的主峰(单峰)的保留时间在9.5-10.5分钟之间。聚集体的保留时间应该早于上述单体的保留时间。
操作G：抗体-药物偶联物疏水性测量
使用高效液相色谱疏水层析色谱法(HIC)分析抗体-药物偶联物的疏水性，方法如下：
高效液相色谱系统：Agilent 1260 Infinity II HPLC system
检测器：Ultraviolet absorption spectrometer(检测波长：280nm)
色谱柱型号：TOSOH TSKgel Butyl-NPR(4.6mm I.D.×3.5cm,2.5μm)
流动相A：mol/L(NH4)2SO4,50mmol/L KHPO4,pH7.0
流动相B：50mmol/L KHPO4,25％(v/v)isopropanol,pH7.0
分析时间：25min
柱温：室温
洗脱程序(B％)：0％-25％(0-1分钟),25％(1-3分钟),25％-80％(3-13分钟),80％(13-17分钟),80％-0％(17-17.10分钟),0％(17.10-25分钟)
进样量：10μL
数据分析：质控品(QC，L1H5裸抗)的疏水层析色谱图如图1B和图22所示；质控品参照抗体的疏水层析色谱图如图22所示。通常而言，保留时间越短的样品的疏水性越弱，相比于未偶联药物分子的裸抗，抗体-药物偶联物的疏水性更高，因此其保留时间应更长。
实施例6：制备抗体-药物偶联物L1H5-LP3
抗体的还原：通过实施例5中操作B(抗体在280nm下的消光系数采用1.49mLmg-1cm-1)和操作C将实施例4制备的抗体L1H5用PBS7.0/EDTA进行换液，换液后的抗体浓度为20.76mg/mL。在481.70μL的L1H5抗体的水溶液中加入93.33μL的5mM的TCEP溶液(相当于抗体含量的7倍当量)，同时加入200μL的50mM的磷酸盐缓冲液(pH 7.0,PBS7.0)以及224.97μL的超纯水，将混合液置于37℃环境中反应2小时。
抗体与连接子-有效荷载的偶联：将上述混合液于4℃环境中孵育10分钟，实施例3制备的连接子-有效荷载LP3溶解在N,N二甲基乙酰胺(DMA)后加入混合液中，加入体积为93.33μL(相当于抗体含量的14倍当量)，混合液于22℃条件下继续反应30分钟。
抗体-药物偶联物的纯化：将上述反应液采用实施例5中操作D的方法进行纯化，获得抗体-药物偶联物L1H5-LP3。
抗体-药物偶联物的表征：采用实施例5中操作E(εD,280＝5186和εD,370＝13688)，操作F和操作G对获得的抗体-药物偶联物进行表征。
通过操作E测量计算得到抗体-药物偶联物的浓度为5.73mg/mL，通过操作E测量计算得到每个抗体上平均偶联的有效荷载的个数为7.78。图2A示出聚集体的检测图谱，通过操作F测量得到抗体-药物偶联物L1H5-LP3的聚集体含量为2.20％。图2B示出抗体-药物偶联物L1H5-LP3的疏水层析检测图谱，通过操作G测量的抗体-药物偶联物的保留时间为6.169min。
实施例7：制备抗体-药物偶联物L1H5-LP1
抗体的还原：通过实施例5的操作B(抗体在280nm下的消光系数采用1.49mLmg-1cm-1)和操作C将抗体用PBS7.0/EDTA进行换液，换液后的抗体浓度为11.44mg/mL。在1048.95μL的实施例4制备的L1H5抗体的水溶液中加入160μL的5mM的TCEP溶液(相当于抗体含量的10倍当量)，同时加入320μL的50mM的PBS7.0以及71.05μL的超纯水，将混合液置于37℃环境中反应2小时。
抗体与连接子-有效荷载的偶联：将上述混合液置于4℃环境中孵育10分钟，实施例1制备的连接子-有效荷载LP1溶解在DMA中后加入混合液中，加入体积为120μL(相当于抗体含量的15倍当量)，混合液于22℃环境中继续反应30分钟。
抗体-药物偶联物的纯化：将上述反应液采用实施例5中操作D的方法进行纯化，获得抗体-药物偶联物L1H5-LP1。
抗体-药物偶联物的表征：采用实施例5的操作E(εD,280＝6384和εD,370＝16180)，操作F和操作G对获得的抗体-药物偶联物进行表征。
通过操作E测量计算得到抗体药物偶联物的浓度为6.12mg/mL，通过操作E测量计算得到每个抗体上平均偶联的有效荷载的个数为8.03。图3A示出聚集体的检测图谱，通过操作F测量得到抗体-药物偶联物L1H5-LP1的聚集体含量为1.60％。图3B示出抗体-药物偶联物L1H5-LP1的疏水层析检测图谱，通过操作G测量的抗体-药物偶联物L1H5-LP1的保留时间为6.234min。
其他抗体，例如L1H4及L4H4，和LP1的药物偶联物制备方法参照实施例7所描述的方法。
实施例8：制备抗体-药物偶联物L1H5-LP2
抗体的还原：通过实施例5的操作B(抗体在280nm下的消光系数采用1.49mLmg-1cm-1)和操作C将抗体用PBS7.0/EDTA进行换液，换液后的抗体浓度为11.44mg/mL。在1048.95μL的实施例4制备的L1H5抗体的水溶液中加入160μL的5mM的TCEP溶液(相当于抗体含量 的10倍当量)，同时加入320μL的50mM的PBS7.0以及71.05μL的超纯水，将混合液置于37℃环境中反应2小时。
抗体与连接子-有效荷载的偶联：将上述混合液置于4℃环境中孵育10分钟，实施例2制备的连接子-有效荷载LP2溶解在DMA中后加入混合液中，加入体积为120μL(相当于抗体含量的15倍当量)，混合液于22℃环境中继续反应30分钟。
抗体-药物偶联物的纯化：将上述反应液采用实施例5中操作D的方法进行纯化，获得抗体-药物偶联物L1H5-LP2。
抗体-药物偶联物的表征：采用实施例5的操作E(εD,280＝5814和εD,370＝14742)，操作F和操作G对获得的抗体-药物偶联物进行表征。
通过操作E测量计算得到抗体药物偶联物的浓度为6.28mg/mL，通过操作E测量计算得到每个抗体上平均偶联的有效荷载的个数为8.89。图4A示出聚集体的检测图谱，通过操作F测量得到抗体-药物偶联物L1H5-LP2的聚集体含量为1.89％。图4B示出抗体-药物偶联物L1H5-LP2的疏水层析检测图谱，通过操作G测量的抗体-药物偶联物L1H5-LP2的保留时间为6.599min。
对比例1：制备抗体-药物偶联物参照ADC
抗体的还原：通过实施例5中的操作B(抗体在280nm下的消光系数采用1.77mLmg-1cm-1)和操作C将抗体用PBS7.0/EDTA进行换液，换液后的抗体浓度为9.44mg/mL。在0.037mL的参照抗体(抗体序列参见专利US20190151328A1中SEQ ID NO:69-72，U1-59)的水溶液中加入3.27μL的5mM的TCEP溶液(相当于抗体含量的7倍当量)，同时加入14μL的50mM的PBS7.0以及15.66μL mL的去离子水，将混合液置于37℃环境中反应2小时。
抗体与连接子-有效荷载的偶联：将上述混合液于4℃环境中孵育10分钟，连接子-有效荷载GGFG-DXd(购自DC Chemicals,DC50025)溶解在DMA中后加入到混合液中，加入体积为3.27μL(相当于抗体含量的14倍当量)，混合液于22℃条件下继续反应30分钟。
抗体-药物偶联物的纯化：将上述反应液采用实施例5中操作D的方法进行纯化，获得抗体-药物偶联物参照ADC。
抗体-药物偶联物的表征：采用实施例5中的操作E(εD,280＝5178和εD,370＝20217)，操作F和操作G对获得的抗体-药物偶联物进行表征。
通过操作B测量计算得到抗体-药物偶联物的浓度为3.10mg/mL，通过操作E测量计算得到每个抗体上平均偶联的有效荷载的个数为6.63。图23A示出聚集体的检测图谱，通过操作F测量得到抗体-药物偶联物参照ADC的聚集体含量为2.04％。图23B示出抗体-药物偶联物参 照ADC的疏水层析检测图谱，通过操作G测量的抗体-药物偶联物参照抗体-DXd的保留时间为8.215min。
同时，图22示出实施例4制备的L1H5抗体，实施例6制备的抗体-药物偶联物L1H5-LP3，参照抗体以及抗体-药物偶联物参照ADC的疏水性测量对比图，表3示出各检测样品的保留时间。结果显示，与阳性对照参照抗体及药物-抗体偶联物参照ADC相比，L1H5抗体及L1H5-LP3的保留时间更短，表明无论是参照抗体还是药物-抗体偶联物参照ADC，疏水性都强于L1H5抗体和抗体-药物偶联物L1H5-LP3。可以预期，由于L1H5抗体及L1H5-LP3的疏水性弱，在体内具有更高的稳定性。
表3 L1H5、L1H5-LP3、参照抗体和参照ADC的保留时间
对比例2：制备抗体-药物偶联物参照抗体-LP3
抗体的还原：通过实施例5中的操作B(抗体在280nm下的消光系数采用1.77mLmg-1cm-1)和操作C将抗体用PBS7.0/EDTA进行换液，换液后的抗体浓度为15.5mg/mL。在1.858mL的参照抗体(序列同对例比1)的水溶液中加入268.80μL的5mM的TCEP溶液(相当于抗体含量的7倍当量)，同时加入360μL的100mM的PBS7.0以及1113.14μL的去离子水，将混合液置于37℃环境中反应2小时。
抗体与连接子-有效荷载的偶联：将上述混合液于4℃环境中孵育10分钟，连接子-有效荷载LP3溶解在DMA中后加入到混合液中，加入体积为268.80μL(相当于抗体含量的14倍当量)，混合液于22℃条件下继续反应30分钟。
抗体-药物偶联物的纯化：将上述反应液采用实施例5中操作D的方法进行纯化，获得抗体-药物偶联物参照抗体-LP3。
抗体-药物偶联物的表征：采用实施例5中的操作E(εD,280＝5186和εD,370＝13688)，操作F和操作G对获得的抗体-药物偶联物进行表征。
通过操作E测量计算得到抗体-药物偶联物的浓度为8.45mg/mL，通过操作E测量计算得到每个抗体上平均偶联的有效荷载的个数为7.60。图24A示出聚集体的检测图谱，通过操作F测量得到抗体-药物偶联物参照抗体-LP3的聚集体含量为1.92％。图24B示出抗体-药物偶联物 参照抗体-LP3的疏水层析检测图谱，通过操作G测量的抗体-药物偶联物参照抗体-MCE8的保留时间为6.262min。
对比例3：制备抗体-药物偶联物L1H5-DXd
抗体的还原：通过实施例5中的操作B(抗体在280nm下的消光系数采用1.49mLmg-1cm-1)和操作C将抗体用PBS7.0/EDTA进行换液，换液后的抗体浓度为11.44mg/mL。在0.59mL的L1H5抗体的水溶液中加入90μL的5mM的TCEP溶液(相当于抗体含量的10倍当量)，同时加入180μL的50mM的PBS7.0以及39.97μL的去离子水，将混合液置于37℃环境中反应2小时。
抗体与连接子-有效荷载的偶联：将上述混合液于4℃环境中孵育10分钟，连接子-有效荷载GGFG-DXd(购自DC Chemicals,DC50025)溶解在DMA中后加入到混合液中，加入体积为67.50μL(相当于抗体含量的15倍当量)，混合液于22℃条件下继续反应30分钟。
抗体-药物偶联物的纯化：将上述反应液采用实施例5中操作D的方法进行纯化，获得抗体-药物偶联物L1H5-DXd。
抗体-药物偶联物的表征：采用实施例5中的操作E(εD,280＝5178和εD,370＝20217)，操作F和操作G对获得的抗体-药物偶联物进行表征。
通过操作E测量计算得到抗体-药物偶联物的浓度为5.17mg/mL，通过操作E测量计算得到每个抗体上平均偶联的有效荷载的个数为6.54。图25A示出聚集体的检测图谱，通过操作F测量得到抗体-药物偶联物L1H5-DXd的聚集体含量为2.02％。图25B示出抗体-药物偶联物L1H5-DXd的疏水层析检测图谱，通过操作G测量的抗体-药物偶联物L1H5-DXd的保留时间为7.807min。
对比例4：制备抗体-药物偶联物Dxd同型对照ADC
抗体的还原：通过实施例5中的操作B(抗体在280nm下的消光系数采用1.35mLmg-1cm-1)和操作C将抗体用PBS7.0/EDTA进行换液，换液后的抗体浓度为10mg/mL。在2.45mL的同型对照抗体人IgG(购自北京索莱宝科技有限公司，产品型号为SP001)的水溶液中加入326.67μL的5mM的TCEP溶液(相当于抗体含量的10倍当量)，同时加入700μL的50mM的PBS7.0以及23.33μL的去离子水，将混合液置于37℃环境中反应2小时。
抗体与连接子-有效荷载的偶联：将上述混合液于4℃环境中孵育10分钟，连接子-有效荷载GGFG-DXd溶解在DMA中后加入到混合液中，加入体积为294μL(相当于抗体含量的18倍当量)，混合液于22℃条件下继续反应30分钟。
抗体-药物偶联物的纯化：将上述反应液采用实施例5中操作D的方法进行纯化，获得抗体-药物偶联物Dxd同型对照ADC。
抗体-药物偶联物的表征：采用实施例5中的操作E(εD,280＝5178和εD,370＝20217)，操作F和操作G对获得的抗体-药物偶联物进行表征。
通过操作E测量计算得到抗体-药物偶联物的浓度为8.20mg/mL，通过操作E测量计算得到每个抗体上平均偶联的有效荷载的个数为7.08。图26A示出聚集体的检测图谱，通过操作F测量得到抗体-药物偶联物Dxd同型对照ADC的聚集体含量为4.25％。图26B示出抗体-药物偶联物Dxd同型对照ADC的疏水层析检测图谱，通过操作G测量的抗体-药物偶联物Dxd同型对照ADC的保留时间为8.222min。
对比例5：制备抗体-药物偶联物LP3同型对照ADC
抗体的还原：通过实施例5中的操作B(抗体在280nm下的消光系数采用1.35mLmg-1cm-1)和操作C将抗体用PBS7.0/EDTA进行换液，换液后的抗体浓度为10mg/mL。在4mL的同型对照抗体人IgG的水溶液中加入672μL的5mM的TCEP溶液(相当于抗体含量的7倍当量)，同时加入1440μL的50mM的PBS7.0以及1088μL的去离子水，将混合液置于37℃环境中反应2小时。
抗体与连接子-有效荷载的偶联：将上述混合液于4℃环境中孵育10分钟，连接子-有效荷载LP3溶解在DMA中后加入到混合液中，加入体积为672μL(相当于抗体含量的14倍当量)，混合液于22℃条件下继续反应30分钟。
抗体-药物偶联物的纯化：将上述反应液采用实施例5中操作D的方法进行纯化，获得抗体-药物偶联物LP3同型对照ADC。
抗体-药物偶联物的表征：采用实施例5中的操作E(εD,280＝5186和εD,370＝13688)，操作F和操作G对获得的抗体-药物偶联物进行表征。
通过操作E测量计算得到抗体-药物偶联物的浓度为7.42mg/mL，通过操作E测量计算得到每个抗体上平均偶联的有效荷载的个数为7.28。图27A示出聚集体的检测图谱，通过操作F测量得到抗体-药物偶联物LP3同型对照ADC的聚集体含量为5.37％。图27B示出抗体-药物偶联物LP3同型对照ADC的疏水层析检测图谱，通过操作G测量的抗体-药物偶联物LP3同型对照ADC的保留时间为6.450min。
检测例1：Mu4O3抗体与不同HER3表达量细胞的细胞流式检测
分别将4种细胞系，MCF-7(人乳腺癌细胞，购自中国科学院典型培养物保藏委员会细胞库)，SW620(人结肠癌细胞，购自浙江美森细胞科技有限公司)，SK-BR-3(人乳腺癌细胞， 购自上海勋庆生物科技有限公司)，MDA-MB-231(人乳腺癌细胞，购自赛百慷(上海)生物技术股份有限公司)在培养皿中使用胰酶进行消化，消化细胞经过1000rpm离心5min后用10％山羊血清(购自北京索莱宝科技有限公司，货号SL038)封闭30min。封闭完成后以20μg/mL终浓度加入实施例4制备的Mu4O3抗体孵育1h，磷酸盐缓冲液(PBS，pH 7.2-7.4)清洗2遍后按照1:500加入FITC标记的羊抗鼠二抗(购自Jackson ImmunoResarch，货号111-545-003)孵育1h，最后PBS清洗2遍后使用流式细胞仪分析结果。
结果如图5所示，在HER3阳性的3个细胞系(MCF-7,SW620,SK-BR-3)中，Mu4O3抗体的检测结果均为到阳性；在HER3阴性细胞(MDA-MB-231)中，检测结果为阴性，无荧光信号检出。结果表明，Mu4O3抗体具有特异性。
检测例2：Mu4O3抗体在HER3-GFP Tag过表达293T细胞中的免疫荧光检测
将293T细胞(购自中国科学院典型培养物保藏委员会细胞库)接种在24孔细胞培养板中，使其细胞密度达到70％，将带有GFP标签的人HER3重组质粒HER3-GFP Tag(购自湖南科爱医疗器械有限公司，货号G109862)用阳离子聚合物-聚乙烯亚胺(PEI)转染法进行细胞转染，具体方法为：将0.5μg质粒和1.5μg的PEI在500μL的Opti-MEM培养基(购自赛默飞世尔科技(中国)有限公司，货号31985070)中进行混合，室温稳定15min后将混合液缓慢加入到细胞培养孔中，放回37℃细胞培养箱。24h后细胞使用PBS清洗并使用4％组织细胞固定液(PFA)进行固定10min，PBS清洗后使用10％山羊血清(购自北京索莱宝科技有限公司，货号SL038)封闭30min。封闭完成后以20μg/mL终浓度加入Mu4O3抗体孵育1h，PBS清洗2遍后1:500加入APC标记的羊抗鼠二抗(购自Jackson ImmunoResarch，货号111-585-003)孵育1h，PBS清洗2遍，加入DAPI(4',6-二脒基-2-苯基吲哚)溶液孵育5min，PBS清洗2遍后荧光显微镜镜检拍摄。图6示出Mu4O3抗体在HER3-GFP Tag过表达293T细胞中的免疫荧光图像，结果显示HER3蛋白和Mu4O3抗体染色有明显的共定位特征。
图6中，标记为GFP的图片仅显示绿色荧光，表明HER3蛋白成功转染进入293T细胞，并在胞浆和胞膜均有表达；标记为Mu4O3的图片仅显示红色荧光，表明Mu4O3抗体成功将过表达细胞染色，且染色定位为膜定位；标记为DAPI的图片仅显示蓝色荧光，表明为细胞核的染色；标记为MERGED的图片为将上述3张单独染色图进行叠加处理后的合并图片，其中，部分膜定位绿光能够和膜定位红光实现完全位置重合，且荧光强度保持一致，证明Mu4O3抗体特异性染色过表达HER3蛋白，且在没有发生过表达的细胞(仅细胞核有蓝色染色，无绿色发光)中没有发现Mu4O3结合的红色荧光染色，说明Mu4O3抗体无非特异性染色。
检测例3：Mu4O3抗体对SW620细胞的体外杀伤检测
培养SW620细胞(人结肠癌细胞，购自浙江美森细胞科技有限公司)使细胞密度达到80％，收集细胞，铺96孔板，调整细胞密度至2-5x 104/ml。每孔铺100μl，实施例4制备的Mu4O3抗体或鼠抗IgG(MouseIgG，购自艾比玛特医药科技(上海)有限公司)从300nM为起始浓度进行3倍梯度稀释，稀释完成后加入细胞培养液，同时加入2μg/mL的MMAE偶联羊抗鼠二抗(购自艾比玛特医药科技(上海)有限公司，货号B30008)，静置培养5天。期间定期观察细胞凋亡情况。5天后，直接向96孔板中加入15μl CCK-8原液，37℃培养箱反应0.5-2h后测量450nm处吸光度，根据检测结果以及抗体稀释梯度绘制细胞存活曲线。
结果如图7所示，显示Mu4O3抗体有明显的特异性细胞杀伤效果。
检测例4：Hu4O3抗体候选分子在MDA-MB-453和SW620细胞系中的流式亲和力检测
分别将SW620(人结肠癌细胞)，MDA-MB-453(人乳腺癌细胞，购自浙江美森细胞科技有限公司)从培养皿中用胰酶进行消化，消化细胞经过1000rpm离心5min后用10％山羊血清(购自北京索莱宝科技有限公司，货号SL038)封闭30min。Hu4O3抗体以500nM为起始浓度，进行3倍梯度稀释，完成后将梯度稀释的Hu4O3抗体加入细胞中孵育1h，PBS清洗2遍后1:500加入FITC标记的羊抗人二抗(购自Jackson ImmunoResarch，货号109-545-008)孵育1h，最后PBS清洗2遍后进行流式细胞仪分析结果。
图8和图9为Hu4O3抗体候选分子L1H4、L1H5、L2H4、L2H5、L4H4、L4H5、L4H7在MDA-MB-453和SW620细胞系中的流式亲和力检测数据。结果显示，所有候选分子对两个细胞系均有特异性结合，且结合亲和力各不相同。L1H4和L1H5对于MDA-MB-453细胞展示出较优的亲和力，EC50分别为71.5nM和121.7nM。L1H4、L1H5、L4H4和L4H7对于SW620细胞展示出较优的亲和力，EC50分别为193.5nM、146.7nM、90.0nM、21.9nM，L2H4次之，EC50为1203nM。
检测例5：L1H5抗体和参照抗体对SK-BR-3细胞系的体外细胞增殖抑制实验
培养SK-BR-3(人乳腺癌细胞)使细胞密度达到80％，收集细胞，铺96孔板，调整细胞密度至2-5x 104/ml。每孔铺100μl，抗体以100μg/ml终浓度加入细胞培养液静置培养5天。期间定期观察细胞凋亡情况。5天后，向96孔板中加入15μl CCK-8原液，37℃培养箱反应0.5-2h后测量450nm处吸光度，根据检测结果对比空白对照计算细胞存活比例。
图10为实施例4制备的L1H5抗体、参照抗体和空白对照在SK-BR-3细胞系中的细胞增殖抑制率。结果表明，L1H5对SK-BR-3的体外细胞增殖抑制效果优于参考抗体。
检测例6：小鼠乳腺癌CDX模型体内肿瘤抑制实验
6周龄的Balb/c裸鼠购买自江苏集萃药康生物科技股份有限公司。每只小鼠皮下接种五百万BT-474细胞(人乳腺导管癌细胞)，在平均肿瘤体积约150mm3，按照20mg/kg的剂量分别皮下注射给予实施例4制备的L1H5、参照抗体(阳性对照)以及空白对照PBS(阴性对照)。每周1次，共治疗两周。给药后使用游标卡尺每周测量两次肿瘤体积，并按照如下公式计算肿瘤体积：TV＝(长×宽)2/2。
图11显示出BT-474乳腺癌小鼠模型的体内肿瘤体积-时间变化曲线图，结果显示，L1H5能够抑制肿瘤生长并且和阳性参照抗体相当。
检测例7：Hu4O3抗体候选分子-药物偶联物对SW620细胞的体外杀伤检测
培养SW620(人结肠癌细胞)，使细胞密度达到80％，收集细胞，铺96孔板，调整细胞密度至2-5x 104/ml。每孔铺100μl，ADC分子以300nM为起始浓度进行3倍梯度稀释，稀释完成后加入细胞培养液静置培养5天。期间定期观察细胞凋亡情况。5天后，向96孔板中加入15μl CCK-8原液，37℃培养箱反应0.5-2h后测量450nm处吸光度，根据检测结果及ADC的稀释梯度绘制细胞存活曲线。
图12为实施例7制备的抗体-药物偶联物L1H4-LP1、L1H5-LP1、L4H4-LP1、对比例1制备的抗体-药物偶联物阳性对照参照ADC在SW620细胞系中的细胞存活曲线。结果表明，L1H4-LP1、L1H5-LP1和L4H4-LP1对SW620细胞系的体外细胞杀伤效果均优于参照ADC，L1H5-LP1对于SW620细胞系的细胞增殖抑制效果最优。
检测例8：L1H5抗体、L1H5-LP3和参照抗体、参照ADC对SK-BR-3和BXPC-3细胞系的体外细胞杀伤实验
培养SK-BR-3(人乳腺癌细胞)和BXPC-3(人胰腺癌细胞，购自中国科学院典型培养物保藏委员会细胞库)使细胞密度达到80％，收集细胞，铺96孔板，调整细胞密度至2-5x 104/ml。每孔铺100μl，抗体和ADC分子均以300nM为起始浓度进行3倍梯度稀释，稀释完成后加入细胞培养液静置培养5天。期间定期观察细胞凋亡情况。5天后，向96孔板中加入15μl CCK-8原液，37℃培养箱反应0.5-2h后测量450nm处吸光度，根据检测结果及抗体和ADC的稀释梯度绘制细胞存活曲线。
图13和图14分别为实施例4制备的L1H5抗体、实施例6制备的抗体-药物偶联物L1H5-LP3、参照抗体(阳性对照)和对比例1制备的抗体-药物偶联物参照ADC(阳性对照)在SK-BR-3细胞系和BXPC-3细胞系中的细胞存活曲线。结果表明，L1H5-LP3对两个细胞系的体外细胞杀伤效果明显优于参照ADC，L1H5抗体对于SK-BR-3细胞系的细胞增殖抑制效果优于参照抗体，L1H5抗体和参照抗体对BXPC-3细胞系均未表现出体外杀伤效果。
检测例9：L1H5-LP1和L1H5-LP2对HCT-15细胞的体外杀伤检测
培养HCT-15(人结肠癌细胞)，使细胞密度达到80％，收集细胞，铺96孔板，调整细胞密度至2-5x 104/ml。每孔铺100μl，ADC分子以300nM为起始浓度进行3倍梯度稀释，稀释完成后加入细胞培养液静置培养5天。期间定期观察细胞凋亡情况。5天后，向96孔板中加入15μl CCK-8原液，37℃培养箱反应0.5-2h后测量450nm处吸光度，根据检测结果及ADC的稀释梯度绘制细胞存活曲线。
图15为实施例7制备的抗体-药物偶联物L1H5-LP1、实施例8制备的L1H5-LP2、对比例1制备的抗体-药物偶联物阳性对照参照ADC在HCT-15细胞系中的细胞存活曲线。结果表明，L1H5-LP1、L1H5-LP2对HCT-15细胞系的体外细胞杀伤效果均显著优于参照ADC。
检测例10：小鼠结肠癌CDX模型体内肿瘤抑制实验
6周龄的Balb/c裸鼠购买自江苏集萃药康生物科技股份有限公司。每只小鼠皮下接种五百万HCT-15细胞，在平均肿瘤体积约150mm3，按照10mg/kg的剂量分别静脉注射对比例1制备的参照ADC、实施例8制备的L1H5-LP2、实施例7制备的L1H5-LP1，并设置空白对照(阴性对照)组，静脉注射等剂量PBS。每周1次，共给药三次。利用游标卡尺每周测量两次肿瘤体积，并按照如下公式计算肿瘤体积：TV＝(长×宽)2/2。图16显示出HCT-15结肠癌小鼠模型的体内肿瘤体积-时间变化曲线图，结果显示，L1H5-LP1和L1H5-LP2均能够抑制肿瘤生长并且略优于阳性参照ADC。
检测例11：小鼠结肠癌PDX模型体内肿瘤抑制实验
6周龄的NU/NU小鼠，雌性，体重18-21g，购买于北京维通利华实验动物技术有限公司。小鼠皮下接种结肠癌瘤块(结肠癌组织的标本编号为361795，来源于西安立迪生物技术有限公司)。当平均肿瘤体积达到150mm3时，按照10mg/kg的给药量分别静脉注射给予对比例1制备的参照ADC、实施例6制备的L1H5-LP3、实施例7制备的L1H5-LP1、对比例4制备的Dxd同型对照ADC、对比例5制备的LP3同型对照ADC，并设置空白对照(阴性对照)组，静脉注射给与等剂量PBS。每周1次，共给药3次。给药后使用游标卡尺每周测量两次肿瘤体积，并按照如下公式计算肿瘤体积：TV＝(长×宽)2/2。
图17示出结肠癌小鼠模型的体内肿瘤体积-时间变化曲线图，结果显示，和阳性对照参照ADC相比，L1H5-LP3及L1H5-LP1显著抑制肿瘤生长。
检测例12：小鼠EGFR-TKI耐药肺腺癌PDX模型的体内肿瘤抑制实验
6周龄的NU/NU小鼠，雌性，体重18-21g，购买于北京维通利华实验动物技术有限公司。每只小鼠皮下接种EGFR-TKI耐药肺腺癌瘤块(EGFR-TKI耐药肺腺癌组织的标本编号为0025- 200717，来源于西安立迪生物技术有限公司)。当平均肿瘤体积达到150mm3时，按照10mg/kg的给药剂量分别静脉注射给予对比例1制备的参照ADC、实施例6制备的L1H5-LP3、实施例7制备的L1H5-LP1、对比例4制备的Dxd同型对照ADC、对比例5制备的LP3同型对照ADC，并设置对照Vehicle组，静脉注射给与等剂量PBS。每周1次，共给药2次。给药后利用游标卡尺每周测量两次肿瘤体积，并按照如下公式计算肿瘤体积：TV＝(长×宽)2/2。
图18示出EGFR-TKI耐药肺腺癌小鼠模型的体内肿瘤体积-时间变化曲线，结果显示，和阳性对照参照ADC相比，L1H5-LP3及L1H5-LP1显著抑制肿瘤生长。
检测例13：小鼠结肠癌CDX模型的体内肿瘤抑制实验
6周龄的Balb/c裸鼠购买自江苏集萃药康生物科技股份有限公司。每只小鼠皮下接种五百万SW620细胞，在平均肿瘤体积约150mm3，按照10mg/kg的剂量分别静脉注射给予对比例3制备的L1H5-DXd、对比例2制备的参照抗体-LP3、实施例6制备的L1H5-LP3、对比例1制备的参照ADC，以及阴性对照PBS。每周1次，共治疗三周。给药后使用游标卡尺每周测量两次肿瘤体积，并按照如下公式计算肿瘤体积：TV＝(长×宽)2/2。
图19为小鼠结肠癌CDX模型的体内肿瘤体积-时间变化曲线，可以看出L1H5-DXd、L1H5-LP3和参照抗体-LP3均比阳性对照参照ADC更有优势。
图20为图19去掉阴性对照PBS组后的局部放大图。从图中可以明显看出，四种活性分子按照整体体内抑瘤效果从高至低排列，分别为L1H5-LP3>L1H5-DXd>参照抗体-LP3>参照ADC。
检测例14：小鼠胰腺癌CDX模型的体内肿瘤抑制实验
6周龄的NU/NU小鼠，雌性，体重18-21g，购买于北京维通利华实验动物技术有限公司。每只小鼠皮下接种胰腺癌瘤块(胰腺癌组织的标本编号为：0033-361319，来源于西安立迪生物技术有限公司)。当平均肿瘤体积达到150mm3时，按照10mg/kg的给药剂量分别静脉注射给予对比例1制备的参照ADC、实施例6制备的L1H5-LP3、实施例7制备的L1H5-LP1；对比例4制备的Dxd同型对照ADC、对比例5制备的LP3同型对照ADC，并设置空白对照组，静脉注射等剂量PBS。每周1次，共给药三次。利用游标卡尺每周测量两次肿瘤体积，并按照如下公式计算肿瘤体积：TV＝(长×宽)2/2。
图21为胰腺癌小鼠模型的体内肿瘤抑制曲线，结果显示，阳性对照参照ADC、L1H5-LP3和L1H5-LP1在给药初期均能显著抑制肿瘤生长，在给药周期内，L1H5-LP3和L1H5-LP1的抑瘤效果明显优于阳性对照参照ADC；且抑瘤持久时间明显长于参照ADC。
本公开实施例制备的抗体-药物偶联物具有较偶联GGFG-DXd的ADC更为优异的体内抗肿瘤作用，L1H5-LP3在多个肿瘤模型中均体现出优于参照ADC的体内药效；且L1H5-LP3在个别模型中均体现出更持久的抑瘤效果。并且，L1H5-LP3具有与GGFG-Dxd ADC相似的最大耐受剂量(MTD)，预期该药物偶联物比偶联GGFG-Dxd的ADC具有更高的治疗窗口，本公开提供的抗体-药物偶联物具有优异的安全性。

Claims (58)

  1. 抗HER3抗体或其抗原结合片段，包括至少一个轻链可变区(VL)和重链可变区(VH)，其中，
    VL的CDR1包含如SEQ ID NO:1所示的氨基酸序列，CDR2包含如SEQ ID NO:2所示的氨基酸序列，CDR3包含如SEQ ID NO:3所示的氨基酸序列；
    VH的CDR1包含如SEQ ID NO:4所示的氨基酸序列，CDR2包含与SEQ ID NO:5所示的氨基酸序列相差不超过5,4,3,2,1,0个突变的氨基酸序列，CDR3包含如SEQ ID NO:6所示的氨基酸序列。
  2. 根据权利要求1所述的抗HER3抗体或其抗原结合片段，所述VH的CDR2包含选自(a)或(b)中的一个或多个突变：
    (a)C52N，T62N，T66K和G67S；
    (b)C52Y，T62N，T66K和G67S。
  3. 根据权利要求1或2所述的抗HER3抗体或其抗原结合片段，所述VH的CDR2包含(a)或(b)的突变：
    (a)C52N，T62N，T66K和G67S；
    (b)C52Y，T62N，T66K和G67S。
  4. 根据权利要求1-3之一所述的抗HER3抗体或其抗原结合片段，其中，所述抗HER3抗体或其抗原结合片段包含的VH和VL组合选自(c)-(j)的组中的一种：
    (c)VL和VH分别包含如SEQ ID NO:9与SEQ ID NO:10所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；
    (d)VL和VH分别包含如SEQ ID NO:11与SEQ ID NO:14所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；
    (e)VL和VH分别包含如SEQ ID NO:11与SEQ ID NO:15所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；
    (f)VL和VH分别包含如SEQ ID NO:12与SEQ ID NO:14所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；
    (g)VL和VH分别包含如SEQ ID NO:12与SEQ ID NO:15所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；
    (h)VL和VH分别包含如SEQ ID NO:13与SEQ ID NO:14所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；
    (i)VL和VH分别包含如SEQ ID NO:13与SEQ ID NO:15所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列；和
    (j)VL和VH分别包含如SEQ ID NO:13与SEQ ID NO:16所示的氨基酸序列至少具有85％、90％、95％、96％、97％、98％、99％同一性的氨基酸序列。
  5. 根据权利要求1-4之一所述的抗HER3抗体或其抗原结合片段，其中，所述抗HER3抗体或其抗原结合片段包含的VH和VL组合选自(c)-(j)的组中的一种：
    (c)VL包含如SEQ ID NO:9所示的氨基酸序列及其保守取代变体，VH包含如SEQ ID NO:10所示的氨基酸序列及其保守取代变体；
    (d)VL包含如SEQ ID NO:11所示的氨基酸序列及其保守取代变体，VH包含如SEQ ID NO:14所示的氨基酸序列及其保守取代变体；
    (e)VL包含如SEQ ID NO:11所示的氨基酸序列及其保守取代变体，VH包含如SEQ ID NO:15所示的氨基酸序列及其保守取代变体；
    (f)VL包含如SEQ ID NO:12所示的氨基酸序列及其保守取代变体，VH包含如SEQ ID NO:14所示的氨基酸序列及其保守取代变体；
    (g)VL包含如SEQ ID NO:12所示的氨基酸序列及其保守取代变体，VH包含如SEQ ID NO:15所示的氨基酸序列及其保守取代变体；
    (h)VL包含如SEQ ID NO:13所示的氨基酸序列及其保守取代变体，VH包含如SEQ ID NO:14所示的氨基酸序列及其保守取代变体；
    (i)VL包含如SEQ ID NO:13所示的氨基酸序列及其保守取代变体，VH包含如SEQ ID NO:15所示的氨基酸序列及其保守取代变体；
    (j)VL包含如SEQ ID NO:13所示的氨基酸序列及其保守取代变体，VH包含如SEQ ID NO:16所示的氨基酸序列及其保守取代变体。
  6. 根据权利要求1-5之一所述的抗HER3抗体或其抗原结合片段，其中，所述抗HER3抗体或其抗原结合片段与人HER3特异性结合。
  7. 核酸，其编码权利要求1-6之一所述的抗HER3抗体或其抗原结合片段。
  8. 载体，其包含权利要求7所述的核酸。
  9. 宿主细胞，其包含权利要求7所述的核酸和/或权利要求8所述的载体。
  10. 具有式I所示结构的抗体-药物偶联物，
    Ab-(L-D)n   (I)
    或其异构体、同位素变体、药学上可接受的盐、前药、溶剂合物，或其组合，
    其中，Ab是权利要求1-6任一项所述的抗HER3抗体或其抗原结合片段；
    L是分别与Ab和D共价连接的连接子；
    D是有效荷载；
    n为1～10之间的数值。
  11. 根据权利要求10所述的抗体-药物偶联物，其中所述连接子为可切割连接子和不可切割连接子。
  12. 根据权利要求10或11所述的抗体-药物偶联物，其中所述连接子包括可切割肽。
  13. 根据权利要求12所述的抗体-药物偶联物，其中所述可切割肽可被酶切割。
  14. 根据权利要求13所述的抗体-药物偶联物，其中所述酶包括组织蛋白酶B。
  15. 根据权利要求10-14之一所述的抗体-药物偶联物，其中所述可切割肽或L包含氨基酸单元。
  16. 根据权利要求15所述的抗体-药物偶联物，其中所述氨基酸单元包括二肽、三肽、四肽或五肽。
  17. 根据权利要求16所述的抗体-药物偶联物，其中所述氨基酸单元选自：Val-Cit、Val-Ala、Glu-Val-Cit、Ala-Ala-Asn、Gly-Val-Cit、Gly-Gly-Gly和Gly-Gly-Phe-Gly中的任意或组合。
  18. 根据权利要求10-17之一所述的抗体-药物偶联物，所述连接子包含自降解单元。
  19. 根据权利要求18所述的抗体-药物偶联物，其中所述自降解单元包含对氨基苯甲氧基羰基(PABC)或对氨基苄基(PAB)。
  20. 根据权利要求12-19之一所述的抗体-药物偶联物，其中所述可切割肽直接剪切至所述自降解单元。
  21. 根据权利要求10-20之一所述的抗体-药物偶联物，其中所述连接子包含如-L1-L2-L3-所示的结构，
    L1表示-(琥珀酰亚胺基-3-基-N)-(CH2)m1-C(＝O)-、-CH2-C(＝O)-NH-(CH2)m2-C(＝O)-或-C(＝O)-(CH2)m3-C(＝O)-，其中m1表示2～8的整数，m2表示1～8的整数，m3表示1～8的整数；
    L2表示氨基酸单元；
    L3表示自降解单元。
  22. 根据权利要求10-21之一所述的抗体-药物偶联物，其中所述L选自：
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-GGFG-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-PABC-；
    -CH2-C(＝O)-NH-CH2CH2-C(＝O)-GGFG-PABC-；
    -C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-GGFG-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2-O-CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2-O-CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
    -CH2-C(＝O)-NH-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-VA-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-PABC-；
    -CH2-C(＝O)-NH-CH2CH2-C(＝O)-VA-PABC-；
    -C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-VA-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2-O-CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2-O-CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
    -CH2-C(＝O)-NH-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；和
    -C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-。
  23. 根据权利要求19-22之一所述的抗体-药物偶联物，其中所述对氨基苯甲氧基羰基(PABC)或对氨基苄基(PAB)连接有聚肌氨酸(聚-N-甲基甘氨酸)残基或甲氨基。
  24. 根据权利要求10-23之一所述的抗体-药物偶联物，其中连接子如式II所示，
    式II所示连接子通过琥珀酰亚胺基与抗体链间二硫链还原后的巯基通过硫醚键键合；
    式II所示连接子的酯基中的羰基与有效荷载中的氨基连接；
    R1、R2各自独立地选自氢、甲基或异丙基；
    R3表示-(CR5HCONH)n1-(CH2CONH)n2-或单键，R5选自氢或苯甲基，n1表示0～2的整数，n2表示0～2的整数；
    R4表示甲氨基或-(NCH3COCH2)n3-NCH3COCH3，n3表示1～20的整数。
  25. 根据权利要求24所述的抗体-药物偶联物，式II所示的连接子中，R4表示-(NCH3COCH2)n3-NCH3COCH3，n3表示8～15的整数。
  26. 根据权利要求24或25所述的抗体-药物偶联物，式II所示的连接子中，R4表示-(NCH3COCH2)n3-NCH3COCH3，n3表示10～12的整数。
  27. 根据权利要求24-26之一所述的抗体-药物偶联物，式II所示的连接子中，R3表示-(CR5HCONH)n1-(CH2CONH)n2-或单键，R5选自苯甲基，n1表示1或2，n2表示1或2；R4表示-(NCH3COCH2)n3-NCH3COCH3，n3表示8～15的整数。
  28. 根据权利要求24-27之一所述的抗体-药物偶联物，式II所示的连接子中，R3表示单键；R4表示-(NCH3COCH2)n3-NCH3COCH3，n3表示8～15的整数。
  29. 根据权利要求24-28之一所述的抗体-药物偶联物，式II所示的连接子中，R3表示单键；R4表示甲氨基。
  30. 根据权利要求10-29之一所述抗体-药物偶联物，所述连接子选自以下组中的一种或多种，

  31. 根据权利要求10-30之一所述的抗体-药物偶联物，所述有效荷载选自包括细胞毒剂、标记物、核酸、放射性核素、激素、免疫调节剂、前体药物转化酶、核糖核酸酶、激动性抗体、拮抗性抗体和其片段、融合蛋白或衍生物的组中的至少一种。
  32. 根据权利要求31所述的抗体-药物偶联物，所述细胞毒剂包括微管蛋白抑制剂和/或拓扑异构酶抑制剂；
    所述微管蛋白抑制剂包括奥瑞他汀或其衍生物，美登素或其衍生物；
    所述拓扑异构酶抑制剂包括喜树碱或其衍生物。
  33. 根据权利要求10-32之一所述的抗体-药物偶联物，所述有效荷载为式III所示的依喜替康，以其环己烷环上氨基的氮原子与连接子连接，
  34. 根据权利要求10-33之一所述的抗体-药物偶联物，其选自以下组中的一种

    n为1～10或4～10。
  35. 权利要求10-34之一所述的抗体-药物偶联物的制备方法，包括以下步骤：
    抗体或其抗原结合片段经还原处理后链间二硫键至少部分被还原，与连接子-有效荷载中连接子的反应基团反应，得到具有式I所示结构的抗体-药物偶联物，
    Ab-(L-D)n   (I)
    或其异构体、同位素变体、药学上可接受的盐、前药、溶剂合物，或其组合，
    其中，Ab是权利要求1-6任一项所述的抗HER3抗体或其抗原结合片段；
    L是分别与Ab和D共价连接的连接子；
    D是有效荷载；
    n为1～10之间的数值。
  36. 根据权利要求35所述的制备方法，其中所述连接子为可切割连接子和不可切割连接子。
  37. 根据权利要求35或36所述的制备方法，其中所述连接子包括可切割肽。
  38. 根据权利要求37所述的制备方法，其中所述可切割肽可被酶切割。
  39. 根据权利要求38所述的制备方法，其中所述酶包括组织蛋白酶B。
  40. 根据权利要求35-39之一所述的制备方法，其中所述可切割肽或L包含氨基酸单元。
  41. 根据权利要求40所述的制备方法，其中所述氨基酸单元包括二肽、三肽、四肽或五肽。
  42. 根据权利要求41所述的制备方法，其中所述氨基酸单元选自：Val-Cit、Val-Ala、Glu-Val-Cit、Ala-Ala-Asn、Gly-Val-Cit、Gly-Gly-Gly和Gly-Gly-Phe-Gly中的任意或组合。
  43. 根据权利要求35-42之一所述的制备方法，所述连接子包含自降解单元。
  44. 根据权利要求43所述的制备方法，其中所述自降解单元包含对氨基苯甲氧基羰基(PABC)或对氨基苄基(PAB)。
  45. 根据权利要求37-44之一所述的制备方法，其中所述可切割肽直接剪切至所述自降解单元。
  46. 根据权利要求35-45之一所述的制备方法，其中所述连接子包含如-L1-L2-L3-所示的结构，
    L1表示-(琥珀酰亚胺基-3-基-N)-(CH2)m1-C(＝O)-、-CH2-C(＝O)-NH-(CH2)m2-C(＝O)-或-C(＝O)-(CH2)m3-C(＝O)-，其中m1表示2～8的整数，m2表示1～8的整数，m3表示1～8的整数；
    L2表示氨基酸单元；
    L3表示自降解单元。
  47. 根据权利要求35-49之一所述的制备方法，其中所述L选自：
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-GGFG-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-PABC-；
    -CH2-C(＝O)-NH-CH2CH2-C(＝O)-GGFG-PABC-；
    -C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-GGFG-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2-O-CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2-O-CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-GGFG-NH-CH2CH2-C(＝O)-；
    -CH2-C(＝O)-NH-CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-GGFG-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-VA-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-PABC-；
    -CH2-C(＝O)-NH-CH2CH2-C(＝O)-VA-PABC-；
    -C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-VA-PABC-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2-O-CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2-O-CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；
    -(琥珀酰亚胺基-3-基-N)-CH2CH2-C(＝O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(＝O)-VA-NH-CH2CH2-C(＝O)-；
    -CH2-C(＝O)-NH-CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-；和
    -C(＝O)-CH2CH2CH2CH2CH2CH2-C(＝O)-VA-NH-CH2CH2CH2-C(＝O)-。
  48. 根据权利要求44-47之一所述的制备方法，其中所述对氨基苯甲氧基羰基(PABC)或对氨基苄基(PAB)连接有聚肌氨酸(聚-N-甲基甘氨酸)残基或甲氨基。
  49. 权利要求35-48之一所述的制备方法，包括以下步骤：抗HER3抗体或其抗原结合片段经还原处理后链间二硫键至少部分被还原，与连接子-有效荷载中式IV所示连接子部分的马来酰亚胺-N-基的3位碳原子进行反应，
    所述连接子-有效荷载中，式IV所示连接子的酯基中的羰基与有效荷载的氨基连接；
    式IV中，R1、R2各自独立地选自氢、甲基或异丙基；
    R3表示-(CR5HCONH)n1-(CH2CONH)n2-或单键，R5选自氢或苯甲基，n1表示0～2的整数，n2表示0～2的整数；
    R4表示甲氨基或-(NCH3COCH2)n3-NCH3COCH3，n3表示1～20的整数。
  50. 根据权利要求49所述的制备方法，所述方法还包括：抗HER3抗体或其抗原结合片段在含有螯合剂的缓冲溶液中与还原剂反应，加入连接子-有效荷载的溶解液，调节pH。
  51. 根据权利要求49或50所述的制备方法，所述方法还包括：所述有效荷载为式III所示的依喜替康，以其环己烷环上氨基的氮原子与式IV中酯基的羰基连接，
  52. 药物组合物，其包括权利要求1-6之一所述的抗HER3抗体或其抗原结合片段或权利要求10-34之一所述的抗体-药物偶联物，或其异构体、同位素变体、药学上可接受的盐、前药、溶剂合物，或其组合，以及药学可接受的辅料。
  53. 试剂盒，其包括1-6之一所述的抗HER3抗体或其抗原结合片段或权利要求10-34之一所述的抗体-药物偶联物，或其异构体、同位素变体、药学上可接受的盐、前药、溶剂合物，或其组合。
  54. 权利要求1-6之一所述的抗HER3抗体或其抗原结合片段，权利要求10-34之一所述的抗体-药物偶联物，权利要求35～51之一所述方法制备的抗体-药物偶联物或者权利 要求52所述的药物组合物，或者权利要求53所述的试剂盒在制备诊断、预防、治疗肿瘤疾病的治疗剂中的用途。
  55. 根据权利要求54所述的用途，所述用途包括在制备靶向HER3的药物中的用途。
  56. 根据权利要求54或55所述的用途，所述肿瘤包括表达HER3的实体瘤。
  57. 根据权利要求54-56之一所述的用途，所述肿瘤疾病包括肺癌、肾癌、尿路上皮癌、结直肠癌、前列腺癌、多形性成胶质细胞瘤、卵巢癌、胰腺癌、乳腺癌、转移性乳腺癌、管腔乳腺癌、黑素瘤、肝癌、膀胱癌、胃癌、胃肠道间质瘤、宫颈癌、头颈癌、食道癌、表皮样癌、腹膜癌、成体多形性成胶质细胞瘤、肝癌、肝细胞癌、结肠癌、直肠癌、结肠和直肠癌、子宫内膜癌、子宫癌、唾液腺癌、肾脏癌、外阴癌、甲状腺癌、肝恶性肿瘤、肛门癌、阴茎癌和肺腺癌。
  58. 诊断、预防和治疗肿瘤疾病的方法，包括向受试者给与治疗剂量的治疗剂，所述治疗剂包括权利要求1～6之一所述的抗HER3抗体或其抗原结合片段，权利要求10-34之一所述的抗体-药物偶联物，权利要求35～51之一所述方法制备的抗体-药物偶联物，权利要求52所述的药物组合物，或者权利要求53所述的试剂盒。
PCT/CN2023/125269 2022-10-19 2023-10-18 抗体-药物偶联物及其制备方法和在抗肿瘤中的用途 Ceased WO2024083166A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2023362061A AU2023362061A1 (en) 2022-10-19 2023-10-18 Antibody-drug conjugate, preparation method therefor and use thereof in resisting tumors
EP23879154.5A EP4606822A1 (en) 2022-10-19 2023-10-18 Antibody-drug conjugate, preparation method therefor and use thereof in resisting tumors
IL320034A IL320034A (en) 2022-10-19 2023-10-18 Antibody-drug conjugate, preparation method therefor and use thereof in resisting tumors
CN202380073861.XA CN120077074A (zh) 2022-10-19 2023-10-18 抗体-药物偶联物及其制备方法和在抗肿瘤中的用途
JP2025522931A JP2025535442A (ja) 2022-10-19 2023-10-18 抗体－薬物コンジュゲート、その調製方法、および、その抗腫瘍への使用
KR1020257016319A KR20250089539A (ko) 2022-10-19 2023-10-18 항체-약물 접합체, 그의 제조 방법 및 그의 항-종양 용도
MX2025004607A MX2025004607A (es) 2022-10-19 2025-04-16 Conjugado anticuerpo-farmaco, metodo de preparacion para el mismo y uso antitumoral del mismo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/126269 2022-10-19
CN2022126269 2022-10-19

Publications (1)

Publication Number Publication Date
WO2024083166A1 true WO2024083166A1 (zh) 2024-04-25

Family

ID=90736968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/125269 Ceased WO2024083166A1 (zh) 2022-10-19 2023-10-18 抗体-药物偶联物及其制备方法和在抗肿瘤中的用途

Country Status (8)

Country Link
EP (1) EP4606822A1 (zh)
JP (1) JP2025535442A (zh)
KR (1) KR20250089539A (zh)
CN (1) CN120077074A (zh)
AU (1) AU2023362061A1 (zh)
IL (1) IL320034A (zh)
MX (1) MX2025004607A (zh)
WO (1) WO2024083166A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024248123A1 (ja) 2023-06-02 2024-12-05 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007861A1 (en) 1988-12-28 1990-07-26 Protein Design Labs, Inc. CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR
US5244903A (en) 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
WO2012019024A2 (en) * 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
CN104093743A (zh) * 2011-11-23 2014-10-08 医学免疫有限责任公司 特异于her3的结合分子及其用途
US20160297890A1 (en) 2013-12-25 2016-10-13 Daiichi Sankyo Company, Limited Anti-trop2 antibody-drug conjugate
CN106163559A (zh) * 2014-04-10 2016-11-23 第三共株式会社 抗her3抗体‑药物偶联物
WO2019241893A2 (en) * 2018-06-22 2019-12-26 Crd Pharmaceuticals Inc Anti-her3 antibody and uses thereof
WO2022078425A1 (zh) * 2020-10-14 2022-04-21 江苏恒瑞医药股份有限公司 抗her3抗体和抗her3抗体药物偶联物及其医药用途

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244903A (en) 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
WO1990007861A1 (en) 1988-12-28 1990-07-26 Protein Design Labs, Inc. CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR
WO2012019024A2 (en) * 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
CN104093743A (zh) * 2011-11-23 2014-10-08 医学免疫有限责任公司 特异于her3的结合分子及其用途
US20160297890A1 (en) 2013-12-25 2016-10-13 Daiichi Sankyo Company, Limited Anti-trop2 antibody-drug conjugate
CN106163559A (zh) * 2014-04-10 2016-11-23 第三共株式会社 抗her3抗体‑药物偶联物
US20190151328A1 (en) 2014-04-10 2019-05-23 Daiichi Sankyo Company, Limited Anti-her3 antibody-drug conjugate
WO2019241893A2 (en) * 2018-06-22 2019-12-26 Crd Pharmaceuticals Inc Anti-her3 antibody and uses thereof
WO2022078425A1 (zh) * 2020-10-14 2022-04-21 江苏恒瑞医药股份有限公司 抗her3抗体和抗her3抗体药物偶联物及其医药用途

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"Monoclonal Antibodies", 1980, PLENUM PRESS, N. Y, pages: 365 - 367
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL ET AL., NUC. ACIDS RES, vol. 25, 1997, pages 3389 - 3402
ANGEW. CHEM. INT. ED, vol. 54, 2015, pages 7492 - 7509
BIOORG. MED. CHEM. LETT, vol. 26, 2016, pages 1542 - 1545
CLIN CANCER RES, vol. 20, no. 6, 15 March 2014 (2014-03-15)
HERMANSON, G. T: "Bioconjugate Techniques", 1996, ACADEMIC PRESS, pages: 456 - 493
KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
KUMIKO KOYAMA, HIROKAZU ISHIKAWA , MANABU ABE, YOSHINOBU SHIOSE , SUGURU UENO , YANG QIU , KENJI NAKAMARU , MASATO MURAKAMI: "Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression", PLOS ONE, vol. 17, no. 5, 3 May 2022 (2022-05-03), US , pages 1 - 10, XP093160639, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0267027 *
KUROIWA, Y ET AL., NUCL. ACIDS RES., vol. 26, 1998, pages 3447 - 3448
KYOJI TSUCHIKAMA ET AL.: "Antibody-drug conjugates: recent advances in conjugation and linker chemistrie", PROTEIN CELL, vol. 9, no. 1, January 2018 (2018-01-01), pages 33 - 46, XP055461467, DOI: 10.1007/s13238-016-0323-0
NATURE, vol. 321, 1986, pages 522 - 525
NICOLAS JOUBERT ET AL.: "Antibody-Drug Conjugates: The Last Decade", PHARMACEUTICALS, vol. 13, no. 9, 14 September 2020 (2020-09-14), pages 245, XP093134939, DOI: 10.3390/ph13090245
PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 6851 - 6855
PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 2423
QUEEN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 86, 1989, pages 10029 - 10033
RADER ET AL., PROC. NAT. ACAD. SCI. U.S.A., vol. 95, 1998, pages 8910 - 8915
SHIGEHIRO KOGANEMARU; YASUTOSHI KUBOKI; YOSHIKATSU KOGA; TAKASHI KOJIMA; MAYUMI YAMAUCHI; NAOYUKI MAEDA; TAKASHI KAGARI; KENJI HIR: "U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer", MOLECULAR CANCER THERAPEUTICS, vol. 18, no. 11, 1 November 2019 (2019-11-01), US , pages 2043 - 2050, XP093160642, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-19-0452 *
STEINBERGER ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 36073 - 36078
TOMIZUKA, K ET AL., NATURE GENETICS, vol. 16, 1997, pages 133 - 143
WINTERMILSTEIN, NATURE, vol. 349, 1991, pages 293 - 299
YOSHIDA, H ET AL.: "Ansel Introduction to Pharmaceutical Dosage Forms", vol. 10, 1999, KLUWER ACADEMIC PUBLISHERS, pages: 69 - 73
YUSUKE OGITANI ET AL., CLIN CANCER RES, vol. 22, no. 20, 2016, pages 5097 - 5108

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024248123A1 (ja) 2023-06-02 2024-12-05 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ

Also Published As

Publication number Publication date
JP2025535442A (ja) 2025-10-24
KR20250089539A (ko) 2025-06-18
MX2025004607A (es) 2025-05-02
CN120077074A (zh) 2025-05-30
EP4606822A1 (en) 2025-08-27
IL320034A (en) 2025-06-01
AU2023362061A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
JP7705809B2 (ja) 抗体薬物複合体の用量
WO2023046202A1 (zh) 一种抗体及其药物偶联物和用途
ES2690469T3 (es) Anticuerpo anti-CDH3 que tiene alta capacidad de internalización
BR112020005212A2 (pt) conjugado de anticorpo, kit, composição farmacêutica, e, métodos de tratamento ou prevenção e de diagnóstico de uma doença ou condição.
EP3380122B1 (en) Anti-5t4 antibodies and antibody-drug conjugates
CN110651045A (zh) 抗cdh6抗体和抗cdh6抗体-药物缀合物
TW201406780A (zh) 抗－Ｌｙ６Ｅ抗體及免疫結合物及其使用方法
WO2023102875A1 (en) Anti-cdh6 antibody drug conjugate
TW202233251A (zh) 抗體藥物綴合物
WO2022078279A1 (zh) 抗体-药物偶联物及其应用
EP4534105A1 (en) Anti-cldn18.2 antibody, and antibody-drug conjugate and use thereof
CN119487076A (zh) 抗ceacam5抗体及其缀合物和用途
JP2024545170A (ja) 抗ｃｄｈ６抗体及びその抗体薬物複合体
WO2024083161A1 (en) Antibody-drug conjugate, preparation method and use thereof
US12496354B2 (en) CD142 antibodies, antibody-drug conjugates, preparations and uses thereof
WO2024083166A1 (zh) 抗体-药物偶联物及其制备方法和在抗肿瘤中的用途
AU2023278315A1 (en) Pharmaceutical composition of recombinant anti-human cldn18.2 monoclonal antibody-mmae conjugate
CN117999101A (zh) 靶向EGFR的Fc抗原结合片段-药物缀合物
CN119255825A (zh) 抗-cdh6抗体-药物缀合物的剂量方案
CA3270684A1 (en) Antibody-drug conjugate, perparation method therefor, and anti-tumor use thereof
EA052998B1 (ru) Конъюгат антитело-лекарственное средство, способ его получения и его противоопухолевое применение
WO2025026338A1 (zh) 具有高药物负载的抗体-药物缀合物及其用途
CN121494985A (zh) 靶向Trop2/EpCAM的双特异性抗体、抗体偶联药物及其制备方法与应用
EA053275B1 (ru) Конъюгат антитело-лекарственное средство, способ его получения и применение
TW202515913A (zh) Nectin-4抗體及抗體藥物結合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23879154

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 320034

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: AU2023362061

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2025522931

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025522931

Country of ref document: JP

Ref document number: 202380073861.X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2023362061

Country of ref document: AU

Date of ref document: 20231018

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 820879

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 202591200

Country of ref document: EA

Ref document number: 202517047431

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20257016319

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020257016319

Country of ref document: KR

Ref document number: 2023879154

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023879154

Country of ref document: EP

Effective date: 20250519

WWE Wipo information: entry into national phase

Ref document number: 11202502563V

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202502563V

Country of ref document: SG

Ref document number: 202380073861.X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202517047431

Country of ref document: IN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025007725

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020257016319

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2023879154

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112025007725

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20250417